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SUMMARY
“The identification at the beginning o f the decade of the hepatitis C virus (HCV) as 
the cause o f a major proportion o f non-A, non-B hepatitis has stimulated extensive 
research into the biology and clinical aspects o f infection with this virus, and its 
epidemiology and public health importance as a cause o f morbidity and mortality 
in human populations. The findings o f epidemiological studies suggest substantial 
prevalence o f infection in populations, together with the observation o f high rates 
o f persistence o f infection, and high levels o f morbidity in exposed individuals 
strongly supports the view that HCV represents a major clinical and public health 
challenge. The design and implementation o f a strategy to control HCV infection is, 
therefore, a clear priority. However, control o f HCV infection must be founded 
upon a knowledge o f the history and dynamics o f HCV transmission within the 
population. Such knowledge remains patchy at present and is poorly intergrated. ”
Viral Hepatitis Prevention Board , Barcelona, 1995.
xvi
To investigate the prevalence of hepatitis C virus in saliva, the saliva of a group of 
haemophiliacs and blood donors, who were previously shown to be anti HCV positive by 
second generation immunoassay and a recombinant immunoblot, was examined using 
reverse transcription and the polymerase chain reaction. Both studies indicated that HCV 
was present in the saliva of a proportion (47.6% and 34% respectively) of each study 
group.
With a view to utilizing the polymerase chain reaction on saliva as a routine 
diagnostic tool for the detection of HCV, a revised protocol was sought, from the numerous 
procedures available, to reduce the sophisticated technique to a reproducible, reliable 
method. All aspects of the entire protocol from beginning to end were considered. HCV 
RNA extraction was assessed using two commercially available kits, in addition to the 
more traditional lysis with a chaotrophic agent followed by organic extraction and ethanol 
precipitation. Two procedures involving separate reverse transcription and the polymerase 
chain reaction were compared with a combined one step reverse transcription and 
polymerase chain reaction, to establish a protocol ensuring maximum amplification while 
reducing the possibility of false positive results. Finally, a sensitive and specific method 
was sought that would enable accurate detection of the desired product in a non-laborious 
manner.
The appropriateness of the polymerase chain reaction performed on saliva samples 
as an alternative to blood was evaluated among a group of HCV infected blood donors 
enrolled in a trial of interferon. Observation and treatment patients were monitored using 
biochemical and virological markers. Blood and saliva were collected in parallel and tested 
for HCV RNA. Results indicated that saliva was not a suitable alternative to blood for 
determining response to treatment.
In every study, both whole saliva and oral fluid collected in commercially available 
devices were obtained. HCV RNA could be detected in both specimen types but often not 
in parallel. These discrepancies may have resulted from deficiencies in the sample handling 
protocols. It is likely that specimen processing and storage conditions may influence the 
stability of HCV RNA. This was evaluated by studying saliva samples collected from 
known HCV seropositive intravenous drug users, which had been subjected to a number of 
handling and storage conditions. No single method was shown to be appropriate for both 
saliva and oral fluid.
The evaluation of paired serum and saliva samples for HCV RNA indicated that 
some individuals had HCV RNA present in saliva but not in blood. DNA sequencing was 
employed to confirm the presence of HCV RNA in saliva and to genotype the isolates 
amplified. The presence of different subtypes and even genotypes in the mouth and serum 
was observed.
The source of HCV within the mouth and the potential risk of transmission through 
saliva are discussed.
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Chapter 1 
General Introduction
The Hepatitis Viruses
Acute viral hepatitis is a common and sometimes serious viral infection of the 
liver, leading to inflammation and necrosis. On the basis of clinical and epidemiologic 
features it has been clear for many years that there are various types of this disease. In the 
1960s, the different types of infectious hepatitis started to be identified (Krugman et al.. 
1967). The initial breakthrough came when the hepatitis B surface antigen (HBsAg) was 
discovered and linked to hepatitis B (Blumberg et al.. 1967). This was followed in 1973 
by the identification of hepatitis A (Feinstone et al.. 1973). The delta agent or hepatitis D 
virus (HDV), which is also capable of causing viral hepatitis in conjunction with hepatitis 
B, was discovered in 1977 (Rizetto et al.. 1977). Since then, two further agents causing 
non-A, non-B hepatitis have been described, hepatitis C virus (HCV) (Choo et al.. 1989) 
and hepatitis E virus (HEV) (Reyes et al.. 1990). The main features of these five viruses 
which cause hepatitis in man are summarised in Table 1.1
Hepatitis non-A, non-B : Hepatitis C virus
In the 1960s, before the identification of hepatitis A virus (HAV) and hepatitis B 
virus (HBV), it was noted that the period of incubation for transfusion-associated hepatitis 
was on average approximately 7 weeks. This was later recognised as being intermediate 
between that for HAV infection (2-6 weeks) and for HBV (2-6 months). Little weight 
however was given to this clinical observation. Only with the development of sensitive 
serological tests for identifying infection with HBV was it recognised that HBV could only 
be implicated in as few as 25% of transfusion-associated hepatitis cases.
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TABLE 1.1 
The Major Hepatitis Viruses
Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E
Virus group Picornavirus Hepadnavirus Pesti/Flavi- Plant virus­ Calcivirus-like
virus like like
G enetic material RNA DNA RNA RNA RNA
Routes o f Faecal-oral Blood-borne Blood-borne Blood-borne Faecal-oral
transmission Vertical Vertical
Sexual Sexual?
Incubation 2-6 weeks 8-24 weeks 4-20 weeks 3-12 weeks 3-7 weeks
period
Chronicity No Yes Yes Yes No
The main characteristics of the major viruses known to cause hepatitis in man.
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An early report by Koretz et al.. (1973) described post transfusion hepatitis in 
patients who developed non-B hepatitis after receiving HBsAg negative blood. It was also 
shown that antibody to HBsAg , known to correlate with immunity to HBV when present 
in a recipient’s blood before transfusion, did not protect that recipient from hepatitis after 
transfusion.
Initially it became fashionable to implicate HAV in these non-B cases following 
transfusion. However, once serological tests were developed to identify HAV infection, 
several studies demonstrated convincingly that HAV played no role in post-transfusion 
hepatitis (Alter et al., 1975a; 1975b; Dienstag et al.. 1977; Feinstone et al.. 1975). 
Thus, it became apparent that there existed at least one blood-borne human hepatitis virus 
previously unrecognised and unrelated to hepatitis A and B. By exclusion, this was 
termed non-A, non-B hepatitis (NANBH). Information gathered from clinical 
observations and studies of transmission in chimpanzees allowed certain characteristics 
of the virus to be deduced and a better understanding of the disease and its pathogenesis 
to be obtained. However, it took almost 15 years to detect the virus serologically through 
application of molecular biologic techniques (Choo et al.. 1989).
In May 1988, the American Chiron Corporation described in a press conference 
the identification, cloning and expression of proteins from the agent responsible for most 
cases of post transfusion-non-A, non-B hepatitis (PT-NANBH). Cloning was initiated by 
ultracentrifugation of large volumes of infectious chimpanzee plasma known to contain 
the NANBH agent. From the pellet formed, the nucleic acid was recovered and 
denatured to allow either DNA or RNA to serve as a template for reverse transcription 
using random primers. The resultant cDNA was then inserted into a cloning vector, Xgtll, 
and expressed in E.coli. Following lysis of the bacteria, the proteins expressed were
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absorbed to an overlying filter and immunoscreened with serum from a patient with 
chronic NANBH which was presumed to contain antibody to the virus. After screening 
many clones, one single clone was reactive by radiography. The insert in this clone was 
then cut and used as a hybridisation probe to the original library of cDNA, and from 
several overlapping clones, a larger clone was obtained (c 100-3). This was then 
expressed in yeast as a fusion protein using human superoxide dismutase sequence to 
facilitate expression (Choo et al., 1991). This led to dramatic advances in our 
understanding of the virus which was named HCV. It was now possible to detect the 
virus, but knowledge of the epidemiology and natural history of HCV infection remains 
incomplete.
i) Genomic Organisation of HCV
HCV contains a positive-stranded RNA genome reported to be about 9,400- 
10,000 nucleotides. The genome contains a 5' non-coding region (5’ NCR) followed by a 
single open reading frame which is believed to encode a polypeptide precursor of just 
over 3,000 amino acids (Chan et al.. 1992). Comparison of the sequence of both the 
genome and its encoded polypeptide with other known viral sequences revealed little 
homology. However, evidence showing a distant relationship to the pestiviruses and the 
flaviviruses has resulted in HCV, pestiviruses and flaviviruses all being considered 
separate genera of the Flaviviridae family (Choo et al.. 1991; Miller and Purcell, 1990). 
As information regarding the genetic and polypeptide organisation of the HCV genome 
has accumulated, it has emerged that,despite poor overall primary sequence similarity 
between the three virus types, the basic structure and organisation of their encoded
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polypeptides are comparable with regard to their hydropathicity profiles (Choo et al..
1991). However, an exception is the 5' NCR, upstream from the sequence encoding the 
large polyprotein which is highly homologous with the equivalent region in the 
pestiviruses (Choo et al.. 1991; Takamizawa et al.. 1991). An important role for this 
region in some aspect of viral replication has been suggested. Comparisons have been 
made to the lengthy 5' NCR present in the RNA genomes of picornaviruses (Inchauspe et 
al., 1991). These allow for cap-independent translation at internal ribosome entry sites 
(IRES) and also contain cis-acting sites which allow internal entry of ribosomes.
Although no significant nucleotide sequence relatedness exists, reports of such structures 
in the 5' NCR of the HCV genome have been made (Brown et al., 1992; Selby et al..
1993; Yoo et al.. 1992). Which structure, if indeed either, is important to viral replication 
and polyprotein translation remains to be determined.
HCV encodes a single polyprotein precursor from which individual proteins are 
processed. Whether this occurs co-translationally and/or post-translationally through the 
action of host and viral encoded protease has not yet been resolved. Schematically, four 
domains can be identified: two NCR found at the 5' and 3' end, the 5' structural region 
(containing the core and envelope proteins ), and a 3' nonstructural region (encoding a 
variety of proteins, NS1-NS5). The structural proteins form the viral particle, whereas the 
nonstructural proteins are involved in replication of the virus.
By transfecting cloned cDNA into mammalian cells via a range of expression 
vectors it has been possible for some protein products to be identified (Figure 1.1). A 
nucleocapsid protein of about 22kD and two glycoproteins (gp) of approximately 33kD and 
72kD are processed from the 5' terminal region of the genome. By comparison with the
5
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pestiviruses and flaviviruses, gp33 is probably equivalent to a matrix glycoprotein in the 
virion while gp72 is a viral envelope glycoprotein corresponding to gp53/55 of the 
pestiviruses. Gp72 may also represent the first NS protein analogous to the NS1 
glycoprotein of the flaviviruses (Houghton et al.. 1994). It has been indicated that gp72 is 
more likely to be equivalent to the pestiviral protein as,unlike the flaviviral glycoprotein, it 
is not secreted. However, it has also been shown that in contrast to the pestiviral protein, 
the flaviviral NS1 and HCV NS1 contain potential glycosylation sites (Takamizawa et al..
1991). Comparison of the available E2/NS1 sequences revealed the presence of a 
hypervariable region. This region seems to lack a conserved secondary structure and 
resembles the V3 loop of HIV gpl20 (Weiner et al.. 1992). Specific antibody reactions 
have been detected against peptides corresponding to linear epitopes in this region, 
indicating that this part of the E2 region encodes antigenically distinct variants subject to 
immune selection (Weiner et al.. 1992; Lesniewski et al.. 1993: Taniguchi et al.. 1993). 
The variability of gp72 is likely to have significant implications for vaccine strategies. 
From the nonstructural region, proteins of 23 and 60kD, corresponding to the flaviviral 
NS2 and NS3 proteins, have been identified. Both the NS2 and NS3 of HCV encodes 
different proteases. The NS3 protein appears to contain a nucleotide triphosphate-binding 
helicase enzyme and a serine protease that is presumably involved in the unwinding of the 
RNA template during replication, translation and /or assembly of the poly protein precursor 
into the mature proteins. Selby et al, (1993), report that NS3 cleaves itself from the 
polyprotein precursor before catalysing cleavage reactions to liberate NS4 and NS5. Less is 
known about NS4 and NS5 proteins. NS4 appears hydrophobic and codes for two proteins 
(4a,4b). Both contain highly immunogenic epitopes and may be associated with cellular 
membranes (Houghton et al.. 1994). NS5 is thought to contain the RNA dependent RNA
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polymerase needed for replication (Takamizawa et al.. 1991). It has been shown that NS5 
is processed into two proteins NS5a and NS5b, by NS3 (Selby et al.. 1993). The 
processing of the NS5 domain into the 2 proteins resembles the situation for the 
pestiviruses and is in contrast to that of the flaviviruses. This reaction implies that HCV 
more closely resembles the pestiviruses (Collett et al.. 1988). NS5b has been reportedly 
shown to encode the viral replicase. The function of NS5a remains unknown.
ii) Immunodiagnostics for HCV
a) First Generation Tests
The cloning of the HCV genome facilitated the production of a panel of 
recombinant antigens. Large quantities produced in E. coli and yeast formed the basis of 
the widely used immunodiagnostic assays aimed at detecting antibody to HCV. Sequence 
data have also enabled production of synthetic peptides for use in these assays as well. 
The original antibody test developed incorporated the c 100-3 polypeptide expressed in 
yeast as a fusion protein with human superoxide dismutase (SOD). This polypeptide 
corresponded to nearly all of the NS4 protein of the original isolate (Choo et al.. 1989; 
Houghton et al.. 1991), but represented only about 12% of the coding capacity of HCV 
(Chien et al.. 1992). This recombinant antigen was attached onto the surface of 
microwells for use in a solid-phase capture assay.
The original test developed was a radioimmunoassay (RIA).This was succeeded 
by a commercially available enzyme-linked immunoassay (ELISA) developed by Ortho 
Diagnostic Systems (Raritan, NJ, USA) with recombinant antigens provided by Chiron.
Subsequently, another anti-HCV first generation ELISA assay was produced by Abbott 
Laboratories (Nth Chicago, 111, USA). The presence of antibody to c 100-3 proved a good
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marker for infection with HCV and was detected in about 80% of chronic HCV cases 
whether sporadic or PT-NANBH (Courouce and Janot, 1994). However, following the 
introduction of these assays as a routine clinical and screening tool it became apparent that 
the tests were unsatisfactory with regard to sensitivity and specificity. False positive 
results were encountered in patients with superoxide dismutase antibodies, rheumatoid 
factors and autoantibodies (McFarlane et al.. 1990). Such reports created controversy over 
the widespread implementation of the first generation assay, as the frequency of false 
positives increased significantly in low-risk populations such as blood donors and those 
with sporadic disease (Contreras and Barbara, 1989; Dodd, 1992; Flegg, 1989). It should 
be remembered, however, that the introduction of these first generation assays was an 
improvement from the use of surrogate markers, and represented a very important step in 
the diagnosis of HCV infection, reducing the incidence of PT-NANBH by 50-85% or 
more (Dodd, 1992; Courouce and Janot, 1994).
The cause of the false positive results with the first generation assays remains 
unresolved. Nonspecific serum 'stickiness' to the solid phase has been considered 
(McFarlane et al.. 1990). The assay also lacked sensitivity in that not all persons with 
HCV seroconvert according to the first generation antibody test. Some never produce 
detectable levels of anti c l00-3, while in others anti c 100-3 disappears rapidly (Bonino et 
al., 1993). The test is also limited by the delay in antibody production often observed.
This suggests that there is a lengthy ‘window period’ during which a patient may have a 
negative test result using first generation assays. It is interesting to note that even in direct 
comparison, the Abbott and Ortho first generation ELISAs do not identify the same anti- 
HCV positive specimens. Both use the solid phase antigen licensed by Chiron 
Corporation but the tests have different assay designs, Ortho using the microtiterplate,
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and Abbott a latex bead. How much of an effect the design has on the test has not been 
assessed or considered by other researchers. Perhaps incorporation into the different test 
designs presents epitopes in a slightly different conformation. More often, differences 
resulting from individual workers are held responsible for these discrepancies.
b) Second Generation and Onwards
The deficiencies in the first generation tests | led to the 
development of second generation tests. These assays incorporated additional 
recombinant antigens from the HCV genome (Table 1.2). At present, the Ortho HCV 3.0 
ELISA test system is widely used in blood donor screening. Sensitivity is further 
increased by addition of antigen derived from the NS5 region. This shows an even greater 
increase in sensitivity than the second generation assay when compared to the original 
tests. The format of the third generation assay is however the same as the first two and 
therefore has the same risk of false positive results in low risk populations, such as blood 
donors.
c) Supplemental Tests for HCV
In order to confirm results obtained by any ELISA, for any viral antibody, there 
should be a test that is of equal sensitivity and specificity, and utilises a different assay 
format and uses different antigens. Most of the available confirmatory tests only fulfil two 
of these criteria, and as a result they should be considered as supplementary rather than 
truly confirmatory.
The first confirmatory test was a recombinant immunoblot assay (RIBA) 
purchased from the Chiron Corporation through Ortho Diagnostic Systems. This first
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TABLE 1.2
H C V  p ro te ins
M an u fac tu re r N ature N am e R eg ion
O rtho  D. S. recom binan t C  22-3 core
C 200: C 33c N S3
C l 00-3 N S 4
A bbott recom binan t C 22-3 core
C 33c N S3
C l 00-3 N S 4
S anofi Pasteur recom binan t N C  450 core
4091-1 N S3
U B I synthetic  peptides 3K  243E core
3K  204H N S 4
M urex-W ellcom e recom binan t / core
N S3
N S5
B ehring synthetic  peptides / core
N S 4
C om m ercia lly  ava ilab le  second generation  screen ing  an ti-H C V  E L IS A  assays. 
T he  tab le sum m arises the nature , nam e, and source o f  the H C V  pro te in s used  as 
an tigens in the assays.
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generation test used the three recombinant antigens: the composite C l00-3 produced in 
yeast, the original 5-1-1 produced in E. coli, and SOD. The C100-3 and the 5-1-1 antigens 
are superoxide dismutase-fusion polypeptides of HCV hence the SOD antigen is present as 
a control to detect the presence of antibody to SOD. All three antigens are blotted onto 
nitrocellulose strips along with two levels of human IgG as internal controls. For this assay, 
a positive result requires reactivity to two HCV antigens with bands of intensity at least 
equal to the low IgG control band. Confirmatory HCV neutralisation assays were also 
developed by Abbott Laboratories. These are based on the principle that HCV antigens in 
solution may block or neutralise the binding of antibodies to HCV-coated polystyrene 
beads in the HCV ELISA. Second and third generation supplemental tests are available 
from a number of manufacturers (Table 1.3).
Evaluation of these newer assays is still ongoing. With the introduction of 
additional antigens, the newer assays do exhibit better reproducibility, specificity and 
sensitivity than the first generation assays , owing to the presence of core and NS3 proteins. 
Antibodies to C22-3 and C33c are detectable earlier , more regularly and for a longer 
period than C 100-3 (Courouce and Janot, 1994). Some patients develop antibodies to C22- 
3 alone or C33 and C22-3 but not to C l00-3 (Lelie et al., 1992).
On the above evidence, the strategy to assess true HCV status in low risk 
populations involves initial anti-HCV detection by a screening ELISA followed by an 
alternative ELISA and a supplemental assay. Because the available anti-HCV supplemental 
assay systems employ different methods from the screening ELISA, it is reasoned that their 
agreement can be used to classify anti-HCV status (Dow et al.. 1993). Problems arise, 
however, when RIB A-indeterminate results are obtained. Some patients develop antibodies 
to c22-3 only or c33c and can be viraemic. The significance of such RIBA-2 patterns may
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TABLE 1.3
N a m e  o f  
te s t
C ore N S3 N S 4 N S5 M an u fac tu re r
R IB A -2 C 22-3 RP C 33-c R P 5-1-1 R P 
C l 00-3  RP
C hiron
R IB A -3 peptide C 33-c R P pep tide R P C hiron
M atrix R P C 33-c R P C l 00-3 (yeast) 
C l 00-3 (E. co li)
A bbott
D eciscan C 1 = N C 450  R P 
C 2=  pep tides
409.1 R P peptide S anofi -P asteu r
Inno-L ia four pep tides peptide pep tide Innogenetics
C om m ercia lly  availab le  second  and  th ird  generation  an ti-H C V  
supp lem en tal tests, and the H C V  ep itopes used in the im m unoblo ts. 
R P= recom binan t protein.
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differ between blood donors and high risk individuals. In patients with symptoms, or those 
who are asymptomatic but fall into a recognised risk group, a positive result in the 
screening ELISA is likely to be specific, even if only an indeterminate result is obtained 
with a supplemental test (Skidmore, 1994). Indeterminate results obtained from normal low 
risk individuals are an important problem for the Blood Transfusion Service. Such donors 
need to be confirmed as true positives to prevent the unnecessary loss of units for 
transfusion. The introduction of third generation supplemental tests shows good correlation 
with viraemia and has improved the above situation.
It is important to consider here that available assays, while measuring antibody 
against epitopes of non-assembled HCV proteins, may miss those against tertiary and 
quaternary structure dependent epitopes (Bonino et al.. 1993). It has also to be remembered 
that a sample giving a positive reaction in one assay may be negative in another due to 
different combinations of antigen being employed in different assays. A further important 
consideration is that currently employed assays use antigens derived from HCV type 1 
sequences. As a result, diagnosis of infections with other HCV genotypes relies on 
detecting cross-reacting antibodies. However, the degree of cross-reactivity will depend on 
the degree of sequence similarity between genotypes. It is known that sequence similarity 
varies throughout the genome and one would expect this to affect cross-reactivity. For 
example, the c 100-3 recombinant protein used in first generation assays was derived from 
the NS4 region. This part of the genome varies significantly between types 1,2 and 3. 
Studies have shown weak (or absent) reactivity to c l00-3 from individuals infected with 
variants other than type 1 (McOmish et al., 1993; Nagayama et al., 1993). The use of c22-3 
reduces the risk of missing infections by other types due to the higher degree of amino acid
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sequence conservation (Tsukiyama-Kofaara et al.. 1993). All donors; infected with types 2-6 
react strongly with the recom binant core protein (M cOmish et ail., 1994).
Routine screening of blood donations; with the aforementioned assays has had a 
direct im pact on reducing the incidence of post transfusion hepatitis. Important information 
on epidemiology and knowledge of the disease has also been provided indirectly.
d) Polymerase Chaim Reaction (PCR) for HCV
Initially it w;as reported that antibody, once formed, persisted throughout the 
course o f chronic hepatitis, suggesting that loss of previously detec ted antibody was a  
good indicator of recovery (Alter et al.. 1939). This is not always the case. Later 
studies, show that antibody response varies from person to person and depends on the 
immune responsiveness of the host. In young children, HCV infection is often associate d 
with an incomplete serological response possibly as a  result o f the immaturity o f the 
imimune system at the time of infection (Borlotti et al.. 1994). Antibody can be 
intermittently positive and disappear at variable intervals during follow up (Puoti et a l..
1992).
Even with the available serological assays, it is unclear w hether a positive anti- 
HCV result implies infecttivity or simply a past infection. Assessm ent o f potential 
infectivity depends on direct detection o f HCV either by testing for HCV antigens or 
HCV RNA. Antigenic markers for HCV are being developed, but concentrations of H CV 
antigen in serum  are at the lower limit o f detectability using the available immunoassay 
techniques. However, the ability to detect HCV nucleic acid by amplifying reverse 
transcribed complementary DNA has been developed (Kato et al ., 1990; W einer et a l.. 
1990). The principles of PCR have been described elsewhere (Ehrlich and Sirko,, 1994;
14
Saiki et al.. 1988). The application of PCR has provided a sensitive and specific assay for 
viral RNA present in the bloodstream and other tissues.
Detection of viral RNA can now be made within 1-2 weeks of exposure, long 
before antibody can be detected using conventional assays (Figure 1.2). At present, the only 
definitive test for diagnosis of HCV infection is a positive PCR result (Brown and 
Dusheiko, 1993; Rubin et al.. 1994; Dow et al.. 1994). A complicated and expensive 
technique, PCR is unavailable in the majority of diagnostic laboratories. However, the 
introduction of PCR has yielded valuable information regarding the pattern of HCV 
replication, its relation to antibody levels and the clinical course of NANBH.
Theoretically there remain potentially infectious individuals, who have become 
infected in the recent past, which the best tests currently available may not detect. Some 
PCR positive blood donations may not be detected even when using third generation 
serological assays (Dow et al 1994). On the other hand, not all anti-HCV positive sera are 
PCR positive. There are several possible explanations for this: patterns of fluctuating 
viraemia, low grade viraemia below the level of detection by current PCR assays, infection 
with a strain of HCV significantly different in nucleic acid sequence so as not to be 
recognised by the primers employed, or the deleterious effect of storage and treatment on 
the samples (Cuypers, 1994).
Standardisation and quality assurance between laboratories does need 
improvement, and a positive result, though indicative of viremia and potential infectivity, 
like a negative, should be interpreted with care (Van der Poel, 1994a; Zaaijer et al.. 1993). 
The clinical value of PCR depends on the sensitivity and reproducibility of applied 
procedures. The importance of primer selection and its effect on PCR results is a
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FIGURE 1.2
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We&ks a%r exposure
Serological course in acute resolving HCV infection 
Adapted from Brown and Dusheiko, 1994
recognised source of inconsistencies. Investigators have shown significant heterogeneity at 
several regions of different HCV strains which may lead to false negative results in PCR 
assays when primer-template mismatch occurs (Bukh et al.. 1992; Chan et al.. 1992; 
Okamoto et al., 1992a; b). It is believed that primers derived from the 5' noncoding and 
core regions are highly conserved and provide the best sensitivity. PCR sensitivity may 
vary among different clones owing to minor sequence variations in the 5' NCR. A recent 
study by Smith and colleagues (1995) compared 314 5’NCR sequences of viruses of 
genotypes 1 to 6 and identified primers that would be equally efficient in detecting RNA 
from different virus genotypes. Sensitivity can be maximised by using double or nested 
PCR. However, such an approach increases the risk of assay contamination (Cuypers,
1994). Recent reports have indicated that the use of one-stage PCR amplification combined 
with sensitive detection methods, for example Southern blot or liquid hybridization with 
radioactive oligonucleotide probes, is sensitive enough, with less risk of contamination 
(Geiger and Caselmann, 1992; Gretch et al.. 1993; Hu et al.. 1992; 1993). However, 
potentially hazardous radiolabelled probes are also unwanted, therefore, 'nested' PCR 
remains the most popular way of detecting HCV. The impact of specimen handling and 
storage has also been considered to have dramatic effects on the validity of PCR results.
To ensure maximum sensitivity specimens should ideally be processed immediately and 
frozen in aliquots to prevent repeated freeze-thawing (Busch et al., 1992; Cuypers et al.. 
1992; Wang etal., 1992b).
e) Quantification of HCV RNA
Rather than merely determining the presence or absence of viral RNA, quantifying 
the amount of HCV RNA may be used as an aid in defining the key features of the disease
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process. Additionally, quantitative analysis of HCV in serum may provide a marker of 
response to therapeutic intervention. Different methods to quantify HCV RNA have been 
used:
1) The limiting dilution PCR assay estimates the HCV RNA titre through the 
performance of serial ten fold dilutions of extracted RNA prior to PCR. The titre is 
calculated from the highest dilution giving a positive result (Sherman et al.. 1993; 
Simmonds et al., 1990)
2) The competitive Reverse Transcription (RT) - PCR assay measures the HCV RNA 
concentration by mixing the cDNA with ten fold serial dilutions of a competitor 
DNA that differs from cDNA by having a small deletion (Hagiwara et al.. 1993; Kato 
et al.. 1993; Kumar et al.. 1994).
Both the above have limited use in clinical practice as they are expensive, time-consuming, 
laborious and difficult to reproduce.
3) A competitive PCR method with colorimetric detection of the amplified products has 
been developed. (Lundeberg etal., 1991; Yun et al.. 1994; Shindo et al.. 1994). After 
RT, one tenth of the resulting cDNA, and the same volume of serially diluted cloned 
competitor DNA, are coamplified by nested PCR. The competitor DNA consists of the 
amplified region of the wild type cDNA with an internal region substituted with the lac 
operator sequence.
4) Recently a branched DNA (bDNA) signal amplification method has been developed. 
This assay is based upon hybridisation of HCV RNA by synthetic oligonucleotides to 
the highly conserved 5’ noncoding and core regions immobilised on the surface of a 
micro well plate. Oligonucleotides complementary to different HCV genotype 
variations are incorporated in regions with minor genomic variation. Synthetic bDNA
17
amplifier molecules and multiple copies of a probe are hybridised to the complex. The 
complex is incubated with a luminescent substrate and the light emission is measured, 
the signal being proportional to the level of target nucleic acid. Quantification of HCV 
RNA is then determined from a standard curve (Davies et al.. 1992; Urdea., 1993). 
Unfortunately, the bDNA assay is not yet as sensitive as PCR for the detection of HCV 
(Bresters et a l .. 1994), but for quantification it is easier to handle and less time 
consuming than the aforementioned techniques.
iii) Patterns of Immune Response to HCV
With the array of antigens in the current tests, researchers have sought to 
relate an epidemiological or clinical feature of chronic infection, or viral replication with a 
particular antibody response to individual antigens (Chemello et al.. 1993; Lelie et al.,
1992; Puoti et al.. 1992). Apart from NS5, PCR positivity can be seen in blood donors 
with only single antigen reactivity to either C l00, C22-3, or C33 in REBA-3 (Follet et al..
1992). A strong correlation has been reported between the presence of core antibodies and 
viral carrier status (De Beenhouwer et al.. 1992; Lelie et al.. 1992; Tanaka et al.. 1993).
The lack of reactivity against c22 antigens in PCR negative blood donors has also been 
observed (Perrons and Garson, 1993). It is, however, apparent that even with the many 
tests available, no combination can identify viraemic donations exclusively. It is likely 
that it is the extreme heterogeneity of the anti-HCV immune response, which has been 
reported to be dependent on the immune responsiveness of the host, that causes the 
various antibody patterns recorded.
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iv) Genotyping of HCV
With the increase of information in the literature regarding the nucleotide 
sequence of different HCV isolates, it has become apparent that many differ strikingly from 
the original prototype HCV (HCV-1) (Choo et al.. 1991). Indeed, comparison of the 
original American isolate with Japanese and European isolates reveals significant 
heterogeneity in both nucleotide and polypeptide sequence. Such heterogeneity even exists 
within most persistently infected individuals (Simmonds, 1994). There are at least five 
different systems of nomenclature that differ in the degree of sequence divergence required 
to assign a new virus type ( Houghton et al., 1991; Cha et al.. 1992; Chan et al.. 1992; 
Simmonds et al.. 1993: Okamoto et al.. 1992b; Enomoto etal., 1990; Tsukiyama- 
Kohara et al.,1991). The European and USA groupl isolates of Chan et al.(1992) are 
classified as Type 1 by Houghton et al.(1991). and as group K1 by Enomoto etal.(1990). 
Far East group 1 isolates of Chan et al.(1992) are equivalent to Type II by Houghton et al. 
(1991), and group 2 are equivalent to Type III. Group 2 also correspond to group K2 as 
described by Enomoto et al.(1990). Chan etal.(1992) have also recently differentiated two 
clusters of group 2 sequences. Controversy remains over which method of classification is 
the most appropriate to accommodate the growing number of distinct sequences identified. 
The lack of consensus leads to confusion when work from different laboratories is 
compared. In consequence, a system for the nomenclature of hepatitis C viral genotypes, 
believed to reflect the observed two-tiered nature of HCV sequence variation found in the 
coding regions of the genome, was proposed and accepted at the 2nd International 
Conference of HCV and Related Viruses (Aug 1994, San Diego, California) (Table 1.4) 
(Simmonds et al.. 1994a).
19
TABLE 1.4
P roposed
nam es C h Si
A lterna tive  n am es3 
O k En T s
la I la I PT N C
lb II lb II K1 I
lc N C NC NC N C N C
2a III 2a III K 2a II
2b III 2b IV K 2b II
2c III NC N C N C N C
3a IV 3 V N C N C
3b IV NC VI N C N C
4a NC 4 NC N C N C
5a V N C N C N C N C
6a N C N C N C N C N C
P roposed  nom enclatu re and com parison  w ith  ex isting  schem es fo r H C V  
types.
N C , not c la s s if ie d ;a N om encla tu re  accord ing  to ex isting  schem es: Ch, 
H oughton  et al and C ha et al; Si C han  et al and  S im m onds e t al; Ok,
O kam oto  et al and M ori et al; En± E nom oto  et al; Ts  ^T su k iy am a-K o h ara  e t al.
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Various methods of genotyping HCV have been described. Direct sequencing, 
with analysis of consensus sequences, is the gold standard for genotype analysis but is not 
suitable for large numbers of clinical samples. Sequence information has also enabled the 
development of type-specific primers and probes (Okamoto et al.. 1992b; 1993; Enomoto 
et al.. 1990; Stuvver et al.. 1993; Simmonds et al.. 1993; Zhang et al.. 1995). Although 
widely used, it is predictable that such primers and probes would fail to amplify or 
hybridise to sequences unrecognised when the primers/probes were designed. For example, 
the primers described by Okamoto et all  1992b; 1993), for identifying genotypes I, II, El, 
IVand V (Types la, lb, 2a, 2b and 3a respectively), would fail to amplify type 3b, 4, 5 and 
6 sequences. Recently a commercially available test for HCV typing has been developed by 
Innogenetics (Zwijnaarde, Belgium). This assay uses oligonucleotides derived from the 
5’NCR as specific probes for each genotype. Although published data suggest that this line 
probe assay (LiPA) is able to identify HCV subtypes, in its present form, the test would fail 
to distinguish between subtypes 3a and 3b, and to identify gentoype 6 (Andonov and 
Chaudhary, 1995; Stuyver et al.. 1993). The use of restriction fragment length 
polymorphism (RFLP) appears more accommodating to new types ( Nakao et al.. 1991; 
McOmish et al., 1994). With the available sequence data, it is possible to predict a range of 
electropherotypes. This can be used reliably to differentiate genotypes 1, 2, 3,4, 5 and 6, 
and provisionally for subtypes la, lb, 2a, 2b, 3a and 3b (Murphy et al.. 1994; McOmish et 
al., 1994; Dusheiko et al.. 1994; Davidson et al.. 1995). Both RFLP and LiPA are 
methodologically simple and are able to be continuously modified to accommodate new 
major genotypes and subtypes.
Information to date indicates that types 1, 2 and 3 are the predominant 
genotypes infecting blood donors throughout Europe. In particular, type la  and 3a
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infections are more common in Northern countries. Types 2 and 3 are not found in 
Eastern European countries. Interestingly, North America and Australia show a 
remarkably similar genotype distribution to Northern Europe (Simmonds, 1994; Lau et 
aL, 1995; Davidson et al.. 1995). In contrast with Europe and North America, type la  is 
notably absent in the Far East (Japan and Taiwan). Only types lb, 2a and 2b have been 
detected in Japanese blood donors. Type 6a has only been found in Hong Kong and 
neighbouring Macau, although it is believed that future studies will identify a greater 
frequency of type 6 in the Far East. Unlike the Far East, South East Asia shows a 
predominance of type 3 with la  and lb rather than 2. Sequence analysis of type 3 here has 
also revealed several new subtypes as yet untypable. In South Africa, type 5a prevails 
among both black and white blood donors. In contrast, type 4 has been established as the 
predominant genotype in central and North Africa. In particular, HCV infection among 
Egyptians is only by type 4 (Simmonds, 1994; Davidson et al.. 1995).
Whether distinct clinical features of type C hepatitis or the oncogenicity of 
HCV are associated with a particular viral type has not yet been clarified. The issue of 
genotype pathogenicity is complex. Other host and viral factors such as viral load, host 
immunity, age, mode of acquisition or coexistent infection may determine the outcome 
(Dusheiko et al.. 1994., Dusheiko and Simmonds, 1994). It has been suggested that 
infection by ‘Japanese-type HCV’ (HCV type 1, genotype la) is more frequently 
associated with chronic active hepatitis or cirrhosis. Likewise, reports of patients infected 
with HCV type II (genotype lb, HCV Kl), having a lower response rate to interferon 
alpha than patients with HCV type III and IV (genotype 2 and 3, HCV K2a) have been 
made (Simmonds, 1994).
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These are important areas of research. The effect of HCV genotype may be 
interdependent on other factors. Should these findings be confirmed, then the existence of 
geographical variation in the predominant circulating genotypes in different countries 
would lead to the adoption of different treatment policies for patient management. 
Furthermore, the documented antigenic differences between genotypes will have 
important implications for blood donor screening and for the design and composition of 
future candidate vaccines for HCV in different countries
v) Epidemiology of Hepatitis C Virus Infection
Epidemiologic studies show that HCV is efficiently transmitted through the 
transfusion of blood or blood products, the transplantation of organs from infected 
donors and through the sharing of contaminated needles amongst injecting-drug users. 
However, up to 50% of patients with HCV infection report no history of percutaneous 
exposure and are classified as sporadic cases. A number of studies suggest that perinatal, 
sexual, household and occupational transmission does occur but our knowledge of 
transmission in these settings remains incomplete.
There are a number of points to remember when assessing earlier studies on 
transmission. First, many original studies from which prevalence rates for HCV are quoted, 
used first generation assays. Up until 1992, published literature mainly describes the 
epidemiology of HCV based on results from ELISA-1 assays. In a limited number of 
studies, ELISA-1 results were confirmed by RIBA-1. Introduction of second generation 
assays and supplemental tests in later studies are likely to have predicted prevalence rates 
more accurately. Secondly, results obtained from anti-HCV and PCR tests have produced
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discrepancies. However, it should be remembered that the presence of HCV RNA in the 
chronic carrier state does not always correlate with the presence of anti-HCV, and vice- 
versa. The possibility of such discrepancies resulting from false negatives must always be 
considered when comparing prevalence rates between these tests.
The transmission of HCV can conveniently be considered in relation to specific 
routes of infection and the particular groups of individuals at risk of infection.
a) Parenteral Transmission
i) Recipients of Blood and Blood Products
Before the advent of anti-HCV testing (1989), the frequency of post-transfusion 
(PT)-hepatitis in recipients of blood was 10-12% in the USA, 2-4% in Northern Europe 
and 6-18% in the South of Europe (Van der Poel, 1994b). Prospective studies indicated 
that 50-100% of these cases were due to HCV (Van der Poel, 1994b; Kitchen and 
Barbara, 1993). Transmission was linked to the number of units of blood transfused and 
specifically to those units with HCV RNA (Farci etal., 1991; Takano et al.. 1992). 
Routine screening of blood donors for anti-HCV is now performed in almost every 
country that can afford the cost of testing.
Haemodialysis patients are a high risk group because of the dangers of long 
term intensive transfusion therapy. The prevalence of anti-HCV in this group of patients 
varies widely (2.4%- 52%) (Van der Poel, 1994b). Studies of anti-HCV antibodies 
among patients attending dialysis centres have shown a higher prevalence among patients 
in areas with a high prevalence of HCV infection in the general (blood donating) 
population (Tamura et al.. 1990). As yet the mechanism of transmission in haemodialysis 
units remains undefined. Anti-HCV appears to correlate with the duration of the dialysis
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period (Schlipkoter eLal., 1990), and the number of units transfused (Mondelli et al.. 
1990). Patients may have acquired HCV via the blood transfusion or via the dialysis 
procedure itself. However, with the duration of treatment, the chances increase that a 
patient has received transfusions (Van der Poel et al.. 1994b).
ii) Recipients of Products Derived from Large Pools of Plasma
Treatment of haemophilia, thalassaemia and other acquired coagulation disorders 
with untreated blood and blood products is a well recognised route of transmission. With 
the relatively insensitive first generation assays, between 60 and 100% of haemophiliacs 
who had at any time received untreated products were shown to be anti-HCV positive 
(Roggendorf et al.. 1989; Makris et al.. 1990; Lim et al.. 1991). With second generation 
assays, the prevalence of HCV infection in these patients was later recognised as being 
approximately 100%. These patients have a particularly short incubation period. This may 
reflect a higher dose of virus introduced in the pooled concentrate. The introduction of 
heat-inactivated factor VIII and IX concentrates in 1985 has resulted in a dramatic 
decrease in the number of seroconversions (Kitchen and Barbara, 1993; Van der Poel., 
1994b).With the successful treatment of plasma concentrates to inactivate any virus, the 
problem of HCV infection in patients with blood clotting disorders should be solved. 
However, there will remain a residuum of patients who have been infected already.
iii) Through Organ Transplantation
There is now evidence to suggest that HCV infection may be transmitted through 
organ transplantation (Belli et al.. 1993; Chan et al.. 1993; Diethelm et al.. 1992; Konig et 
al., 1992; Muller et al.. 1992; Periera et al.. 1993; Shah et al.. 1992; Silvain etal., 1992;).
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Whether the same risk applies with all organs (liver, heart, kidney and pancreas), remains 
to be seen. Chronic liver disease can be related to HCV positivity in both donors and 
recipients. Screening of potential donors for anti-HCV is now routine. However, 
disagreement exists over whether to accept organs from donors who have anti-HCV but 
no viraemia (Skidmore 1993). As mentioned earlier, not all anti-HCV positive sera are 
PCR positive. However, the problems asssociated with PCR discussed earlier must be 
considered. Rejection of organs on the basis of anti-HCV alone is likely to eliminate a 
number of potential donors who may not transmit HCV infection.
iv) Through Intravenous Drug Use
Exposure through parenteral drug use is now considered to be the major route 
of transmission. This was expected as individuals sharing syringes or needles for 
intravenous drug use have a high risk of infection by parenterally transmitted blood-borne 
infectious agents. Studies worldwide indicate a seroprevalence of approximately 80% 
among intravenous drug users (Kitchen and Barbara, 1993; Van der Poel, 1994b).
v) Through Occupational Exposure
Needlestick injury poses less of a risk of infection with HCV than intravenous 
drug use, probably because there is only a single exposure, and very little blood is 
transferred. Seven cases of HCV transmission to health care workers following 
needlestick injuries have been documented (Seef, 1991; Suzuki et al.. 1994; Tsude et al.. 
1992; Vaglia et al., 1990). In general, there is a low incidence of HCV infection in 
medical personnel even in high prevalence areas (Van der Poel, 1994b). Dentists are
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exposed to blood of numerous patients in the course of their work. One study in New 
York City using first generation assays demonstrated a higher prevalence of seropositivity 
among dentists (1.75%) compared with controls (0.14%) (Klein et al.. 1991). The level of 
seropositivity was especially high among oral surgeons (9.3%), and was also greater in 
those providing dental treatment for large numbers of drug addicts (Klein et al.. 1991). A 
smaller study of 94 dentists in South Wales, UK, failed to detect any who were HCV 
seropositive (Herbet et al.. 1992). Although HCV seroconversion following needlestick 
exposure has been reported, the seroprevalence of HCV among healthcare personnel at 
risk for blood exposure is no greater than that of the general population (Hernandez et al.. 
1992; Norrgren et al.. 1992; Zuckerman et al., 1994).
b) Undefined Routes of Nonparenteral Transmission
i) Sexual Transmission
By analogy with HBV, sexual transmission seemed a likely mode of 
transmission for HCV. Alter and co-workers were the first to suggest that sexual 
transmission had an important role in the spread of HCV (Alter MJ et al.. 1982; 1989; 
1990). Since then other published literature has provided controversial evidence for the 
existence of sexual transmission of HCV in groups with different sexual behaviour.
a) Prostitutes and Patients Attending Clinics for Sexually Transmitted Diseases
Prevalence studies in patients attending clinics for sexually transmitted diseases 
(STD) and prostitutes have shown anti-HCV at a greater prevalence than in blood donors 
(Corona et al.. 1991; Nakashima etal., 1992; Thomas, 1995; Weinstock et a l .. 1993; Wu
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et a l 1993). Transmission in prostitutes and individuals with multiple partners may 
indicate that the risk factor for sexual transmission is the number of partners.
b) Homosexuals
The prevalence of HCV in homosexual men has provided further mixed evidence 
for and against sexual transmission. Early studies prior to the identification of HCV could 
not identify homosexuality as a risk factor for NANBH (Alter MJ et al., 1989). This is in 
sharp contrast to the transmission of HBV and HIV since this is more likely to occur during 
homosexual than during heterosexual intercourse. Later reports on the seroprevalence of 
anti-HCV in homosexual men ranged from 0-50% (Melby et al.. 1990; Osmond et al.. 
1993a; Tedder et al.. 1991). Although accepted as being low, the prevalence is higher than 
that observed in the normal blood donor population.
c) Sexual Contacts of HCV Positive Patients
Reports showing sexual transmission to contacts of HCV seropositive patients 
have so far been controversial. (Akahane et al.. 1992; 1994; Brackmann et al., 1993; 
Bresters et a l ., 1993; Hallam et al.. 1993; Kao et al., 1992; Kolho et al., 1991; Osmond 
et al.. 1993b; Pachuki et al.. 1991; Peano et al.. 1992; Scaraggi et a l .. 1993; Seef and 
Alter, 1994). Evidence for transmission is supported by reports of an increase in anti- 
HCV prevalence with increasing age (Nishioka et al.. 1991; Lee et al., 1991). More 
recently, the frequency of HCV infection has been reported to correlate with the duration 
of relationship (Akahane et a l .. 1994; Oshita et al.. 1993). Whether a preference exists 
for the direction of transmission, from male to female or vice-versa, is undecided.
Osmond and co-workers reported transmission from male to female as being more
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efficient (Osmond etal., 1993b). On the other hand, Kao et al found the converse true 
(Kao e ta f , 1992).
Overall, sexual transmission of HCV does occur to some extent although it does 
not seem to be an efficient route of transmission.
It is not clear whether the divergent results are due to differences in susceptibility 
of different populations to HCV infections, differences in the level of infectivity in 
patients, or infection with different strains of HCV that may have different degrees of 
infectivity. It has been suggested that as a result of low levels of circulating HCV, 
transmission is more likely if exposure is repetitive and extended over a long period of 
time (Akahane et al., 1994). It is known that levels of viraemia fluctuate widely and, 
therefore, transmission may occur only at times of high levels of viraemia. Indirect 
evidence for this comes from studies of partners of patients infected with both HCV and 
HIV. Anti-HCV positivity is significantly associated with the presence of anti-HIV in all 
studies. HIV may be a cofactor for transmission. Similar reports identify a sexual partner 
belonging to a 'high-risk' group for HIV infection as a risk factor for HCV (Van Doornum 
et al..l991). The assumption is that HCV concentrations are higher in the 
immunocompromised host. A number of studies, however, have been unable to confirm 
that HIV acts as a cofactor for sexual transmission of HCV (Hallam et al., 1993; Scaraggi 
et al.. 1993).
As mentioned before, early studies based on first generation serological tests may 
be inaccurate due to the lack of sensitivity and specificity. In addition, other risk factors 
for HCV infection have often not been excluded. In particular, reports of previous 
episodes of parenteral exposure are often inaccurate, especially in studies of homosexual 
men, prostitutes and STD clients where histories of past intravenous drug use may not be
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available. Later studies have employed nucleotide sequence analysis within dually 
infected couples (Akahane et al.. 1994; Healey et al.. 1995; Kao etal., 1993; Riceet 
al., 1993). However, the finding of conserved HCV subtypes among two infected spouses 
at best only indicates that both spouses may have been infected with the same isolate, but 
this is not proof of sexual transmission. Nonetheless, on the evidence of the published 
material there is general agreement that if sexual transmission does occur, then it is at a 
significantly lower frequency than HIV, HBV, and other STDs.
ii) Vertical (mother-to-child) Transmission
With the initial tests, vertical transmission of HCV was difficult to assess. The 
advent of PCR has provided the ability to detect, genotype and compare virus sequences to 
determine the similarity of HCV strains isolated in mother-child pairs (Inoue et a l .. 1992; 
Novati et a l .. 1992; Ohto et al.. 1994; Weiner et al., 1993). The incidence of vertical 
transmission of HCV has also been shown to be increased in cases of HIV co-infection in 
the mother (Kao et al.. 1992; Weintrub et al.. 1990; Zanetti et al.. 1995). It is likely that an 
anti-HIV positive woman would have a higher rate of HCV replication because of 
immunodeficiency. Thus, the risk of vertical transmission of HCV may be dose related, 
occurring only when the mother has high levels of viraemia. Ohto and associates reported 
that in their study no woman whose titre of HCV RNA was below 106 per milliliter 
transmitted the virus to her infant (Ohto et al.. 1994). Exactly how and when the virus is 
transferred has not yet been studied, but transplacental transmission, transmission at birth, 
and post-partum transmission have all to be considered.
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iii) Intrafamilial (household) Spread
Person-to-person spread by nonsexual household contacts is very rare. The Centre 
for Disease Control could only associate 3% of patients with household exposure (Alter 
MJ et a l .. 1990). However, intrafamilial transmission does appear to occur. Reports of 
anti-HCV seroprevalence in family members of HCV positive patients vary from 8-23% 
(Bellobuono etal., 1991; Honda et al.. 1993; Ho et al.. 1994; Nishiguchi et al.. 1992; 
Oshita et al.. 1993). The inaccuracy of reporting episodes of intravenous drug use or covert 
percutaneous exposure for example sharing razors or toothbrushes serves to confound 
many of these studies and the actual route of transmission in such situations remains to be 
established.
With all the controversial data on the transmission patterns of community 
acquired HCV, experimental methods using animal models and studies of body fluids other 
than blood have been used increasingly as a means for evaluating possible nonparenteral 
routes of transmission. Transmission of HCV has been demonstrated in chimpanzee 
experiments (Abe and Inchauspe., 1991; Abe et al.. 1987). A recent study, however, failed 
to show conclusive evidence of sexual or mother-to-infant transmission in a colony of 
chimpanzees (Suzuki et al.. 1993). Acute HCV infection following a human bite has been 
documented (Dusheiko et al.. 1990; Figueiredo et a l .. 1994). Although this indicates that 
saliva is a potential source of infection, one should consider that in the quoted studies, 
saliva was inoculated into the recipient rather than ingested. Whether ingestion results in 
the same level of infection has not been considered. Using PCR, other investigators have 
also reported the presence of HCV RNA in saliva and salivary glands of patients with 
hepatitis C (Chen et a l .. 1995; Couzigou et al.. 1993; Liou et al.. 1992; Mariette et a l ., 
1995; Numato et a l .. 1993; Punchammer-Stockl et al.. 1993; Takamatsu et al.. 1991; 1992;
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Thieme et a l 1992; Wang et al.. 1991; 1992a;). The source of HCV RNA in saliva is 
unclear. Apart from contamination of saliva with blood, transudation of fluid containing 
virus from the general circulation and active viral replication at the site of secretion must 
all be considered.
If sexual or personal contact were an important mode of transmission, one would 
expect HCV to be present in not only saliva but other body secretions too. Indeed,
PCR has been successful in detecting HCV RNA in various body fluids including urine and 
semen (Liou et al.. 1992; Kotwal et al.. 1992; Numato et al.. 1993; Punchammer-Stochl et 
al., 1994). However, in 19 patients with chronic HCV infection and who tested positive for 
HCV RNA in serum, viral RNA was not detected in any sample of saliva, semen, urine, 
stool or vaginal secretions (Hsu et al.. 1991). In another study, HCV RNA was also absent 
from the semen of patients with chronic hepatitis C, even though it was present in serum 
(Fried et al.. 1992). One must remember, however, the problems associated with PCR and 
consider these when interpreting the data.
vi) Natural Course of Hepatitis C Virus Infection
Few patients with acute hepatitis C infection develop clinical illness with 
jaundice. The majority of infections remain undetected as a result of most having 
subclinical or mild features. Although clinically indistinguishable from other forms of 
viral hepatitis, HCV has an incubation period shorter than that seen with HBV (8-24 
weeks) and longer than HAV (2-6 weeks). Despite its relatively mild nature, acute hepatitis 
C infection has a propensity to become chronic. Early post-transfusion studies using serum 
alanine aminotransferase (ALT) levels as an indicator for persistence estimated progression 
to chronicity in -50% of cases (Berman et al.. 1979). Later studies monitoring HCV RNA
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estimate that persistent infection occurs in the majority of infected individuals (Cordoba et 
a l 1994; Sherlock, 1994)
Although few studies have examined chronicity in sporadic HCV infection, 
progression to cirrhosis and possibly hepatocellular carcinoma (HCC) can occur 
regardless of how the disease was initially contracted. As yet the mechanism for this high 
chronicity rate in HCV infections is not well defined, although host and viral factors such 
as the size of the infectious inoculum at the initial infection, infecting HCV genotypes and 
the ability of the virus to evade the host’s immunosurveillance system have all been 
considered (Kivosawa et al.. 1994). Chronic persistent hepatitis (CPH), will eventually 
progress to chronic active hepatitis (CAH) and cirrhosis over 10-20 years. Liver biopsies 
often reveal CAH in -60% of chronically infected patients and cirrhosis in -20% (Di 
Bisceglie et al.. 1991; Mattsson et al.. 1993). Most patients are asymptomatic until they 
develop advanced liver disease. Symptoms such as fatigue and liver tenderness are rarely 
observed. More commonly, infection is noticed as a biochemical disease, with fluctuating 
ALT levels, appearing normal at times, and slowly progressive histopathological findings. 
The progression from CPH to CAH to cirrhosis and, finally, to fatal hepatocellular 
carcinoma in some individuals with HCV infection is well established from several 
studies, although the actual role of HCV in the development of HCC remains unknown. 
HCV has neither reverse transcriptase activity nor a viral oncogene. It is believed that 
HCV most likely influences the development of carcinogenesis through the activation of 
proto-oncogenes and inactivation of suppressor genes during the regeneration of 
continuously damaged cells in CAH (Kiyosawa and Furuta, 1994)
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vii) Treatment of Hepatitis C Virus with Interferon
Interferons (IFNs) are natural proteins with anti-viral, anti-tumour, and 
immunomodulatory functions. IFNs consist of three families of proteins (alpha, beta and 
gamma) (Bresters, 1994; Dianzini, 1993; Finter etal., 1994). So far alpha, and to a lesser 
extent beta, IFNs have been used successfully for the treatment of chronic HCV infection. 
IFN is believed to work by its antiviral activity on the primary cytopathic HCV rather than 
through an immune modulatory mechanism (unlike its effect on HBV) (Rubin et al..
1994). Since the original pilot study in 1986 (Hoofnagle et al.. 1986), numerous trials have 
confirmed the suppressive effect of interferon on disease activity and its ability to induce 
remission. Prolonged therapy with interferon leads to improvement in approximately 50% 
of patients. However, a sustained response is only maintained in 10-25% (Bresters, 1994).
Although IFNa is now considered the therapy of choice for chronic hepatitis C, 
there are several unanswered questions concerning its use, as follows
a) Who to Treat
At present, IFNa cannot be recommended for all patients. EFNa is licensed for 
the treatment of those who have serological evidence of disease, elevated serum 
aminotransferase activity, chronic hepatitis C by liver biopsy, and no other serious 
complicating liver illness (Hoofnagle et al.. 1993; Mutimer et al.. 1993). Those criteria 
for selection eliminate some patients who may deserve treatment, such as patients with 
acute hepatitis C, those with advanced cirrhosis, those with normal transaminase levels, 
those who are immunosuppressed and patients who are anti-HCV negative.
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i) Patients with Acute Hepatitis C
Although HCV causes very little symptomatic disease, progression to chronic 
hepatitis C with persistence of viraemia is common. For this reason, treatment to prevent 
chronicity and the associated liver injury of chronic hepatitis would be justified. Few 
studies have examined the role of IFN for acute hepatitis C (Esteban, 1993; Hwang et al.. 
1994; Lampertico et a l .. 1994; Omata et al.. 1991). All have been small trials, examining 
different types and doses of interferon. A recent study by Tassopoulos and colleagues 
reported the failure of IFN-a2b to prevent progression to chronic hepatitis C in anti-HCV 
positive cases (Tassopoulos et al.. 1993). Colombo and associates also report short term 
improvement that fades with time after IFN withdrawal (Colombo et al.. 1993). Studies 
suggest the benefit of IFN therapy, but in practice few cases are treated. Arguments against 
treatment include the unnecessary expense and side effects of treatment in a group of 
patients where recovery may occur spontaneously. However, where it is clear that the 
disease is not resolving normally, therapy should be considered.
ii) Patients with Decompensated Liver Disease
Patients with early or mildly decompensated liver cirrhosis can respond to therapy 
(Jouet et a l .. 1994). However, these patients do suffer troublesome side effects and often 
therapy does not reverse the established cirrhosis and end stage liver disease.
iii) Children with Chronic Hepatitis C
Chronic hepatitis C is rare in childhood. However, it has been indicated that 
children will respond and tolerate IFN in the same way as adults and recommendations for 
treatment are the same (Ruiz-Moreno et al., 1992).
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iv) Patients with Atypical Serology
Treatment of patients with atypical serology raises another problem. The 
sensitivity and specificity of serological investigation has improved with the development 
of second and third generation anti-HCV tests. However, as mentioned earlier, some 
patients with chronic hepatitis C can test negative for anti-HCV (false negatives). On the 
other hand, some other forms of liver disease (autoimmune hepatitis or alchoholic liver 
disease) will test positive by ELISA due to a non-specific reaction (McFarlane et al.. 
1990). It is important to exclude patients with autoimmune disease, as treatment with IFN 
will cause the disease to worsen (Lenzi et al „ 1990). The availability of PCR has 
enabled direct identification of viraemic individuals. However, this expensive technique 
is not available in all areas and as mentioned earlier, is itself not without problems.
v) Immunosuppressed Patients
An important group of patients are those who have HIV, have received an organ 
transplant, or who are receiving immunosuppressive therapy. Few studies report 
treatment of these patients. Results indicate that HCV disease progresses more rapidly in 
the presence of HIV co-infection, suggesting that IFN may be an appropriate therapy in 
such cases. Indeed, studies have shown IFN to be beneficial in patients who have both 
HCV and HIV (Boyer et al., 1992; Marriott et al.. 1993). This is in contrast to a poor 
response observed in immunocompromised patients with chronic hepatitis B infection. 
This may be explained by the different pathological mechanisms of hepatitis B and C.
The stage of HIV disease may also be an important factor in the response to IFN, an 
aspect which requires clarification.
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Reports suggest that recurrent hepatitis C following organ transplantation can be 
suppressed by therapy with alpha interferon even in the presence of large doses of 
immunosuppressive medication (Wright et al.. 1992)
b) Dose and Duration of Treatment
The dose and duration of therapy remain undecided and are likely to vary with 
different patients. Currently, 3MU subcutaneously thrice weekly for 6 months is 
recommended. However, this dose has been shown to be inadequate in inducing a 
sustained response, or even a response at all. The use of a higher dose can increase 
response rates during treatment. Introduction of IFN at a higher dose, followed by a 
lower dose regime has also been reported as beneficial (Bresters, 1994).
There is also uncertainty on how long therapy should be continued in order to 
minimise relapse following treatment cessation. Some studies have shown that prolonged 
treatment courses improve sustained response rates (Bresters, 1994).
c) Side Effects
Interferon has many side effects, but most are self-limiting and tolerable, and 
almost all are rapidly and fully reversible when the drug is stopped (Hoofnagle, 1993). 
Side effects are dose-dependent and may vary with different patients. The typical dose of 
3MU three times weekly is tolerated well by most patients. In general, early side effects 
are flu-like symptoms which develop 6-8 hours after IFN is given. These features all tend 
to disappear 2-4 weeks into the course of treatment. More troublesome are the long-term 
effects like fatigue, depression, insomnia, anorexia, nausea, irritability, lack of energy and 
alopecia. Although numerous side-effects have been noted, it is rare that all are
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encountered during therapy. Serious side effects are uncommon. These include induction 
of autoimmunity and autoimmune diseases, increased susceptibility to infections and 
severe psychiatric syndromes (Hoofnagle, 1993).
d) Monitoring Treatment
IFN is an effective treatment. However, a long term response is observed in only 
10-25% of patients. Coupled to this, there are difficulties of administration, expense and 
dose-limiting side effects. These problems underline the need for reliable markers to 
assess and monitor therapy. Several potential means for monitoring therapy have been 
examined.
i) Serum Aminotransferase Levels and Liver Histology
Serum aminotransferase levels and liver histology are the commonest features 
monitored. Although good predictors of initial response, they do not predict a sustained 
response (Hoofnagle, 1993). Discrepancies between biochemical and virological 
responses to IFN are also common (Kakumu et a l .. 1993; Liang et al.. 1993; Pawlotsky 
et al., 1994; Picciotto et al.. 1994).
ii) Serum Antibodies to Hepatitis C Virus
Early reports using titres of anti-HCV as a marker indicated that these did not 
change in a consistent manner during treatment (Di Biscegli, 1991; Hoofnagle et al.. 
1993). More recently, preliminary reports have suggested that IgM anti-HCV decreases 
and often disappears in patients with a sustained response but not in those without a 
response or undergoing a transient response (Brillanti et al.. 1992; Nakano et al.. 1993).
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Similar reports suggested that IgG anti-HCV, in particular IgG anti-HCV core, decreased 
in those with sustained clearance (Yuki et al.. 1993; Urushihara et al.. 1994). These 
findings have yet to be confirmed.
iii) HCV RNA Qualitatively and Quantitatively in Serum
The advent of PCR has enabled the presence and the quantity of HCV RNA to 
be monitored during therapy. Retrospective analysis of stored serum from patients 
receiving treatment has shown levels of RNA to decrease and become undetectable in 
those with a good response (Aiyama et al.. 1994 ; Balart et al.. 1993; Yamada et al..
1992). However, loss of HCV RNA in the serum does not predict a sustained response. 
Results have shown that a negative result in PCR does not rule out the presence of low 
level replication of HCV, below the level of sensitivity of the PCR procedure. The 
introduction of a quantitative branched DNA (bDNA) assay may help this problem. This 
assay can quantify HCV RNA to a similar limit of detection as PCR (Davies et a l ..
1992; Li et al.. 1993; Lau et al.. 1993). However, it does lack sensitivity with low viral 
titres (Bresters et a l .. 1994).
iv) HCV RNA Qualitatively and Quantitatively in the Liver and Peripheral 
Mononuclear Cells
Studies have suggested that the presence of HCV RNA in the liver and 
lymphoid cells is a more sensitive marker to determine a sustained response following 
treatment cessation (Balart et al.. 1993; Di Bisceglie et al.. 1993; Gil et al.. 1993; Muller, 
et a l .. 1993; Qian et al.. 1992; Saleh et al.. 1994). It is possible that lymphoid cells 
represent extrahepatic sites of HCV replication where the antiviral effects of IFN are
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limited. If so, the presence of HCV in such sites will need to be monitored to ensure 
complete clearance of the virus. Utilization of liver HCV RNA would provide the most 
specific marker of a sustained response. However, tissue assays are impractical as they 
require a biopsy or serial biopsies, are expensive and unacceptable to the majority of 
patients.
e) Predictors of Response
It would be advantageous if one could identify those patients who are likely to 
have a beneficial response, and those who are likely to sustain this improvement when 
therapy is stopped. Previous studies have been unable to establish clearly if there are any 
pre-treatment variables that might predict response. Shorter disease duration prior to 
treatment, female gender, obesity, less pronounced liver inflammation and absence of 
cirrhosis have been claimed to predict a good response (Reichard et al.. 1994; Hoofnagle et 
al., 1986). However, with the exception of cirrhosis, none have been proven indisputably to 
be of importance (Camps et al.. 1993). Recently, the genotype of HCV and the initial viral 
load have been reported as being good predictors of response (Tsubota et a l .. 1994; 
Chemello et a l .. 1994; Kobavashi et al.. 1992; Yamada et al.. 1992; Lau et al.. 1993; Hino 
et al.. 1994; Yoshioka et al.. 1992). Patients infected with genotype II (type lb), appear to 
respond less well than patients infected with other genotypes (Chemello et a l .. 1994; 
Yoshioka et al.. 1992; Mita et al.. 1994; Hino et al.. 1994). These patients also appear to 
have higher HCV RNA titres (Lau et a l ., 1994; Yoshioka et al., 1992; Hino et al.. 1994). 
Reports have also suggested a better rate of response to IFN in those infected by a single 
HCV type. The quasi-species nature of HCV may allow IFN to exert a selective pressure 
inducing HCV to undergo changes in its population diversity (Taniguchi et al.. 1993;
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Camps et al.. 1993a). This may manifest itself clinically in a relapse following 
treatment.The production of anti-interferon neutralising antibodies may also influence 
response. Occasionally, specific antibodies against recombinant IFN (anti-IFN), are 
demonstrated in patients who do not respond or relapse after an initial response (Antonelli 
et al., 1991; Inglada etal., 1987). The proportion of treated patients who develop anti-IFN 
is variable and likely to be due to variations in IFN preparation or dose schedule. 
Recombinant interferon alpha-2a (ROFERON, Roche) appears to induce neutralising 
antibodies more often than interferon alpha-2b (INTRON, Schering-Plough), or 
lymphoblastoid-derived interferon alpha (Milella et al.. 1993; Camps et al.. 1993a; 
Antonella et al., 1991). The clinical relevance of these antibodies remains to be established. 
Some patients appear unaffected by their production. In others, a breakthrough response 
has been described as a consequence of anti-IFN formation (Milella et al.. 1993; Camps et 
ah, 1993a).
The mechanism for relapse following treatment cessation remains unknown. No 
biochemical, serological or histological feature will predict a sustained response (Lau et al.. 
1994; Shindo et al.. 1991).
viii) Other Antiviral Therapies
At the moment IFN is the only recommended therapy. However, other antiviral 
agents have been considered.
a) Ribavirin
Although costly, ribavirin is absorbed orally, is well tolerated and has known 
activity against many RNA viruses including some flaviviruses. However, studies report a
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similar level of response to ribavirin as to IFN (Di Biscegli, 1992; Reichard et al.. 1993; 
Camps et al.. 1993b).
b) Inosine
Inosine has some direct antiviral activity as well as being able to enhance the 
cellular immune system by influencing Interleukin-2 (IL-2) production and receptor 
expression. One study reported the treatment of chronic liver disease with inosine, 
resulting in the reduction of transaminase levels and absence of HCV RNA, but anti- 
HCV remained (Trohaska et al.. 1991).
c) Corticosteroid
Corticosteroid therapy was given to patients with NANB hepatitis prior to the 
discovery of HCV markers. Response was variable, but no controlled trials were 
documented.
Further studies are needed to assess new and old antiviral agents alone or in 
combination with IFN.
ix) HCV Vaccines
Without an effective and reliable cell-culture system for HCV, an inactivated, 
whole-virus vaccine is not yet possible. Likewise, the scarcity of suitable primate hosts 
and the lack of markers of virulence and attenuation limits the prospect for a live 
attenuated vaccine. Therefore, a vaccine based on recombinant DNA technology appears 
to be the way forward. Techniques based on approaches used for preparing vaccines
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against flaviviruses and pestiviruses should be employed (Zuckerman and Zuckerman,
1995). Any effective HCV vaccine will need to induce immune responses against 
multiple strains, whether through recognition of conserved regions among isolates, the 
inclusion of multiple epitopes in a single vaccine or both. Initial studies are hopeful 
(Choo et al.. 1994). Many problems remain to be overcome and important questions still 
to be resolved. For example, if a vaccine becomes available, who should be vaccinated 
and when:,
SALIVA
Saliva is a combination of the secretions of three pairs of major glands, the 
parotid, the submandibular and the sublingual glands, together with the secretions of the 
minor salivary glands, exogenous elements like serous transudate, cells, micro-organisms 
and food particles ( Levine, 1993; Haeckel, 1989).
i) Salivary Secretion
Salivary glands are composed of two general regions, the acinar and ductal (Figure 
1.3). Saliva formation occurs in two stages. The first stage takes place in the acinar region 
and generates an isotonic primary fluid, rich in exocrine proteins. All secretion 
occurs in response to neurotransmitter stimulation. There is no spontaneous salivary 
secretion (Baum, 1993). The second stage of salivation is fluid modification during passage 
through the ductal region. This includes electrolyte flux, as well as secretion of additional 
proteins. The saliva which finally enters the mouth is markedly hypotonic containing, on 
average, ~25mEq/L of NaCl and -2-5 mg/ml protein (Kaplan and Baum, 1993).
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Schematic depiction of saliva formation in the two general regions of the 
salivary gland.
Stimulation also affects many other acinar cell functions such as intermediary metabolism, 
protein synthesis, secretory protein N-glycosylation and membrane transport protein 
activity. Such broad responsiveness can influence the movement of many compounds from 
the blood into saliva.
Saliva has several specific, essential functions including protection of dentition 
and mucosa, antimicrobial action, facilitation of digestion, physical cleansing and 
buffering. These properties are generally mediated by specific proteins. However, most 
proteins are multifunctional, enabling large variations in the concentration of different 
components without affecting the overall protective qualities of saliva.
Salivary constituents (fluid, electrolytes and proteins) are found in saliva as a 
result of specific, tightly regulated processes. Very little appears accidentally or by leakage, 
although this is the case for low molecular weight serum constituents found in trace 
levels in secretions from healthy glands. These levels increase several fold with disease 
and in particular with inflammatory conditions.
ii) Testing for Salivary Antibodies
Mixed saliva contains primarily secretory IgA (slgA) and low levels of IgG and 
IgM. Most of this IgG and IgM is derived from gingival crevicular fluid via transudation 
from local blood capillaries (Challacombe et al.. 1978), and as such, for the purpose of 
diagnosis may be regarded as a dilution of a subject’s plasma.
Interest in salivary antiviral antibodies was initiated by Archibald et al (1986). 
Since then, salivary IgG antibodies have been detected against HAV (Parry et al.. 1987, 
1988; 1989; Piacentini et al.. 1993), HBV (Parry et al., 1987; 1988; 1989; 1993; Piacentini 
et al.. 1993), rubella, mumps and measles viruses (Parry et al.. 1987; Parry, 1993), and
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HCV (Parry, 1993; Piacentini et al.. 1993; Thieme et al.. 1992) at a rate comparable to that 
of serum testing. Despite this, salivary testing has only been considered seriously for HIV 
testing. Several kits developed for serum/plasma testing have been modified to allow their 
application to saliva. As yet, few commercial anti-HIV assay have been developed for the 
sole purpose of salivary testing. Tests for salivary IgM have also been developed for HAV 
and HBV, and for mumps, measles and rubella (Parry, 1993).
iii) Testing for Salivary Antigens
In addition to measuring antibody, there is growing interest in identifying antigens 
in saliva. Apart from being a more specific indicator of infection, diagnosis can often be 
made long before the subject has seroconverted. Application of the polymerase chain 
reaction (PCR) has provided a powerful tool for amplication of viral nucleic acid in blood. 
However, researchers have indicated the presence of a PCR interfering substance in the 
saliva (Warren et al.. 1992; Ochert et al.. 1994).
A Specimen of Convenience
Most diagnosis of disease needs some type of testing of a body fluid or tissue. At 
present, blood is the fluid of choice, used for a wide range of diagnostic tests. Saliva testing 
is limited to a few distinct clinical conditions (Mortimer and Parry, 1988; Parry, 1993). 
However, with the increasing recognition of the risk of disease transmission associated 
with needlestick injuries and the relative inconvenience of obtaining blood samples, 
particularly among haemophiliacs, serological testing has become unattractive. Saliva 
testing has emerged as the forerunner in the search for a reliable, non-invasive specimen. 
The main advantages of saliva over blood are:
45
1) Greater subject acceptability - less painful and traumatic
2) Convenience - rapid, simple and inexpensive. Collection does not necessarily 
have to be in a clinical environment.
3) Collection is less hazardous to both the subject and the investigator.
4) Easier access to hard-to-reach populations (eg IVDU, prostitutes) and large 
populations (eg clinic attenders).
Lack of knowledge about the normal content of saliva, as compared with serum, 
low target concentration and inadequate sample volume have all delayed widespread 
acceptance of saliva testing. Saliva is certainly not sterile and contains many degradative 
enzymes. As a result, organic components are susceptible to rapid degradation unless the 
saliva is sterilized or the degradative enzymes inactivated (Dawes, 1993; Kaplan and 
Baum, 1993; Goodman, 1993). Of course, such treatment may affect the component of 
interest. However, with current advances in technology, highly sensitive tests have been 
developed such that low concentration and small sample volume are no longer limiting 
factors. Methods for saliva collection giving stabilized specimens of consistent quality are 
also being continually improved. As a result of such progress, saliva is now being 
considered as a useful test fluid.
Salivary Testing for Hepatitis C Virus
In recent years, there has been increasing interest in the shedding of viruses in 
saliva. Such shedding has obvious implications for the spread of infection and 
understanding of the epidemiology of infectious diseases. More recently, the value of saliva 
as a diagnostic fluid has become increasingly apparent. Both of these issues are currently of 
interest in relation to HCV, because of our poor understanding of the epidemiology of
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infection with this organism. Despite our knowledge of the transmission of HC V, up to 
40% of HCV-seropositive patients have become infected by an unknown route. One 
potential mode of transmission is via body secretions such as saliva. A number of studies 
have evaluated saliva, amongst other body fluids, for HCV testing. By making minor 
modifications to the commercially available serological test kits, some researchers have 
been able to demonstrate anti-HCV in saliva (Sherman etal., 1994; Thieme et al.. 1992). 
Problems with low concentrations of HCV in saliva and small sample volume have been 
resolved by the development of PCR. Using PCR, the successful detection of HCV RNA in 
saliva has been reported (Chen et a l .. 1995; Couzigou et a l .. 1993; Liou et al.. 1992; 
Mariette et a l ., 1995; Numato et al.. 1993; Punchammer-Stockl et al.. 1994; Takamatsu et 
aL., 1991; Thieme et a l .. 1992; Wang et a l .. 1991; 1992a; Young KC etal., 1993). 
However, similar studies by other workers report the absence of HCV RNA in saliva (Hsu 
et al.. 1991; Fried et al., 1992). These discrepant results obtained by previous studies may 
be a reflection of the methods used to collect and handle the samples.
This study sought to answer the following questions:
1. Is hepatitis C virus present in the saliva of all HCV-seropositive 
patients ?
2. What is the most appropriate method for collection of saliva to 
provide stable specimens of consistent quality ?
3. Would it be feasible to introduce PCR testing of saliva for HCV into a 
routine diagnostic laboratory ?
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Chapter 2 
General Materials and Methods
The materials and methods described in this Chapter are those routinely used throughout 
the studies in this thesis. Modifications and methods specifically related to work in 
individual chapters are described in detail in the Materials and Methods section of the 
relevant chapter.
MATERIALS
Consumables used during the course of the studies presented in this thesis were 
obtained from the sources listed below:
DNA
Oligonucleotide primers Oswel DNA Services, University of Edinburgh, Scotland; 
Cruachem Ltd, Todd Campus, West of Scotland Science Park, Acre Road, Glasgow, 
Scotland
Modifying Enzymes
Taq polymerase, Tth polymerase Promega Corporation, Southampton , UK.
Molony Murine Leukaemia Virus (MMLV) reverse transcriptase:- GIBCO-BRL, Life 
Technologies Ltd, Paisley, Scotland.
Dynazyme:- Flowgen Instruments Ltd, Kent, UK.
Chemicals
p-mercaptoethanol, N-lauryl sarcosine, isoamyl alcohol, potassium chloride, magnesium 
chloride, tris base, ethidium bromide, boric acid, EDTA, sodium hydroxide, sodium
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chloride, lithium chloride, taurine, sodium citrate, sodium dodecyl sulphhate, maleic acid, 
diethylpyrocarbonate (DEPC), light mineral o i lS IG M A ,  Dorset, UK.
Guanidine isothiocyanate solution, yeast tRNA, agarose,:- GIBCO-BRL, Life Technologies 
Ltd, Paisley Scotland.
Water saturated phenolRathbum  Chemicals Ltd, Walkerbum, UK.
Nusieve® GTG® Agarose, dynawax Flowgen Instruments Ltd, Kent, UK.
Acetic acid, chloroform, ethanol, methanol, replicote VS, sdtLO BDH Ltd, Poole, UK. 
Acrylamide, ammonium persulphate, bind silane, methylenebis-acrylamide, urea, 
RNAguard® Rnase inhibitor, temed, ultrapure dNTP set 2’-deoxynucleotide 5’- 
triphosphate :-Pharmacia Biotech Ltd, Milton Keynes,UK.
Radioisotopes
[a-35 S] dATP :- Amersham International pic, Buckinghamshire, UK 
Miscellaneous Items
Polaroid film type 667 :- SIGMA, Dorset, UK.
Salivette™ :- Sarstedt, Leicester, UK.
Omnisal™ :- SDS International Ltd, Sovereign Court, London, UK 
Digoxigenin DNA labelling and detection kit, positively charged nylon membrane:- 
Boerhinger Mannheim UK Ltd, East Sussex, UK
Precut filter and blotting pack :- Anachem, Anachem House, Charles Street, Luton, Beds, 
UK
Sequenase PCR product sequencing kit, Hyperfilm™- MP :- Amersham International pic, 
Buckinghamshire, UK
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Nucleic Acid Purification Systems 
QIAamp® Blood K i tQ IA G E N  Ltd, Surrey, UK
GLASSMAX RNA microisolation Spin Cartridge System:- GIBCO-BRL, Life 
Technologies Ltd, Paisley, Scotland
METHODS
Sample collection
For the purpose of this research, the nomenclature used from here on is in 
accordance with that agreed at the New York Academy of Sciences 1992 conference on 
Saliva as a Diagnostic Fluid (Atkinson et a l .. 1993).
i) Whole saliva : The fluid obtained from the mouth by expectoration. Whole unstimulated 
saliva was collected by the spitting method. Saliva was allowed to accumulate in the floor 
of the mouth and the subject spat it out into a sterile plastic Universal container. The whole 
saliva was centrifuged (4000rpm, 5 minutes) the supernate collected and the pellet 
resuspended in 1ml sterile distilled water (sdHiO).
ii) Oral fluid : The fluid obtained by insertion of absorptive collectors into the mouth and 
subsequent removal of the fluid by pressure or centrifugation. Saliva was obtained from a 
Salivette™ by centrifugation (4000rpm, 5 min).
All samples were aliquoted and frozen (-20°C) within 3 hours of collection. Examples of 
these devices are given in Figure 2.1
iii) Blood specimens A clotted blood sample was initially transported to Ruchill Regional 
Virus Laboratory, separated, and the serum stored at -20°C.
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Reverse transcription
On ice, a master mix containing all the reagents less the RNA was set up as shown 
in Table 2.2. Ten microliters of master mix were aliquoted into each reaction tube and 
IOjliI of template RNA was added using a positive displacement pipette. Reverse 
transcription was carried out at 37°C for 30 minutes in a Hybaid Omnigene System 
(Hybaid). The RNA template was destroyed by a further incubation for 10 minutes at 
95°C. Samples were next plunged into ice and the reaction product (cDNA), collected by 
brief centrifugation. The cDNA obtained was then used as a template for PCR 
amplification.
Nested-set polymerase chain reaction
Samples were amplified using two pairs of nested primers from the highly 
conserved 5’ NCR of the genome (Chan et al 1992). Details of the primers are given in 
Table 2.3.
I) First round: PCR was performed over 25 cycles, each consisting of 36 seconds at 94°C, 
42 seconds at 52°C and 3 minutes at 68°C. On ice, a master mix containing all the reagents 
less the cDNA was set up as shown in Table 2.4. The master mix was dispensed in 90pi 
aliquots into each reaction tube and 10|il of template cDNA was added using a dedicated 
positive displacement pipette. 65pl of light mineral oil was layered on top to prevent 
evaporation during the reaction.
ii) Second round: One microliter of the first round reaction mixture was amplified for a 
further 25 cycles with the same cycling programme using the inner pair of nested primers. 
On ice, the same master mix as before was supplemented with 200fiM each of dATP,
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dCTP, dGTP, dTTP (Table 2.4), and dispensed in 99|il aliquots into each reaction tube. 
Amplified DNA (252 bp) was detected by agarose gel electrophoresis and ethidium 
bromide staining.
Agarose gel electrophoresis
Agarose gel electrophoresis was carried out on horizontal agarose gel slabs 
submerged in lx TBE electrophoresis buffer (Table 2.1). Agarose (lg) and Nusieve®
GTG® Agarose (3g) was dissolved to a final concentration of 4% in lxTBE buffer 
(100ml) by heating in a microwave oven. To the molten agarose, ethidium bromide was 
added to a final concentration of l(xg/ml. After cooling, the molten agarose was poured into 
the gel box. After the gel had solidified, the gel was submerged in the electrophoresis 
buffer. Gels were run at a constant voltage of 76V for a minimum of 2 hours. DNA was 
visualised on a UV TM-40 transilluminator (UVP inc, USA) at 302nm and photographed 
using polaroid type 667 film. Unless otherwise stated, all gels shown in this thesis were 4% 
and run in lx TBE at 76V.
Contamination controls
Control experiments were carried out with every PCR experiment. One HCV RNA positive 
control was included from the start of every procedure to ensure the efficiency and 
specificity of RNA extraction, RT and PCR. Three negative controls were included to 
check the RT and the first and second round PCR reagents for contamination.
To avoid contamination of the RT and PCR, all experiments were set up in a 
laminar flow cabinet. All equipment was UV irradiated for 10 min with ^OOpJmin'1 at 
254nm in a UV crosslinker prior to use. Equipment and reagents used in setting up PCRs
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were prepared in batches and aliquoted for storage in convenient-sized lots to prevent 
contamination of stock solution. All liquids were handled using plugged tips to prevent 
aerosols reaching the inside of the pipette itself. All RNA, cDNA and first round product 
were handled using dedicated positive-displacement pipettes.
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TABLE 2.1 
General Stock Solutions and Buffers
lQx Reverse Transcription Buffer
1M KC1 5 ml
1M MgCl2 0.25ml
1M TrisHCl (pH 8.0) 0.25ml
Store at -20°C in IOOjj.1 aliquots. Use at a final concentration of lx
lQx TBE
Tris base 108g
Boric acid 55g
0.5M EDTA (pH 8.0) 40ml
dH20  to 1 litre
Use at a final concentration of lx 
lOmM dNTPs ( T  deoxynucleotide 5’triphosphate) 
dATP lOO^ il
dTTP 100|il
dGTP 100|il
dCTP 100|il
dH20  to 1ml
Store at -20°C in 50j l x 1 aliquots. Use at a final concentration of ImM in reverse 
transcription and 0.2mM in PCR.
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1MKC1
KCI 74.5g
dH2 0  to 1 litre
Sterilise by filtration
1M MgCE
MgCl2 203.3g
dH20  to 1 litre
Sterilise by filtration 
1M Tris (pH 8.0)
Trisbase 121. lg
dH20  900ml
Adjust to pH 8.4 with 84ml concentrated HC1. Make up volume to 1 litre with 
dH20. Sterilise by autoclaving.
Ethidium Bromide (1 mg/ml)
Ethidium bromide lg
dH20  to 1 litre
Store away from light. Use at a final concentration of lpg/ml 
0.5M EDTA (pH 8.0)
EDTA 186. lg
dH20  900ml
Adjust to pH 8.0 with NaOH. Make up volume to 1 litre with dH20 . Sterilise by 
autoclaving.
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TABLE 2.2
R eagen t S tock F inal V ol p e r  20(Xl
R T B uffer lOmM Im M 2 jll1
dN T P lO m M lm M 2 jli1
pd(N )6 50 A 26o units i0 0 p m o l/p l m
M M L V  R T ’ase 200 un its/p l / l|Xl
sdH 20 / / 4  p i
R N A  guard A dd lp l  to the m aster m ix for every  20  sam ples
R everse  tran scrip tio n  m aster m ix. T en  m icro litres o f  m aster m ix 
a liquo ted  into each  reac tio n  tube and 10|il o f  R N A  tem pla te  added.
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TABLE 2.3
N am e R eg ion  P osition  P o larity  S eq u en ce  5 ’-3 ’
o f  5 ’
A T A C T C G A G G T G C A C G  
209 5 ’ N C R  8 - G T C T  A C G  A G  A C C T
C A C T C T C G A G C A C C C T  
211 5 ’ N C R  -29 - A T C A G G C A G T
C T G T G A G G A A C T A C T G  
939 5 ’ N C R  -297 + T C T T
T T C A C G C A G A A A C G T C  
940  5 ’ N C R  -279 + T A G
S equences, sources, positions and polarity  o f  p rim ers used in P C R  reac tion  for 
the am plification  o f H C V . P rim ers 209 and 939 are used in the first round  o f  PC R  
and p rim ers 211 and 940  in the second  round.
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TABLE 2.4
1)
R eagen t S tock F inal V ol p er iOOpl
T aq  pol buffer lOmM Im M 1 OjLll
P 209 / 0 .5 p M l j L L l  *
P 939 / 0 .5 p M lp l  *
sdH 20 / / 7 7 .5 p l
T aq  pol 5 un its /p l 2.5 units 0 .5 p l
2)
R eagen t S tock F ina l V ol p e r lOOpl
T aq  pol buffer lOmM Im M lOpl
dN T Ps lO m M 0.2m M 2pl
P 211 / 0 .5pM lp l  *
P 940 / 0 .5 p M lp l  *
sd H 20 / / 87 .5p l
T aq  pol 5 un its/p l 2.5 units 0 .5 p l
M aste r m ixes used fo r 1) first, and  2) second  round  P C R  reactions.
* V o lum e o f  p rim er used depends on concen tra tion  o f  stock  so lu tion .
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FIGURE 2.1
S aliv a  co llec tion  dev ices for w hole sa liva  and oral flu id  used  in the d e tec tion  o f 
H C V  R N A  by PCR . Left: S alivette™  (S arsted t L td). R ight: a sterile  p lastic 
U niversal for the co llec tio n  o f unstim u lated  w hole saliva.
Chapter 3
Application of the Polymerase Chain Reaction for the 
Diagnosis of Hepatitis C Virus in a 
Routine Clinical Laboratory
INTRODUCTION
Following the successful cloning and characterisation of HCV, diagnosis of 
infection has been facilitated by the development of antibody detection assays. However, as 
mentioned earlier, antibody detection methods are of restricted use because of the long 
seroconversion period following infection (mean 16 weeks). In addition, knowledge of 
antibody status does not provide a means to differentiate between current active infection, 
chronic infection, and past resolved infection. By contrast, although presence of HCV RNA 
is not absolute proof of HCV viraemia, it strongly suggests active virus replication and the 
potential for infectivity.
The principle of the PCR is relatively simple. It involves the chemical rather than 
biological amplification of a specific segment of DNA, and is based on the annealing and 
extension of two synthetic oligonucleotide primers that flank the target DNA. After heat- 
induced denaturation of the DNA, each primer hybridises to its specific corresponding 
region on one of the two separated strands. Annealed primers are then extended on the 
template strand under the influence of a DNA polymerase enzyme. The three steps of 
denaturation, primer binding and DNA synthesis represent a single PCR cycle and the 
resulting product serves as template for the next cycle. Repeated cycles result in the 
exponential accumulation of the target sequence (Saiki et al.. 1988; Ehrlich and Sirko, 
1994).
PCR is widely accepted as a powerful research tool. The technology provides 
direct analysis at the molecular genetic level, overcomes many of the constraints imposed 
by serological data and is independent of the host immune response. However, to date the 
use of PCR has been limited mainly to research applications and to use in a few
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sophisticated clinical reference laboratories. The operation of a high-volume clinical 
diagnostic laboratory stipulates that the methodologies employed must be rapid, 
reproducible, and amenable to batch formatting. Thus, the extension of PCR technology to 
routine clinical use would necessitate simplification of the entire process from beginning to 
end. The technique as currently practised in most research laboratories is labour-intensive 
with a limit on the number of samples that can be analysed due to cumbersome detection 
methods.
The work reported in this thesis has examined PCR for detection of HCV RNA in 
serum, a technique currently recognised as the ‘gold standard’ for confirmation of 
infection. In addition, the role of PCR in detection of HCV in saliva has been studied, since 
saliva would be a convenient alternative non-invasive specimen for diagnosis of this 
infection. Examination of saliva by PCR raises additional problems, and these will be 
alluded to, as appropriate, in the text.
The development of PCR for clinical use should be considered in three separate 
parts. First, it is necessary to develop a specimen protocol that will facilitate the rapid 
release of the target DNA/RNA from clinical samples, with a minimum number of steps, 
manipulations, and container changes. This aspect is often the most time consuming part of 
the processing. Secondly, amplification should be carried out in a manner which reduces 
the possibility of false positives resulting from amplicon carry-over. With regard to HCV, 
amplification by PCR must be preceded by a step which generates cDNA. This step is the 
crucial and often limiting step of RT-PCR assays. There are numerous protocols for the 
cDNA reaction and PCR amplification (Cuypers, 1994). The amount of false positivity due 
to contamination is strongly dependent on the number of steps and manipulations 
performed during the processing of the samples in a given protocol. Finally, a non-
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laborious method of detection, suitable for adaption to a clinical laboratory remains to be 
established. When PCR was first described, radioactively labelled probes were used to 
detect products. As amplification technology improved it became possible to visualise the 
amplified DNA using ethidium bromide stained gels. Detection methods range from 
procedures that are relatively insensitive and non-specific to those that are very sensitive 
and highly specific. The ideal method for detection should allow for an accurate 
determination of the desired product regardless of the number of non-specific bands 
produced.
At the onset of this study, the PCR protocol employed for both serum and saliva 
was one used routinely by the Scottish National Blood Transfusion Service (SNBTS), 
Microbiology Reference Unit, Regional Virus Laboratory, Ruchill Hospital, Glasgow. As 
such it took over two days to perform requiring dedicated personnel and equipment. At this 
point, PCR was unavailable to the National Health Service as a routine clinical laboratory 
method partly due to the problems mentioned above.
Therefore, the work presented in this chapter addressed the mechanics of the 
whole technique and sought to determine the appropriate procedures suitable for use in a 
clinical laboratory for the diagnosis of infection with HCV.
61
MATERIALS & METHODS
a) Comparison of RNA extraction protocols
HCV RNA was isolated from 200fil of HCV positive serum undiluted, or diluted 
1:10, 1:100, or 1:1000 in HCV negative saliva using the following RNA extraction 
procedures : guanidinium isothiocyanate/ acid-phenol method, QIAamp blood kit, and the 
GLASSMAX RNA micro-isolation Spin Cartridge System. Reverse transcription and PCR 
were performed as described earlier in Chapter 2. Following amplification, products were 
subjected to agarose gel electrophoresis, and visualized by UV illumination as described in 
Chapter 2.
i) RNA extraction with guanidinium isothiocyanate / acid-phenol
HCV RNA was isolated by a modification of the procedure described by 
Chomczynski and Sacchi (1987). To 200pl of serum or saliva, 500pl of the denaturing 
solution^4M guanidine isothiocyanate (4MG) (Table 3.1) was added on ice. This was 
supplemented with carrier RNA to a final concentration of 1 jig/ml and 40 units of 
RNAguard. The solution was mixed and left on ice for 15 minutes. An equal volume of 
phenol (water saturated), and chloroform-isoamyl alcohol mixture (24:1) were added with 
thorough mixing and left for a further 15 minutes on ice. Samples were then centrifuged at 
12,500rpm for 5 minutes using an Eppendorf centrifuge (model 5415 C). After 
centrifugation, RNA was present in the aqueous phase while DNA and proteins were 
present in the interphase and phenol phase. The aqueous phase was transferred to a fresh 
tube and mixed with an equal volume of chloroform-isoamyl alcohol mixture (24:1). The 
samples were centrifuged as before. The aqueous phase was again transferred to a fresh
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tube and RNA was precipitated with an equal volume of ethanol (100%) at -70°C for a 
minimum of 2 hours. Following sedimentation in the Eppendorf centrifuge (12,500rpm, 20 
minutes), RNA was washed twice in 70% ethanol. The resulting RNA pellet was air dried 
and dissolved in 20|il sdH20. At this point, the RNA preparation could be used as a 
template for cDNA production (reverse transcription).
ii) RNA extraction with QIAamp blood kit
This was performed according to the manufacturer’s instructions as summarised 
in Table 3.2. The extraction mixture was supplemented with carrier RNA to a final 
concentration of l|ig/ml and 40 units of RNAguard.
iii) RNA extraction with GLASSMAX RNA micro-isolation spin cartridge system
RNA was extracted using the GLASSMAX kit by a modification of the 
manufacturer’s protocol for isolating total RNA from cells or tissues (Table 3.3).
b) Comparison of PCR amplification protocols
HCV RNA was isolated from 200pl of HCV positive serum using the QIAamp 
blood kit. Extracted RNA undiluted, or diluted 1:10, 1:100, or 1:1000 in HCV negative 
saliva underwent amplification either by nested set PCR as described earlier, hot start PCR 
or a combined one-step RT-PCR.
i) Hot start PCR
Hot start PCR followed the same procedure as nested PCR with the exception of 
using two master mixes, upper and lower (Tables 3.4 and 3.5), separated by 65|0,1 of pre­
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warmed wax. Template DNA was added using a dedicated positive displacement pipette to 
the upper master mix. No mineral oil was added in this procedure. The primers and cycling 
parameters used in this procedure were the same as those employed for nested PCR.
ii) Combined one-step RT-PCR
On ice, a master mix containing all the reagents less the RNA was set up as shown 
in Table 3.6. Eighteen microlitres of master mix were aliquoted into each reaction tube and 
2pl of template RNA were added using a dedicated positive displacement pipette. Twenty 
microliters of prewarmed light mineral oil were layered on top to prevent evaporation 
during reverse transcription and amplification. Reverse transcription was performed at 
70°C for 15 min, followed by 1 min at 95°C to facilitate denaturation of RNA-DNA 
heteroduplexes. PCR amplification was performed using the outer set of primers (209 and 
939) over 40 cycles, 2 consisting of 15s at 95°C and 20s at 60°C, followed by 38 of 15s at 
90°C and 20s at 60°C. A final extension step of 4min at 60°C was also included. Ten 
microlitres of the RT-PCR reaction mixture were amplified using the inner pair of nested 
primers (211 and 940) for a further 25 cycles, each consisting of 15sec at 90°C and 20 sec 
at 60°C. A master mix containing all reagents less the first round product was set up as 
shown (Table 3.7) and dispensed in 90pl aliquots into each reaction tube. No further 
enzyme was added to the mix.
c) Comparison of protocols used to detect amplified product
A number of saliva samples obtained from an HCV seropositive blood donor were shown by 
agarose electrophoresis and Ethidium Bromide (EtBr) staining to vary significantly in 
intensity from very strong to barely visible. These samples were probed using a non­
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radioactive format to determine firstly the specificity of the weakly positive products and 
secondly, whether the method of detection could be improved by using a more sensitive 
procedure. Amplified product was detected using the traditional method of gel 
electrophoresis and EtBR staining, with a subsequent hybridisation assay format using a 
digoxigenin labelled probe (5 ’ -CCGGGAGAGCCATAGTGGTCTGCGGAACCGGTG-3 ’).
i) Preparation of DNA probe
a) 3’ Endlabelling with Digoxigenin-11-ddUTP
The preparation of the probe was carried out by Dr K. Takahashi, Periodontology 
Unit, Department of Adult Dental Care, Glasgow Dental Hospital and School. The reaction 
mixture was set-up on ice and contained 4pi 5x stock tailing buffer (GIBCO-BRL),
0.05mM Dig-1 IdUTP (Boehrinhger Mannheim), 40 units Tdt enzyme (GIBCO-BRL), 1- 
2pl DNA probe, and sdH20 to a total volume of 20pl. The contents were mixed and spun 
briefly and the reaction was incubated overnight at 37°C. Unincorporated label, spare probe 
and reaction components were removed from incorporated label by separation through a 
Sephadex G-25 NAP-5™ column (Pharmacia). The column was prepared by removing the 
transport medium and flushing the column three times with 0.1% SSC/ 0.1% SDS in 
DEPC/ sdH20. The reaction mixture was added to the column, washed through with 200pl 
of buffer and collected in an eppendorf tube. This was repeated a further nine times until 10 
fractions were obtained. The fraction containing the labelled probe was identified by dot- 
blot.
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b) Random primed DNA labelling with Digoxigenin-11-dUTP
DNA marker (lOObp ladder) was labelled using a DIG DNA Labelling and 
Detection kit (Boehringer Mannheim) according to the manufacturer’s instructions.
Briefly, the reaction mixture was set up on ice and containedlpg of DNA template (lOObp 
marker), 2pi of hexanucleotide mixture, 2pl of dNTP labelling mixture and sdH20 to a 
final volume of 19pl. Finally, lOOunits of Klenow enzyme were added and the reaction left 
overnight at 37°C. Prior to use, the DNA template was heat-denatured in a boiling water 
bath for lOmin and immediately chilled on ice for 30sec. The reaction was terminated by 
the addition of 2pl of 2mM EDTA, pH 8.0. Labelled DNA was precipitated with a mixture 
of 4M LiCI (Table 3.1)/ 100% ethanol (0.1/3) at -70°C for 30 min. The reaction mixture 
was then centrifuged at 13,000g for 15min using an Eppendorf centrifuge (model 5415 C). 
After centrifugation, the ethanol was decanted and the pellet washed with lOOpl of chilled 
(70%) ethanol. The reaction mixture was centrifuged again at 13,000g for 5min. The 
resulting pellet was freeze-dried and resuspended in 50pl of sdH20. The labelled marker 
was stored at -20°C until required. Labelled DNA was denatured by boiling for 10 min 
prior to use in hybridisation experiments.
ii) Dot blot analysis
Identification of the labelled probe using a dot blot analysis was carried out by Dr 
K. Takahashi, Periodontology Unit, Department of Adult Dental Care, Glasgow Dental 
Hospital and School. Ten squares were marked on a nitrocellulose filter (Gelman Sciences, 
MI). The filter was soaked in 20x SSC for 3min, blotted between 3MM Whatman paper 
and allowed to air dry. One microliter from each fraction was dotted onto the appropriate 
square and allowed to absorb. The DNA label was bound to the filter by exposure to UV
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for 2min in a UVC-508 ultraviolet crosslinker (Anachem). The fraction containing the 
labelled probe was identified using anti-DIG-alkaline phosphatase antibody (Anti-dig-AP, 
Boehringer Mannheim).
iii) Southern blot analysis
PCR product was electrophoresed in 4% agarose gel in lx  TBE buffer, stained 
with ethidium bromide and photographed under UV light as previously described. The gel 
was placed in a glass baking dish and any unused areas of the gel were removed with a 
sharp scalpel. The DNA was denatured by submerging the gel in 200ml of 0.5M NaOH/
1.5M NaCl (Table 3.1), for 2x 15min at room temperature with gentle shaking. The gel 
was rinsed with sdfUO and next neutralised by soaking in 200ml of 0.5M Tris-HCl pH7.5/ 
3M NaCl (Table 3.1), for 2x 15min at room temperature with gentle shaking. The gel was 
now ready for Southern blotting to a hybridisation membrane. Transfer was carried out on a 
commercially available blotting unit (Anachem). Twenty fold SSC buffer was added to the 
unit until the level was just below the support platform. The gel was placed onto the 
saturated platform. A piece of positively charged nylon membrane, cut to the required size, 
was briefly soaked in 20x SSC and placed in position on top of the gel. All air bubbles 
between the gel and the membrane were removed. A stack of pre-cut absorbent towelling 
and filter paper (Anachem) was placed on top and the floating lid of the blotting unit was 
put on top of the stack. A light weight was applied to the stack to ensure even contact 
during blotting. Transfer was allowed to proceed overnight, following which the membrane 
was carefully removed and briefly air dried at room temperature. The membrane was 
placed on a sheet of Whatman 3MM paper and the DNA bound to the nylon membrane in a
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UVC-508 ultraviolet crosslinker (Anachem) for 3min. After UV cross-linking, the 
membrane was rinsed briefly in sdfUO and allowed to air dry.
v) Hybridisation of immobilised DNA to labelled probe and marker
Membranes containing immobilised DNA were hybridised to DIG labelled DNA probe 
and marker using a Midi Dual 14 Hybridization Oven (Hybaid). Hybridisation was carried out in 
bottles as follows. In a plastic box containing 2xSSC, the membrane (DNA side up) was placed 
on top of a nylon mesh (Hybaid). Another piece of mesh was layered on top and the ‘sandwich’ 
was rolled together, ensuring no air bubbles were trapped. The roll was placed in the 
hybridisation bottle and 15ml of 2xSSC added. The ‘sandwich’ was carefully unrolled, again 
ensuring no air bubbles were trapped. SSC was then decanted and replaced with 
6ml hybridisation buffer less probe (Table 3.1). The bottle was clipped onto the rotisserie such 
that it rotated in the oven in the same direction as the membrane was unrolled. Pre-hybridisation 
was carried out at 65°C for lhour. Denatured probe and marker were added to the pre-hybridised 
membrane at a concentration of 5ng/ml in hybridisation buffer. This was accomplished by 
mixing the appropriate volume of probe and marker with 6ml hybridisation buffer. The pre­
hybridisation buffer was discarded and the hybridisation buffer added. Hybridisation was carried 
out overnight in the oven at 65°C. Following hybridisation, buffer was removed and frozen for 
later use. Unbound probe was removed by washing in 2xSSC for 2x5 min in the oven at 65°C. 
Finally, membranes were rinsed in O.lxSSC for 2xl5min and allowed to air dry.
vi) Colorimetric detection of DIG-labelled probe and marker
This was performed using a DIG DNA labelling and detection kit (Boehringer 
Mannheim). Following hybridisation and post-hybridisation, the membrane was equilibrated in
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buffer 1 (Table 3.1) for 1 min. In a freshly washed dish, the membrane was blocked in buffer 2 
(Table 3.1) for 30min with gentle shaking. Anti-DIG alkaline phosphatase was added to the 
membrane at a concentration of 150MU/ml of Buffer 2. This was accomplished by adding 6pi 
of anti-DIG alkaline phosphatase to 30ml of Buffer 2. The membrane was incubated for 30 min in 
the prepared antibody solution. The membrane was next transferred to a new dish, washed in 
Buffer 1 for 2xl5min, and equilibrated for 2min with 20ml Buffer 3 (Table 3.1). Bound 
antibody was detected with colour substrate solution freshly prepared. This was achieved by 
mixing 45pl NBT solution and 35pl X-Phosphate in 10ml of Buffer 3. The membrane was 
incubated in the dark until the desired bands had been detected. Finally the reaction was stopped 
by washing the membrane with 50ml of Buffer 1 for 5min.
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TABLE 3.1 
Stock Solutions and Buffers
4M Guanidine isothiocvanate (4MG)
4M Guanidine solution 60ml
p-mercaptoethanol 300pi
20% N-lauryl sarcosine 600jil
Stored at -20°C in 5ml aliquots 
20% N-lauryl sarcosine
N-lauryl sarcosine 200g
dH20  to 1 litre
Sterilise by filtration 
QIA gen Protease
Lyophilized QIAGEN protease 25mg 
sdH20  1.3ml
Store at -20°C in 200pl aliquots 
Buffer AW
Reagent AL2 40parts
Reagent ALi 160parts
Store at room temperature in 5ml aliquots
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Buffer AL
Buffer AW concentrate 84ml
Ethanol (100%) 196ml
DEPC-treated water
Diethylpyrocarbonate
dH20
0 .  I j l l I  
to 1 litre
Leave to stand overnight. Sterilise by autoclaving 
GUSCN/ME
GUSCN 2.3ml
P-mercaptoethanol 200pl
Store at 4°C in 200|il 
Wash Buffer
Wash buffer concentrate 8ml
DEPC-treated H20 142ml
Ethanol (100%) 170ml
Store at 4°C in 10ml aliquots 
Q.5M NaOH
NaOH 20g
d H20 to 1 litre
Sterilise by filtration
71
0.5M Tris-HCl (pH 7.5)
Tris base 60.55g
dH20  900ml
Adjust pH to 7.5 with 65ml concentrated HC1. Make up volume to 
1 litre with sdH20  
3M NaCl
NaCl 175.33g
dH20  to 1 litre
Sterilise by autoclaving
20xSSC pH 7.0
NaCl 175.3g
Sodium citrate 88.2g
dH20  800ml
Adjust to pH 7.0 with NaOH. Make up volume to 1 litre. Sterilise by 
autoclaving
10% SDS
Sodium dodecyl sulphate lOOg
dH20  900ml
Heat to 68°C. Adjust to pH 7.2 with HC1. Make up volume to 1 litre.
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0.2M EDTA
EDTA 74.4g
dH20  800ml
Adjust to pH8.0 with NaOH. Make up volume to 1 litre with dH20 . Sterilise by 
autoclaving
4M LiCl
LiCl 169.6g
dH20  to 1 litre
Sterilise by autoclaving 
10% Blocking reagent
Blocking reagent lOg
Buffer 1 100ml
Dissolve reagent by several 30 second heat pulses in a microwave ( 3 to 4 min 
total). Sterilise by autoclaving and store at 4°C 
Hybridisation buffer
20 x SSC 125ml
10% Blocking reagent 50ml
10% N-Laurylsarcosine 5 ml
SDS 1ml
dH20 to 500ml
Store at -20°C
*Proteolytic fragments of casein in powder form.
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Buffer 1
NaCl
Maleic acid 
dH20
Adjust to pH 7.5 with NaOH, 
Buffer 2
10% Blocking reagent 
Hybridisation buffer 
Sterilise by autoclaving 
Buffer 3
Tris-HCl pH 9.3 
NaCl 
MgCl2 
dH20
Sterilise by autoclaving
87.66g
11.61g 
to 900ml 
Sterilise by autoclaving.
50ml
450ml
50ml 
5.84g 
4.76g 
to 500ml
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TABLE 3.2
Viral Nucleic Acid Extraction using QIAamp ® Blood Kit.
1. P ipe tte  2 0 0p l o f  sam ple in to  1.5ml m icro fuge tube.
2. A dd 25pJ Q IA G E N  P ro tease stock  so lu tion , 2 0 0 |il B uffer A L , 4 .2 5 jll1 ca rrie r R N A  
and lp l  R N A  guard  to the sam ple. M ix im m ed ia te ly  by vortex ing .
3. Incubate  at 70°C  for 10 m in
4. A dd 2 1 0p l o f  isopropanol or e thano l (96-100% ) to the sam ple , and  m ix  again  by 
vo rtex ing
5. P lace a Q IA am p spin co lum n in a 2m l co llec tion  m icro tube (p rov ided). C arefu lly  
app ly  the m ix ture from  step 4 to the Q IA am p spin co lum n  w ithou t m o isten ing  the 
rim , close the cap, and cen trifuge at 8000 rpm  (6000xg) for lm in . P lace the Q IA am p 
sp in  co lum n  in a clean  2m l co llec tion  m icro tube (p rov ided), and d iscard  the tube 
con ta in in g  the filtrate.
6. C arefu lly  open  the Q IA am p spin co lum  and add 5 0 0p l o f  B uffer A W  (prov ided). 
C en trifuge  at 8000rpm  (6000xg) for lm in . R em ove the Q IA am p spin  co lum n  from  
the co llec tion  m icro tube, d iscard  the filtrate, and p lace  the Q IA am p spin  co lum n  in 
the sam e co llec tion  m icro tube
7. C are fu lly  open  the Q IA m p spin co lum n and add ano ther 5 0 0p l o f  B u ffe r A W . 
C en trifuge  at 8000rpm  (6000xg) fo r 1 m in, and at full speed  for a fu rth er 10 sec.
8. P lace the Q IA am p spin co lum n  in a clean  1.5ml m icro fuge tube (no t p rov ided ), 
and d iscard  the co llec tion  m icro tube con tain ing  the filtrate.
9. C arefu lly  open  the Q IA am p spin co lum n. E lu te  the nucleic  acid  w ith  50pJ o f  
R N A ase-free  w ater (D E PC  treated) p reheated  to 70°C .
10. Incubate  at 70°C  for 5 m in. C en trifuge  at 8 0 00rpm  (6000xg) for 1 m in.
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TABLE 3.3
Viral Nucleic Acid Extraction using GLASSMAX™ RNA Microisolation 
Spin Cartridge System
1. O n ice, p ipette  200 |il o f  sam ple into 1.5ml m icro fuge tube.
2. A dd 2 0 0p l G U SC N  / M E so lu tion  and 1 jlxI R N A  guard  to the sam ple . M ix 
im m edia tely  by vortexing.
3. A dd 2 8 0p l o f absolu te  ethanol. M ix thorough ly . C en trifuge  the suspension  at 
13000xg for 5 m in at room  tem perature.
4. A fter cen trifugation  , rem ove the supernate  w ith  a s terile  pastette . R em ove the 
liqu id  starting  from  the top to the bo ttom  o f  the tube, as tho ro u g h ly  as possib le .
5. T o  the pellet add 4 5 0p l o f  B ind ing  so lu tion  (p rov ided), fo llow ed  by 4 0 p l o f  
3M  N aO A c, pH 5.5. V ortex  to resuspend  pellet.
6. A dd the so lu tion  from  step 5 to the G lassM A X  spin ca rtridge and  cap  it. 
C en trifuge at 13,000g for 20 sec. E m pty  the tube.
7. A dd 0 .5m l o f  co ld  (4°C ) IX  w ash  b u ffe r to the spin cartridge. C en trifuge at 
13,000g for 20sec. E m pty the tube.
8. R epeat step  7 tw ice.
9. A dd 0 .5m l o f  co ld  (4°C ) 80% (v /v) e thano l to the spin  ca rtridge . C en trifuge at 
13,000g for 20 sec. E m pty the tube.
10. R epeat step 9.
11. C en trifuge at 13,000g for 1 m in.
12. Put cartridge into fresh sam ple recovery  tube. A dd 4 0 p l o f  D E P C -trea ted  
w ater, p reheated  to  65°C , to the spin cartridge.
13. C en trifuge at 13,000g for 20 sec to e lu te  the R N A .
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TABLE 3.4
1)
R eac tion
C om ponen t
S tock F inal V ol p e r lOOpl 
(p e r reaction )
P rim er 939 / 0.5|liM 0 .5 |il*
P rim er 209 / 0 .5 jiM 0 .5 |il*
sd H 20 / / 4 9 p l
2)
R eaction
C o m p o n en t
S tock F inal V o l p e r  iOOpi
PC R  B uffer 10X IX lOjltl
T aq
P olym erase
/ 2.5 units 0.5fil
sdPLO / / 30p l
U p p er and low er m aster m ixes em ployed  in first round  o f  nested  ‘hot s ta rt’ PCR . 
(1) : U pper m aster m ix. (2) : L ow er m aster m ix. * V olum e o f  p rim er used  depends 
on  stock  concen tra tion .
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TABLE 3.5
R eac tion
C om ponen t
S tock F ina l V ol p e r  100*11 
(p e r reac tio n )
P rim er 940 / 0 .5 p M 0 .5 p l*
P rim er 211 / 0 .5 p M 0 .5 p l*
sd H 20 / / 4 9 p l
R eaction
C o m ponen t
S tock F inal V ol p e r lOOpl 
(per reac tio n )
PC R  B uffer 10X IX lO pl
dN T P 10X 0.2X 2 p i
Taq
P olym erase
/ 2.5 units 0 .5 p l
sd H 20 / / 36p l
U p p er and  low er m aster m ixes em ployed  in second  round  o f  nested  ‘h o t s ta rt’ 
PC R .
(1) U p p er m aster m ix. (2) L ow er m aster m ix. * V olum e o f  p rim er used depends 
on stock  concen tra tion .
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TABLE 3.6
R eagen t S tock F inal V ol p e r 20jxl
T th  R T -B uffer lOmM Im M 2 jll1
dN T P lOmM 0.2m M 0 .4 j i 1
M n C L 2 lOmM Im M 2jil
P rim er 939 / 0 . 15pM 0 . 15pl*
P rim er 209 / 0 . 15pM 0 . 15pl*
T th 6 units/p l / lp l
sd H .O / / 11.2 |il
R N A  guard A dd lp l  to  the m aster m ix fo r every  20 sam ples
C o m b in ed  R T -P C R  m aster m ix.
* V o lu m e o f p rim er used depends on stock  concen tra tion .
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TABLE 3.7
R eagen t
■ -
Stock F inal
■ ■
V ol p e r  lOOpl
T th  pol B uffer lOx lx 10 |il
M gC l 2 25m M 2.5m M lOjul
P rim er 940 / 0 .5 p M 0 .5 p i*
P rim er 211 / 0 .5 p M 0 .5 jll1*
dN T P lOmM 0.2m M 2pl
sd H 2Q / / 67p l
S eco n d  round  PC R  m aster m ix used  w ith  com bined  R T -PC R . 
* V o lu m e o f  p rim er used depends on stock  concen tra tion .
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RESULTS
a) Comparison of RNA extraction protocols
Two hundred microliters of HCV positive serum undiluted, or diluted 1:10, 1:100 
or 1:1000 in HCV negative saliva, were subjected to PCR following extraction with 
guanidinium isothiocyanate/ acid-phenol and two commercially available kits. Both the 
guanidinium isothiocyanate/ acid-phenol and the QIAamp blood kit extraction protocols 
had comparable sensitivity and specificity. Both yielded positive results and appeared to 
have removed any potential salivary inhibitors. The GLASSMAX RNA Microisolation 
Spin Cartridge System failed to provide amplifiable RNA (Figure 3.1).
b) Comparison of PCR amplification protocols
RNA was extracted using the QIAamp blood kit, reverse transcribed undiluted, or 
diluted 1:10, 1:100 or 1:1000 in HCV negative saliva and amplified by PCR. Three 
procedures were compared by visualisation with gel electrophoresis and EtBr staining.
Reverse transcription using MMLV-RT, and amplification with Taq pol was carried out 
using two variations of a nested PCR procedure. Hot-start PCR gave a better result detecting lOx 
less HCV RNA than the basic nested PCR. Samples processed by the basic nested PCR 
produced a greater level of background (Figure 3.2). One step RT-PCR employing Tth as 
both the reverse transcriptase and polymerase performed well producing the same results as 
the basic nested and hot-start procedures.
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c) Comparison of methods of detection
Following HCV RNA amplification, a number of saliva samples obtained from 
HCV seropositive blood donors presented faint bands, weak positives barely visible by 
ethidium bromide staining. Use of a digoxigenin labelled probe in a southern blot 
hybridisation format provided no greater sensitivity of detection. Indeed, ethidium bromide 
staining of the amplified products following electrophoresis produced a clearer picture. 
Hybridisation with a digoxigenin labelled probe caused difficulties in differentiating 
between an actual weak positive signal and simple background staining (Figure 3.3).
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FIGURE 3.1
R N A  ex tra c tio n  fro m  H C V  p o s itiv e  se ru m  se ria lly  d ilu te d  ten  fo ld  b y  
1) g u an id in iu m  iso th io c y a n a te / a c id -p h en o l; 2) G L A S S M A X  R N A  M ic ro iso la tio n  
Spin C artr id g e  S y s te m  an d  3) Q IA am p  B lo o d  K it; M ) lOObp D N A  m ark e r.
FIGURE 3.2
E x tra c te d  H C V  R N A  se r ia lly  d i lu te d  ten  fo ld  a n d  a m p lif ie d  b y  1) re v e rs e  
tra n s c r ip t io n  w ith  M M L V -R T  a n d  n e s te d  P C R ; 2 ) re v e rs e  t ra n s c r ip t io n  w ith  
M M L V -R T  a n d  h o t s ta r t P C R  a n d  3 ) O n e  s te p  R T -P C R  u s in g  T th  p o l;
M ) lOObp D N A  m a rk e r .
FIGURE 3.3
1) M
2) M
M
C o m p a r is o n  o f  d e te c t io n  m e th o d s : 1) g e l e le c tro p h o re s is  a n d  e th id iu m  b ro m id e  
s ta in in g ; 2 ) S o u th e rn  b lo t  a n a ly s is  o f  1) u s in g  D ig - la b e l le d  p ro b e ;  M ) lOObp 
D N A  m a rk e r .
DISCUSSION
The extraordinary ability of PCR to exponentially replicate a target DNA sequence 
has made it a very powerful tool. The ability provides the basis for the direct examination 
of a clinical sample for evidence of infection. It is possible to obtain unheard-of 
specificities by careful choice of the oligonucleotides which serve as primers for the 
amplification. These superior characteristics have propelled the field of PCR-based 
molecular diagnostics into the area of applied diagnostics for infectious agents. However, a 
number of issues remain to be considered before PCR becomes sufficiently reliable for 
routine use. These include standardisation of reagents, the ability to reduce sophisticated 
technology into a reproducible technique that can be performed in a standard clinical lab, 
and to increase the number of samples that can be easily processed in one day. In this 
chapter, consideration is given to the applicability of different protocols for each stage of 
the procedure, namely sample processing, amplification and detection.
Successful cDNA synthesis begins with the isolation of high quality RNA free 
of contaminants and inhibitors. RNA can be isolated for use in reverse transcription (RT)- 
PCR by various methods (Cuypers, 1994). These can be divided into three essentially 
different types of extraction. The first is digestion of the specimen with proteinase K in the 
presence of sodium dodecyl sulphate followed by organic extraction with 
phenol/chloroform and ethanol precipitation (Choo et al.. 1991). Secondly, RNA may be 
extracted by lysis of specimen in a chaotrophic agent followed by organic extraction with 
phenol/chloroform and precipitation with ethanol or isopropanol (Chomzynski and Sacchi, 
1987). The final method is incubation of the specimen with guanidinium isothiocyanate
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and absorption of the released nucleic acid to silica hydroxide particles (Boom et al.. 1990). 
A modification of the second method based on the phenol/chloroform extraction was the 
procedure employed initially in this study. We compared the efficiency of HCV RNA 
purification with this method to that using two commercial kits, the GLASSMAX RNA 
Microisolation Spin Cartridge System based on the third method and the QIAamp Blood 
and Tissue Kit which combines the principles of the first and third methods. In our hands, 
both the guanidine isothiocyanate/acid-phenol method and the QIAamp Blood kit gave 
comparable results. However, the QIAamp kit gave pure, ready-to-use RNA in minutes 
without the need for extraction with hazardous or toxic organic solvents. Using the 
GLASSMAX system we failed to obtain amplifiable RNA. This may be a result of the 
adaptations made to facilitate extraction from serum and saliva. Extraction using a 
guanidinium thiocyanate procedure has also previously been shown to be less successful at 
removing PCR inhibitory factors in saliva than other methods of extraction based on 
phenol-chloroform or proteinase K (Ochert et al.. 1994). It is possible to further increase 
the specificity of HCV RNA detection by concentrating large volumes of samples by 
ultracentrifugation. However, ultracentrifugation also increases the risk of cross­
contamination and in our studies, obtaining large volumes of saliva would have been 
impractical.
As the genome of HCV is a single-stranded RNA molecule, amplification by 
PCR must be preceded by a step to generate cDNA. Numerous protocols for reverse 
transcription and PCR have been published (Cuypers, 1994). Amplification of HCV RNA 
by RT-PCR is, in most protocols, a two-step procedure requiring separate enzymes and 
buffer conditions for the cDNA and PCR reactions. A variety of reverse transcriptase 
enzymes are available including Molony Murine Leukemia Virus reverse transcriptase
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(MMLV-RT) and Tth. In both the nested and hot-start PCR, first strand synthesis using 
MMLV-RT is primed using random hexamers. This is a highly non-specific method and is 
likely to influence the amount and variety of cDNA obtained. The most specific method of 
priming is to use a primer containing sequence information complementary to target RNA. 
This is the method used in one-step RT-PCR and has the advantage of producing a specific 
cDNA, resulting in a more specific PCR amplification.
In nearly all the protocols a part of or the complete cDNA reaction is subsequently 
amplified by PCR. This is performed after a change of buffer conditions to one suitable for 
amplification by the DNA polymerase. The need to make a buffer change is cumbersome and 
increases the likelihood of contamination. To avoid this risky step a number of procedures 
have been developed that combine the cDNA reaction and PCR (Cuypers, 1994). The most 
promising of these employs the thermostable DNA polymerase from Thermus thermophilus 
(Tth). Using Tth-polymerase, RNA can be converted to DNA at 70°C in the presence of 
manganese. The addition of EGTA to the reaction switches the template specificity of Tth- 
polymerase from RNA to DNA. Thus a single enzyme can convert RNA to cDNA and then 
amplify the cDNA by PCR. There are several advantages to using Tth-polymerase in a 
combined one-step RT-PCR. First, the ability of Tth-polymerase to reverse transcribe at 70°C 
circumvents the problems associated with the use of reverse transcriptase enzymes. Retroviral 
reverse transcriptases are thermally labile and cannot be used at temperatures above 42°C. The 
lower temperature necessary for enzyme activity also increases the potential for single­
stranded RNA templates to form stable secondary structures. This results in widely varying 
efficiencies of conversion of RNA to cDNA. Indeed the higher temperature at which Tth- 
polymerase is used, increases the specificity of primer extension in the RT-step. Secondly, 
Tth-polymerase does not produce primer-dimers. These structures are characterised by the
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elongation of one primer with a sequence complementary to the other. Once such a product is 
formed, it can serve as an efficient template for primer binding and extension, and can act as a 
reagent sink thereby reducing the efficiency of amplification of the target sequence (Ehrlich 
and Sirko, 1994). Finally, Tth-polymerase as a reverse transcriptase is only suitable for use 
with sequence specific primers and not oligo(dT) or short random primers. As mentioned 
earlier the use of such primers produces a more specific cDNA.
Initially, HCV RNA was amplified using a two-step nested PCR. Using this 
protocol, the first round products were subjected to a second round of PCR using primers 
internal to the first primer pair. Nested amplification offers both advantages and 
disadvantages. The sensitivity of nested PCR is extremely high enabling target to be 
detected by ethidium bromide staining. This circumvents the need for laborious detection 
methods such as hybridisation with labelled probes. Reamplification with a second set of 
internal primers also confirms the specificity of the first round as any non-specific products 
are unlikely to be sufficiently complementary to the nested primers to be able to serve as 
template for any further amplification. Furthermore, the transfer of the first round product 
effectively serves to dilute out inhibitors that might be present in the sample initially. This 
is of importance with regards to amplifying HCV RNA from saliva specimens (Ochert et 
al., 1994).
Despite its advantages, the high risk of cross contamination during the preparation of 
the second round PCR is a major drawback. Some researchers believe that nested PCR is 
totally inappropriate for the clinical setting where diagnostic accuracy is of paramount 
importance. A further disadvantage with this method is the ability of Taq polymerase to 
produce primer-dimers and non-specific products, as mentioned earlier. During PCR, 
primers may bind to non-target DNA as well as to themselves. This may induce Taq
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polymerase to synthesise unwanted DNA. At the end of the initial denaturing step, most 
DNA will be single stranded and incapable of hybridising with other single stranded DNA 
(e.g. primers). However, while the temperature is being ramped to 94°C, there will be some 
single stranded DNA available for primer annealing and spurious DNA synthesis. Hot start 
PCR prevents the primers from having the opportunity to bind single stranded DNA until a 
critical temperature is reached that strongly disfavours the non-specific pathways. This can 
be accomplished by physically separating the primers from the reaction mixture and Taq 
polymerase by the use of a wax. The wax melts at 80°C allowing mixing of the primers and 
other reagents and then serves as an evaporation barrier during the actual cycling.
All of the methods employed were equally sensitive in detecting HCV RNA in 
blood and saliva. The use of hot-start nested PCR should be advocated as a more specific 
method than the basic nested PCR. However, using one-step RT-PCR may reduce the risk 
of contamination. For some applications, RT-PCR alone may be sensitive enough to allow 
direct detection. However, with regard to HCV, the use of a further round of amplification 
cannot be avoided unless a more cumbersome method of detection is used and as we will 
discuss later this is not a preferred option. Therefore, the choice remains between hot-start 
nested PCR involving the transfer of DNA three times or RT-PCR (nested) requiring the 
transfer of DNA twice. Since the problem of product carry-over remains a major obstacle 
to the acceptance of PCR as a routine diagnostic tool it would perhaps be more prudent to 
employ the one-step RT-PCR protocol.
In procedures using nested PCR, amplified products can be analysed by 
visualisation of DNA band(s) of expected sizes on agarose gels stained with ethidium 
bromide (Cuypers, 1994). The major disadvantage to using ethidium bromide as a sole 
method for product detection is that it will only detect bands that contain ~5ng or more of
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DNA. Hybridisation with labelled probes can improve this sensitivity, detecting DNA 
bands with a concentration <lng (Jenkins, 1994). Both these methods detect all PCR 
products, both specific and non-specific. Specificity can be controlled for by Southern blot 
hybridisation using a labelled oligonucleotide probe, which is internal to the primer 
sequences employed in the PCR reaction. Use of radiolabelled probes is a common 
method of detection in many research laboratories. However, the use of radiolabels in a 
diagnostic laboratory would not be encouraged. The development of sensitive non- 
radioisotopic detection methods using probes labelled with detectable moieties such as 
digoxigenin has, however, made such detection formats more amenable to a diagnostic 
laboratory.
In our hands, visualising PCR products using ethidium bromide was 
sufficiently sensitive when amplifying HCV RNA from serum samples. However, for 
saliva samples ethidium bromide staining revealed amplified products of the expected 
length, fluorescing at very low intensities under UV light. Identification of the nested PCR 
product with southern blot hybridisation using a digoxigenin labelled probe did not, 
however, increase the sensitivity of detection. It is likely that further work optimising the 
conditions used would increase the sensitivity of this method. However, taking into 
account the time needed to perform the procedure, we felt justified in remaining with 
visualising the PCR products by EtBr staining. Southern blot hybridisation protocols 
have been developed for HCV detection though these are employed following a single 
round of PCR as an alternative to nested PCR (Cuypers, 1994). The use of such 
hybridisation assays is not itself without problems. Sensitivity can sometimes be 
compromised by inefficient transfer of amplification products onto the filter, while 
specificity of detection with labelled probes requires stringent hybridisation conditions
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between probe and the membrane-bound PCR product. Such a procedure also suffers from 
low signal/noise ratio problems. With regard to a clinical laboratory, the main reason for 
avoiding such a procedure is that it is time-consuming and labour-intensive. For HCV 
diagnosis, detection with ethidium bromide following amplification with two sets of 
primers may be appropriate. The choice of primers is such that the PCR reaction yields a 
single amplified product. However, it must be remembered that the presence of a DNA 
band in an agarose gel whose length corresponds to the length of the expected PCR product 
does not necessarily provide a positive identification.
Like any new, promising technology, PCR has spawned a myriad of 
developmental efforts. Significant progress is being made to develop PCR kits for the 
clinical laboratory. These kits address all needs from sample collection and preparation, 
through amplification and detection. Currently there are two major companies actively 
developing fully integrated PCR-based diagnostic systems, as well as a host of other 
commercial concerns working on sample preparation kits, thermal cyclers, thermostable 
DNA polymerases with assorted secondary characteristics, and methods to detect rapidly 
the PCR amplification products. Out of the current confusion will emerge one or several 
diagnostic configurations which will have survived the rigours of laboratory selection and 
vfill yield clear, consistent results in a timely manner. Standardisation of HCV RNA 
detection is urgently needed. Quality control between and within laboratories is a major 
problem. The European Expert Group on Hepatitis (“Eurohep”) showed only 16% of PCR 
hboratories operating with maximum sensitivity and specificity (Zaaijer et a l .. 1993). At 
this point there is no fully automated system available commercially through which 
specimens can be processed with the generation of reliable results, without significant 
technical effort and expertise.
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Chapter 4
Detection of HCV RNA in Saliva of Haemophiliacs 
and Blood Donors
INTRODUCTION
The diagnosis of most diseases requires some form of testing of a body fluid or 
tissue. Blood is the fluid of choice for a wide range of tests. However, in areas where there 
are cultural barriers to collecting blood and in certain other groups (e.g. children and 
IVDU) the necessity for venepuncture can be ethically unacceptable or potentially difficult. 
In such settings, the use of non-invasive diagnostic testing would prove beneficial. In the 
same way, with the emergence of AIDS, haemophobia has fuelled the search for less 
hazardous yet reliable specimen types.
Of all the possible alternatives to blood, saliva’s popularity has suffered 
because it lacks “the drama of blood, the sincerity of sweat and the emotional appeal of 
tears” (Mandel, 1993). However, sweat and tears are difficult to obtain in sufficient 
quantities for routine testing, and urine will always lack the charisma of other body fluids. 
Saliva is easily obtained on multiple occasions with less trauma than blood sampling and 
without the need for the privacy required for urine collection, yet physicians and dentists 
rarely take such samples.
The main benefits of saliva over blood as a diagnostic fluid are greater 
acceptability to the subject, convenience, economy, and hazard reduction. Saliva specimens 
can be collected by asking the subject to dribble into a sterile pot or by asking the subject to 
chew a small cotton wool cylinder (e.g. Salivette ™). However, low concentration of 
target, small sample volume, degradation of target by proteolytic activity and inconsistent 
collection procedures have all conspired to delay the widespread acceptance of saliva 
testing. Nevertheless, with the development of collection devices, which when used 
correctly can yield stable saliva samples of adequate volume, and with the introduction of
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new and highly sensitive laboratory techniques, the low levels of sample volume are no 
longer considered a limiting factor.
Diagnostic interest in viral specific antibodies in saliva was initiated by 
Archibald et al.in 1986 who reported the presence of anti-HIV in 87.5% of HIV- 
seropositive subjects (Archibald etal., 1986). Since then, the presence of IgG anti-HIV 
(Parry etal., 1987), IgG and IgM anti-HAV (Parry et al.. 1987; Parry etal., 1988; Parry et 
al., 1989; Piacentini et al.. 1993), anti-HBsAg and IgM anti-HBcore (Parry et al.. 1987; 
Parry et al., 1989; Thieme et_al., 1992; Piacentini et al.. 1993), IgG and IgM anti-measles, 
mumps and rubella (Parry et al., 1993) have all been successfully demonstrated in saliva. 
However, despite the demonstration that salivary antibody detection could have broad 
applications in viral epidemiological surveillance, outbreak investigation and vaccine 
monitoring, it has attracted little attention except in the field of HIV where the value of 
saliva in screening for HIV infection is well established.
As mentioned earlier, HCV can be detected earlier by PCR than by serology, and 
is a better predictor of infectivity. However, detection of HCV in saliva by PCR is 
unreliable. A wide variation in the prevalence of HCV RNA in saliva has been reported 
previously (0-100%) (Chen et al., 1995; Couzigou et^al., 1993; Fried et al., 1992; Hsu et 
al., 1991; Liou et al., 1992; Mariette et al., 1995; Numato et a l 1993; Punchammer-Stockl 
et al., 1994; Takamatsu et al.. 1991; Thieme et al.. 1992; Wang et al.. 1991; 1992a; Young 
KC. et al.. 1993). In this chapter, we aimed to determine by PCR the prevalence of HCV in 
saliva of a group of haemophiliacs receiving dental treatment at the Glasgow Royal 
Infirmary, and in a group of blood donors referred to a hepatology clinic at Gartnavel 
General Hospital. The purpose of this study was to determine whether HCV was present in 
the saliva of these patients and at what prevalence ^
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METHODS AND MATERIAL
a) Sample population
Twenty one haemophiliacs aged 21-88 years (mean age 42 years) attending an 
oral surgery unit for the full range of oral and dental care, and 47 blood donors aged 26-70 
years (mean age 37.5 years) attending a hepatology clinic were studied. All of the patients 
were HCV-antibody seropositive on the basis of screening by second generation enzyme 
immunoassay (HCV EIAII System, Abbott Laboratories, Chicago), and by confirmation 
with a recombinant immunoblot system (RIBA 2/3, Ortho Diagnostic Systems, Raritan). 
All patients had been shown previously to be PCR seropositive for HCV RNA. Six of the 
haemophiliac patients were also HIV-antibody seropositive.
b) Sample collection
Saliva was collected as described in Chapter 2. No samples were collected 
from five HIV-positive haemophiliacs. Whole saliva and separate pellet and supemate 
samples were however available to this study for all six HIV co-infected patients. These 
samples had been previously collected and stored by'Ruchill Regional Virus Laboratory, 
Glasgow. Only one duplicate set of fresh saliva samples was obtained from an HIV- 
positive haemophiliac.
c) RNA extraction
Initially RNA was extracted from the samples collected by the modified protocol 
of Chomczynski and Sacchi (1987). This was later superceded by the commercially
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available QIAamp Blood Kit. A detailed account of both these methods was given earlier 
in Chapter 3.
d) Reverse transcription and PCR
Reverse transcription and nested PCR on the saliva specimens were carried out 
as described previously in Chapter 2 with no modification to the methods.
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RESULTS
Ten haemophiliacs (47.6%) with serologically proven HCV infection had HCV 
RNA present in their saliva (Table 4.1). HCV RNA was present in saliva with a greater 
frequency among patients negative (8 of 15) than positive (2 of 6) for HIV infection. From 
the samples provided, HCV RNA was present in 5 (23%) of the Salivette™ specimens, 5 
(23%) of the whole saliva specimens, 5 (23%) of the pellet fractions and 4 ( 19%) of the 
supemates. In only one patient was HCV RNA detected in all four specimens, and for two 
patients, in three of four specimens. The presence of HCV RNA in the supemate and/or 
pellet sample was not predetermined by its presence in the whole saliva specimen.
Five full sets of samples which had been previously shown to contain HCV 
RNA positive saliva were tested again following a further freeze-thaw cycle. No virus 
could be detected in any sample following this process (Table 4.2).
Sixteen (34%) HCV RNA seropositive blood donors had HCV RNA present in 
their saliva (Table 4.3). From the samples provided by these blood donors, HCV RNA was 
detected in 8 (17%) of the whole saliva samples, 12 (25.5%) of the Salivette™ specimens, 
1 (2.1%) of the pellet and 1(2.1%) of the supemate fractions. No patient had HCV RNA 
detectable in all four specimens. Six patients had HCV RNA present in both the whole 
saliva and Salivette™ samples. As before, the presence of HCV RNA in the whole saliva 
did not predetermine its presence in the supemate or pellet samples.
Genotyping using RFLP analysis was available for 23 blood donors. Eight 
donors were infected with genotype 1, three with genotype 2, and twelve with genotype 3. 
Two blood donors with HCV RNA present in their saliva were genotype 1 and five were
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genotype 3. None of the 3 blood donors infected with genotype 2 had detectable HCV in 
their saliva (Table 4.4)
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TABLE 4.1
Patient No Salivette W hole Saliva Pellet Supernate
1 +
+ - -
4 - - -i_ -
6 - - + -
7 - + - -
10 + - - -
11 + + - +
131 2 - - +
14' 2 + i•: •
,
18 + + _j.
19 + - + -
S um m ary  o f  H C V  R N A  positive  saliva spec im ens from  H C V  seropositive  
haem ophiliacs.
1 H IV  co -in fec ted  haem ophiliacs. 2 N o sam ples availab le  fo r testing  .
(+) P ositive PC R  result. (-) N egative  PC R  result.
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TABLE 4.2
Patient No Saliva W hole saliva Pellet Supem ate
1 + + — -
*
— — — —
4 — — + —
*
— — — —
6 — — + —
*
— — — —
11 + + + —
*
— — — —
18 + + + +
*
— — — —
S um m ary  o f  the effec t o f  tw o freeze-thaw  cycles on H C V  R N A  p o sitiv e  saliva.
* A fter tw o freeze-thaw  cy c les .(+) P ositive PC R  result. (-) N egative  P C R  result.
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TABLE 4.3
Patient No.
Iin W hole Saliva Pellet Supem ate
6 ,T 1 — —
9 + + — —
11
____ ____  ......
- — -
12 — —
15 + — —
18 — - -
19 — . — —
22 - — —
26 - — -
28 + - — -
29 + + - -
36 + 4. — —
41 — + - -
42 - - + —
43 - - —
44 — - — +
S um m ary  o f  H C V  R N A  positive sa liva  sam ples from  H C V  sero p o sitiv e  b lood  
donors .
(+) P ositive  PC R  result. (-) N egative  PC R  result.
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TABLE 4.4
Viral genotype 1 HCV RNA 
positive saliva
HCV RNA 
negative saliva
1 2 6
2 0 3
3 5 7
G eno typ ic  analysis o f  H C V  R N A  seropositive  patien ts  w ith  de tec tab le  H C V  R N A  
in th e ir saliva.
1 G eno typ ing  by R FL P  carried  ou t by  S N B T S, E dinburgh .
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DISCUSSION
With the emergence of AIDS, the search for less hazardous yet reliable specimens 
has focused on body fluids such as saliva. When the cost of conventional laboratory testing 
is also being heavily scrutinised and more out-of-laboratory testing (i.e. home- testing) 
systems are being devised, saliva has emerged as the forerunner in the search for an 
acceptable alternative to blood suitable for such applications, providing a safe, yet reliable 
specimen.
In this study, whole saliva and Salivette™ samples were collected from 21 
HCV seropositive haemophiliacs and 47 blood donors whose sera were previously HCV 
RNA positive by nested PCR. HCV RNA was detected in the saliva of 10 (47.6%) 
haemophiliacs and 16 (34%) blood donors. Results of earlier studies to detect HCV RNA 
in saliva from patients with detectable RNA in their serum, have varied substantially 
(Chen et al.. 1995; Couzigou et al.. 1993; Fried et al.. 1992; Hsu et al.. 1991; Liou et al.. 
1992; Mariette et al., 1995; Numato et al.. 1993; Punchammer-Stockl et al.. 1994; 
Takamatsu et al.. 1991; Thieme et al.. 1992; Wang et al.. 1991; 1992a; Young et al.. 
1993). This suggests that HCV is either absent or alternatively, that it is present below the 
level of PCR sensitivity. The complex composition of saliva and the variety of 
physiological and pharmacological factors may influence target concentration. Some of the 
constituents of saliva may also be capable of destroying an RNA template or may even 
interfere with the PCR procedure.
The stability of HCV in saliva also needs to be determined. Whether HCV 
RNA breaks down spontaneously, by the action of enzymes or by heating or freezing 
requires further study as such factors may reduce an already low copy number. The critical
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period for degradation is probably between collection and freezing of samples and in the 
present study this period was limited to a maximum of three hours. Further freeze-thaw 
cycles may also reduce the level of virus. Such handling has been reported to reduce the 
PCR signal in serum (Wang et al.. 1992b) and in this study freeze-thaw cycles significantly 
reduced the viral load in saliva to that below the limit of detectability. The low level of 
HCV RNA positive supemate and pellet samples obtained from blood donors compared to 
those taken from the haemophiliacs is notable. This may have been a result of sample 
storage conditions. The whole saliva and Salivette™ samples from the blood donors were 
tested immediately whilst the pellet and supernate samples were tested at a later date, some 
having been stored for up to six months. Samples obtained from the haemophiliacs were 
tested together soon after collection. Thus, the low level of HCV RNA detected in the 
blood donors’ pellet and supernate samples may have resulted from degradation of the 
virus during storage of the samples.
In this study, two of the six HIV seropositive haemophiliacs had HCV RNA 
present in saliva. Results for this group were, however, obtained from stored samples 
which had undergone a number of freeze-thaw cycles. This may have resulted in an 
unrealistically low rate of detection. Only one fresh sample was obtained from this group of 
patients and in that specimen virus was detected in the whole saliva, pellet and supernate. 
The number of HIV co-infected haemophiliacs in this study is unfortunately too small to 
comment on any association between salivary shedding of HCV and HIV seropositivity and 
this point will require further investigation.
Another consideration is whether or not HCV is bound to salivary proteins or 
cell debris, which are often removed from whole saliva by centrifugation. In this study, 
both the supernate and pellet samples were tested alongside the whole saliva. No data were
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recorded to indicate that HCV was associated with any particular component of saliva. 
However, this lack of association may be a result of any of the aforementioned factors. 
Some studies have indicated that specimens collected by swab or into a pot produced better 
results than samples from Salivettes™ for determination of viral antibody status 
(Mortimer & Parry, 1988). In this study a greater percentage of Salivette™ samples were 
positive for HCV RNA. This discrepancy may result from obtaining a purer sample from 
the Salivette™, containing less degradative factors. Critical analysis of this and earlier 
studies therefore suggests that discrepancies in results from different laboratories may 
relate to sample collection and handling techniques and PCR protocol variations.
With regard to salivary shedding and infection with a particular genotype, again 
the number of blood donors genotyped is too small to draw any conclusions. Although our 
results indicated that patients infected with genotype 2 failed to have detectable HCV RNA 
in their saliva , the small number of donors infected with this particular type makes this 
point invalid.
We conclude that HCV is present in the saliva of some HCV seropositive 
haemophiliacs and blood donors. However, more work is needed to optimise sample 
collection and handling methods, as well as maximising PCR protocols before a true 
analysis of the prevalence of HCV shedding in saliva can be carried out. Finally, HCV was 
detected in the saliva of fewer than 38% of HCV-seropositive patients studied. Therefore, 
at this time, salivary tests for HCV RNA are clearly insufficiently sensitive to replace 
serum assays.
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Chapter 5
Serological and Salivary Markers Compared With 
Biochemical Markers in the Monitoring of Interferon 
Treatment for Hepatitis C Virus Infection
INTRODUCTION
Acute infection with HCV may either be severe or, more commonly, 
asymptomatic and unnoticed. The acute disease may resolve completely, but chronic 
hepatitis C develops in 70-80% of patients who acquire acute infection (Cordoba, 1994). 
Studies indicate that the natural course of HCV infection is variable. Most common though 
is an insidiously progressive liver disease, often clinically negligible, persisting for many 
years. Spontaneous remission appears extremely rare and is thought not to occur. Chronic 
HCV can be associated with chronic liver disease, cirrhosis, and HCC. HCV infection is a 
significant cause of morbidity and mortality from liver disease and as such warrants a 
specific and effective therapy. The main aim of treatment should therefore be to prevent the 
progression of chronic hepatitis to end-stage liver disease by halting inflammatory activity 
in the liver. A complete cure, however, would aim at eliminating the virus completely. At 
the moment, the only agent of proven benefit is IFNa, but the treatment of chronic 
hepatitis C remains problematic and unsatisfactory.
Interferons are natural proteins produced in response to stimuli such as foreign 
cells, bacteria and viruses. There are three main types of proteins, known as a , p, and y 
interferon which have direct antiviral effects (inhibition of viral replication, protein 
synthesis, maturation or release from infected cell) and immunomodulatory effects 
(enhancement of macrophage, cytotoxic T cell and natural killer cell activity) (Dianzini, 
1993; Finter, 1994).
The use of IFNa to treat chronic hepatitis C infection began before the 
identification of HCV (Hoofnagle et al.. 1986). Nowadays there are three single subtype 
recombinant IFNa preparations available for clinical use, IFNa-2a (ROFERON, Roche);
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IFNa-2b (INTRON, Schering-Pluogh) and IFNa-2c (BEREFOR, Boehringer-Ingelheim). 
All are different versions of the same gene product IFNa-2. There have been many trials of 
IFNa preparations in patients with chronic HCV disease providing essentially similar 
results. IFN has been shown to have beneficial effects with short-term and long-term 
response rates averaging 50-70% and 25-80% respectively, as estimated by the 
normalisation or decrease of ALT levels in sera (Brester, 1994). However, more recent 
studies report that in general, improvement in ALT values does not necessarily reflect a 
reduction in HCV RNA levels (Picciotto et al.. 1994; Kakumu et al.. 1993; Liang et al.. 
1993; Pawlotsky et al., 1994). This indicates the importance of monitoring HCV viraemia 
by PCR during treatment.
At present, the monitoring of IFN treatment requires repeated venepuncture, with 
the associated discomfort to patients and potential risks to health-care workers. This study 
was run in parallel with our previous study and aimed to assess the suitability of saliva as 
an alternative to blood monitoring the virological effect of IFNa on a group of HCV 
seropositive blood donors.
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METHODS AND MATERIALS
a) Sample population
Eighteen patients (8  females, 10 males, mean age 35.8 years, range 26-52 years) 
vere studied. All were previously blood donors, who were clinically well and whose HCV 
satus had been detected through routine screening of donated blood. All had provided 
FCV-positive blood donations as determined by second generation enzyme immunoassay 
(ECV EIAII System, Abbott), with confirmation by recombinant immunoblot assay (RIBA- 
2and RIBA-3, Ortho Diagnostic Systems, Raritan) and PCR. All subjects had abnormal 
hstology on liver biopsy, with characteristic features of chronic hepatitis C infection.
b) Interferon treatment
Ethical approval for the trial was obtained from the Western and Gartnavel 
General Hospital Trust Ethics Committee, Glasgow. After written consent was obtained, 
pitients were randomly assigned to a year of treatment or observation. Those patients 
aligned to treatment received self-administered intramuscular injections of 4.5 MU of 
recombinant interferon IFNa-2a (ROFERON, Roche Products Ltd, Welwyn Garden City, 
LK) thrice weekly for 12 weeks. The dosage was reduced to 3 MU for the next 12 weeks, 2 
MU for a further 12 weeks and 1 MU for the final 12 weeks of the course. Patients were 
withdrawn from treatment after the first 12 weeks if no response was observed on the basis 
o: ALT normalisation at that stage. Observation patients received no drug or placebo over 
tie study period.
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c) Follow-up
For the nine patients receiving treatment, liver function tests, including ALT, were 
carried out every week during the first month. This was followed by a sample two weeks 
lcter and after a further six weeks. For the remainder of the study, samples were collected 
ai twelve weekly intervals. Observation patients were followed at 0, 12, 24, 36 and 48 
weeks. Both serum and saliva samples were collected at each of the above visits.
d) Sample collection
Saliva was collected as described previously in Chapter 2. A clotted blood sample 
was collected and stored at -20°C by Sister Elizabeth Spence, Department of 
Gastroenterology, Gartnavel General Hospital.
e> RNA extraction
RNA was extracted using the QIAamp blood kit as described in Chapter 3.
£) Reverse transcription and PCR
Reverse transcription and PCR were carried out as previously described in 
Ciapter 2.
g> Quantitative PCR
Quantitation of HCV RNA was carried out on serum samples collected at 0 and 12 
weeks by Professor Johnson Lau, University of Florida using quantitative branched DNA
106
(bDNA) signal amplification (Quantiplex™- HCV RNA, version 1.0, courtesy of Chiron 
Corporation, USA) as previously described (Lau et al.. 1993).
h) Genotyping
HCV genotyping was carried out by the SNBTS, Edinburgh, using RFLP analysis 
(McOmish et_al., 1993).
i) Definition of response
Responses to IFNa were grouped into three patterns. A complete response was 
defined as the normalisation of aminotransferases, accompanied by the loss of serum HCV 
RNA, before the third month of treatment and persisting at least until the end of the IFN 
course. Normalisation of aminotransferases without the loss of HCV RNA was considered 
a partial response. Patients whose aminotransferase activities remained high and in whom 
serum HCV RNA persisted were considered non-responders. These definitions permitted 
assessment of the capacity of IFNa to induce both biochemical and virological remission 
of the disease.
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RESULTS
Of the eighteen patients enrolled in the study, one observation and two treatment 
patients were lost to follow-up during the year. Complete follow-up data were available for 
14 patients (7 treated and 7 untreated). Table 5.1 gives the demographic and clinical 
features of the patients from treatment and control groups. The two groups were similar 
with respect to age, sex, ALT, AST and alkaline phosphatase levels, risk factors and 
pievalence of HCV RNA. Immediate-pretreatment serum HCV RNA was found to be 
piesent in all but one patient who remained negative throughout treatment. This patient had 
pieviously been shown to be HCV RNA positive by PCR.
Serum ALT levels declined to normal in 5 of the 7 IFN treated patients, but 
remained elevated in two patients by the twelfth week of treatment (Figure 5.1). In the 5 
pitients whose ALT levels returned to normal, loss of detectable HCV RNA was observed 
in only 3. Reduction of interferon from 4.5 MU at the twelve weeks to 3 MU was 
accompanied by a return of HCV RNA in one partial responder. Further reductions to 2 
MU heralded an increase in ALT in the same patient (Figure 5.2). In the remaining 
treatment patients, gradually decreasing the dose of interferon had no adverse effects. No 
significant differences were found between the responding and non-responding groups in 
relation to mean age and pretreatment ALT, AST or alkaline phosphatase (Table 5.2). In all 
olservation patients, ALT levels remained high accompanied by HCV viraemia, 
inermittent in some, throughout the study period (Figure 5.3).
HCV RNA was detected in the serum of 12 out of 14 patients (93%). Of the 7 
pitients receiving treatment, the three with a sustained response to IFNa had a lower pre- 
trtatment viraemia level (mean below cut-off), than either the partial responders (mean
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10.52 x 105 HCV RNA equivalents/ml) or the two non-responders (mean 11.26 x 105 
HCV RNA equivalents/ml) (Table 5.2). Both non-responders had infection with type 1 
HCV, while the complete and partial responders were infected with types 2 or 3 ( Table 
5.3). No patient receiving IFN had HCV RNA in saliva prior to treatment. Virus was 
however detected in the saliva of the two patients who did not respond to IFN during their 
course of treatment and follow-up. HCV was shown to be present in the saliva of all 7 
observation patients at some point during the follow-up period. From the saliva samples 
provided by these 9 patients (7 observation and 2 nonresponders), throughout the year, 
HCV RNA was detected in 10 of the Salivette™ specimens, 11 of the whole saliva 
specimens, 7 of the supernate fractions and 7 of the pellet fractions (Table 5.4). The 
presence of HCV RNA in the supemate and/or pellet sample was not predetermined by its 
presence in whole saliva. In only one patient was HCV RNA detected in all four types of 
specimens, and for three patients, in three of the four specimens. At no point was HCV 
RNA detected in saliva when the parallel serum specimen was negative. Although the 
presence of HCV in saliva did correspond to its presence in serum, no correlation was 
shown between the quantitative level of HCV RNA in serum and the presence of HCV 
RNA in saliva (Table 5.5). No genotype could be associated with the presence of HCV 
RNA in saliva (Table 5.6). The raw data for this study is shown in appendices 2-4.
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TABLE 5.1
T reatm en t 
(n  =  7)
O b se rv a tio n  
(n =  7)
A g e 1 41.6  4 6.8 3 3 .7 - 7 .1
Sex (M /F) 3/4 4/3
L iv er F unction  T e s ts1
A L T 2 1 \ 4 ± 71 .2 94.7  ± 59
A S T 3 6 1 .6 - 3 6 .0 57 .0  ± 13.8
A lkaline  P hosphatase4 1 8 1 .0 1 64.4 142.8 ± 54.5
R isk  Factors
T ransfusion 5 3
IV  drugs 2 2
E ar P ierced 3 4
T attoo 2 2
U nknow n 1 0
G en o ty p e5
1 2 2
2 2 0
3 2 5
N ot K now n 1 0
H C V  R N A
Serum 6 7
S aliva 0 3
D em ograph ic  charac teristics o f  trea tm ent and ob serv atio n  patien ts  at 
en ro llm en t on in terferon  drug trial.
1 D ata  ex p ressed  as m ean ± S.D . 2 N orm al A L T  range 10-50 IU /litre .
3 N orm al A ST  range 10-35 IU /litre. 4 N orm al A lkaline  P ho sp h atase  ran g e  7 0 -2 6 0  
IU /l i t r e .5 G enotyp ing  by RFLP.
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TABLE 5.2
CR (n=3) PR (n=2) NR (n=2)
A ge 4 2 1 10.5 44.5 * 3.5 38 1 1.4
Sex (M /F) 0/3 2/0 1/1
L iver function  te s ts1
A L T 2 91.7  1 65 63.5 1 3.5 1 9 9 * 2 9 .7
A S T 3 51.7 ±30.1 36.5 * 0.7 1 0 1 .5 * 3 4 .6
A lkaline P hosphatase4 158.7 * 91.6 1 9 1 .5 * 2 7 .6 2 0 4 .0 * 6 7 .2
bD N A  lev els5 < 3 .5 10.5 1 8.6 11 .3 *  1.0
P retreatm en t patien t charac te ristic s  accord ing  to response to 
in terferon  treatm ent.
1 D ata exp ressed  as m ean  + S.D . 2 N orm al A L T  range 10- 50 /IU  litre.
3 N orm al A S T  range 10-35 IU /litre. 4 N orm al A lkaline  P hosphatase  range  70 -2 6 0  
IU /litre. 5 b ranched  D N A  levels x 105 H C V  R N A  equ iva len ts/m l.
C R  = C o m ple te  responder. PR  = Partial responder. N R  = N on  responder.
I l l
TABLE 5.3
G enotype1 CR (n=3) PR (n=2) NR (n=2)
1 0 0 2
2 1 1 0
3 1 1 0
Not Known 1 0 0
V iral geno types w ith  regard  to response to in terferon  treatm ent.
1 G eno typ ing  by R FL P. C R  = C om plete  responder. PR  = Partial 
responder. N R  = N on responder.
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TABLE 5.4
Patient W hole saliva Salivette Pellet Supernate
I 1 1/5 2/5 0 1/5
2 1 3/5 2/5 2/5 3/5
3 1 3/5 4/5 2/5 1/5
4 1 2/5 0 0 0
5 1 1/5 0 1/5 0
6 1 0 1/5 0 0
7 1 0 1/5 1/5 1/5
82 1/10 0 0 0
92 0 0 1/10 1/10
S um m ary  o f  H C V  R N A  p ositive  saliva sam ples from  7 o b servation  p a tien ts  and 2 
non-responders.
1 O bservation  p a t ie n ts .2 N on-responders to  in terferon .
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TABLE 5.5
W eekO W eek 12
Patient bDNA5 HCV RNA in bDN A5 HCV RN A  in
\ . Serum Saliva Serum Saliva
l 1 <3.5 + + <3.5 + +
2 1 49.46 + — 4.28 — —
3 l <3.5 + — 4.47 + —
4 1 12.47 + — 10.12 + —
5 1 30.48 + — 3.69 + +
6' 29.47 + + 41.47 + +
t 26.25 + + 34.57 + +
82 11.75 + - 6.76 + —
92 10.77 + — <3.5 + -
103 4.41 + - <3.5 + -
U 3 16.62 + — <3.5 + —
124 <3.5 + — <3.5 — —
134 <3.5 + — <3.5 - -
144 <3.5 — - <3.5 — -
L evel o f  H C V  v iraem ia in serum  in re la tion  to the p resence o f  H C V  R N A  in 
serum  and saliva  by PCR.
1 O bservation  p a t ie n ts .2 N on responders. 3 Partial responders. 4 C o m p le te  
re s p o n d e rs .5 b ranched  D N A  levels x 105 H C V  R N A  equ iva len ts/m l.
114
TABLE 5.6
G enotype1 HCV RNA 
present in saliva
HCV RNA 
absent in saliva
Total
1 4 0 4
2 0 2 2
3 5 2 7
Not Known 0 1 1
V iral geno types o f  H C V  in patien ts w ith re la tion  to the p resence o r absence o f  
H C V  in their saliva.
1 G enotyp ing  by R FLP.
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DISCUSSION
Therapeutic trials with IFN for patients with HCV infection were started when the 
diagnosis of disease was based on exclusion and known as NANBH (Hoofnagle et al.. 
1986). With the introduction of assays for serological diagnosis of HCV, evaluation of IFN 
therapy became more reliable. Beneficial effects of interferon have been reported in 
numerous controlled trials. The efficacy in these trials, however, varies rather widely from 
40-70% with relapses occurring in 25-80% of responders (Bresters, 1994).
In the present study, the therapeutic effect of recombinant IFNa-2a in a step- 
down schedule when evaluated on patients with chronic hepatitis C infection was similar to 
that in other reports. Of the 7 patients treated, 3 showed a complete response, 2 showed 
only a partial response and 2 failed to respond. The observation that both non-responders 
were infected with Type 1 HCV concurs with earlier reports that response to IFN among 
patients infected by Type 1 is very low (Chemello et al.. 1994, Hino et al.. 1994; Mita et 
al., 1994). All 7 untreated observation patients remained positive for serum HCV RNA 
with elevated ALT values.
It should be noted that the optimal duration of therapy is currently unknown, and it 
is likely that different patients may require different lengths of treatment. The duration of 
therapy could be based upon attainment of a complete response, if a means of monitoring 
treatment were used which could correctly identify when HCV had been cleared. 
Establishment of meaningful treatment endpoints requires consideration of biochemical, 
virological and histologic information. Several clinical, serum biochemical, serological and 
histological features such as serum ALT, liver histology and HCV RNA in serum and/or 
liver are possibilities. Serum ALT levels and liver histology, while correlating with a
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response to therapy, have been shown not to predict a sustained response. Many studies 
have reported persistence of viral RNA in patients with normal ALT levels (Liang et al.. 
1993; Kakumu et a l .. 1993; Picciotto et a l .. 1994; Pawlotsky et al.. 1994). In our study, 
two patients maintained HCV RNA despite having normal ALT values. One patient did 
have slightly elevated ALT levels towards the end of treatment but this was attributed to 
the decrease in dosage of interferon (Figure 5.2 ). This patient later relapsed following 
treatment cessation. The other patient maintained normal ALT levels despite the presence 
of HCV RNA (Figure 5.4), and remains in the same situation to date. The mechanism that 
accounts for the lack of biochemical evidence of hepatic inflammation despite HCV 
viraemia in patients with partial responses to treatment remains to be defined.
The advent of PCR has enabled the presence and quantity of HCV RNA to be 
monitored during IFN therapy. Although this has been investigated in blood and levels of 
HCV RNA have been shown to decrease and become undetectable in patients with a good 
response, loss of RNA does not always predict a sustained response ( Lau et al.. 1993; 
Bresters et al.. 1994; Picciotto et al.. 1994; Aivama et al.. 1994; Yamada et al.. 1992). 
Results from our study agree with this point, as three out of four partial and non-responders 
showed a decrease to undetectable levels of HCV RNA by bDNA assay (Figure 5.5 ). Very 
few studies have examined the presence of HCV in other tissues, fluids and organs (Balart 
et al.. 1993; Di Bisceglie et al., 1993; Qian et al., 1992) but there are extra-hepatic sites of 
replication where the anti-viral effects of IFN are not documented. HCV RNA may need to 
be monitored in sites other than the liver and blood to confirm complete clearance of virus 
and to prevent later relapse. Indeed, recent studies report that a sustained response is 
associated with complete hepatic and extra-hepatic clearance (Gill et al.. 1993; Saleh et al..
1994).
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In the present study, monitoring the effect of IFN by evaluating HCV RNA in 
saliva has not shown a direct relationship with HCV RNA in blood. The detection of 
negative-stranded HCV RNA in salivary gland tissue has been reported. However, HCV 
RNA may also appear in saliva as part of the serum transudate in gingival crevicular fluid 
(Challacombe et al.. 1978), in which case the amount of HCV in whole saliva would be 
expected to reflect the amount of virus in blood. In this study, we failed to show any 
correlation between the quantitative level of HCV RNA in serum and the presence of HCV 
in saliva (Table 5.5).
The detection of HCV RNA in the saliva of all untreated observation patients 
confirms that saliva has potential as a diagnostic aid. Furthermore, HCV RNA was also 
detected in the saliva of the two treated patients who did not respond to interferon. HCV 
RNA was not detected in saliva of any of the complete responders although serum HCV 
RNA also became undetectable within two weeks of treatment. For the partial responders, 
HCV RNA was detected intermittently in serum, but never in saliva. There are several 
reasons why HCV RNA may be undetectable in the saliva of patients with detectable virus 
in the serum, all of which were discussed in the previous chapter.
Although we failed to successfully monitor IFN treatment of HCV infection by 
detecting HCV RNA in saliva, we did confirm the shortcomings of using serum ALT alone 
in determining the end-point of treatment. Utilization of serum HCV RNA allows more 
accurate definition of response and earlier identification of relapse. Even better would be 
the use of liver HCV RNA as a marker. Unfortunately, tissue assays are not practical as 
they require a biopsy or serial biopsies.
It has not yet been established if there are reliable pretreatment variables that 
might predict a good response to IFNa. Previous studies have been unable to clearly
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establish if there are any pretreatment variables that might predict response. A younger 
patient without cirrhosis and those with a shorter duration of disease appears more likely to 
respond to treatment (Camps et a l .. 1993a). Obesity has also been considered an 
important factor, possibly as a result of reducing the absorption of the drug when injected 
subcutaneously. There may be an optimal dose of IFN which is likely to vary from one 
patient to another. Initial low viral load has also been identified as a possible predictor of 
response. More recent studies report that viral genotype may be a better predictor of 
response (Bresters, 1994; Hoofnagle, et al.. 1993). The production of anti-interferon (anti- 
IFN) neutralising antibodies may also influence response. Some studies have demonstrated 
anti-IFN in patients who do not respond or relapse after an initial response (Antonelli et 
al., 1991; Milella etal., 1993). Neutralising antibodies were not monitored in this study and 
thus we cannot comment on this point with reference to the partial and non-responders in 
our study.
All of the above variables may determine treatment outcome. Unfortunately most 
studies have identified these factors by univariate models without controlling for 
confounding factors which may influence outcome. As mentioned above, a number of 
researchers have suggested that patients with type 2 or 3 infection are more likely to 
respond to treatment than patients with type 1 infection. Although such a response may be 
entirely related to viral genotype, it could be interdependent on other factors, making it less 
certain that virus genotype per se is an independent predictive factor for response to IFN. 
For example in Europe, type 3a infection is more common in young individuals and a 
greater response rate could feasibly be as a result of younger age, and possibly shorter 
disease duration. In the present study, the two non-responders were both infected with 
HCV type 1, while the complete and partial responders were infected with types 2 and 3
119
(Table 5.3 ). Age did not appear to vary significantly with infecting genotype, therefore we 
cannot say whether age affected this response. Neither can we comment on disease 
duration as a predictive factor as this information was unavailable to the study.
The exact relationship of genotype, level of viraemia and efficacy of IFN therapy 
has yet to be clarified. HCV type lb appears to replicate to a higher titre in plasma than 
type 2, and this difference in virus load may influence the response to IFN. Pretreatment 
levels in our study showed one patient infected with type 2  having a higher titre than those 
infected with type 1. This patient responded partially to IFN and remained a partial 
responder one year after treatment cessation (Figure 5.6). Both type 1 patients failed to 
respond to treatment. Type 3 infected patients had the lowest levels of replicating virus. 
Two of these patients were complete responders and have sustained that response to date. 
The third was classed as a partial responder at the end of treatment and has since relapsed 
with ALT levels returning to pretreatment values. Whether the differences in response to 
EFN are a result of circulating virus load (which may depend on genotype), remains 
unclear. There are no standards for quantifying HCV, and differences in methodology make 
comparison between studies difficult. The development of the quantitative bDNA signal 
amplification assay (Quantiplex™-HCV RNA) may improve the situation. However, the 
assay lacks sensitivity in patients with low viral titres (Bresters et al.. 1994). Our study 
agrees with this point as a number of patients were shown to have HCV RNA below the 
level of detection with the bDNA assay, yet were PCR positive (Table 5.4).
It is important to establish the aims of IFN treatment and to determine if the result 
of treatment outweighs the side-effects. IFN treatment is accompanied by a number of side- 
effects, with no way of predicting who will suffer. All patients receiving treatment did 
suffer an initial ‘flu-like’ syndrome, common to IFN treatment. This improved or resolved
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completely after the first few doses. Fatigue and lethargy were common complaints from 
all patients throughout treatment. Mild alopecia was also suffered by two female patients. 
No serious side-effects were recorded.
One of the main aims of treatment should be the prevention of progression of 
chronic hepatitis to liver cirrhosis and possibly HCC. These complications are usually not 
seen until 10-20 years after infection. As such we cannot comment on the efficacy of IFN 
in this respect. A true cure of HCV should aim for complete elimination of HCV. 
However, as we have discussed, current methodologies for monitoring HCV RNA are still 
relatively insensitive and a negative PCR result is no guarantee that the virus has indeed 
been eliminated.
The results of this drug trial confirmed those of earlier studies. An initial response 
was obtained in 70%, but this decreased to 42% in the follow-up. Although these results 
may seem disappointing, the proportion of patients responding to therapy justifies the need 
for frequent injections and the cost of treatment despite the possible side-effects. Although 
the complex interplay between viral genotype, replication efficacy and IFN sensitivity 
remains unclear, the emerging evidence implies that genotyping and quantifying virus 
levels will become an important part of patient assessment and selection for treatment. 
Interferon is expensive and those patients infected with type 1 may need a different 
treatment strategy, for example a higher dose or longer treatment period, or a combination 
of IFN and Ribavirin.
From this study we conclude that HCV is present in the saliva of some of the 
blood donors enrolled in the drug trial. However, optimisation of methods for sample 
collection and handling are required before we can truly asertain whether saliva is a 
suitable alternative to blood for the diagnosis and monitoring of HCV infection.
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TABLE 5.7
Patient
bDNA levels in Serum4
W eekO W eek 12
8 1 11.75 6.76
9 1 10.77 <3.5
102 4.41 <3.5
l l 2 16.62 <3.5
123 <3.5 <3.5
133 <3.5 <3.5
143 <3.5 <3.5
E ffec t o f  in terferon  on v iraem ia levels in patien ts receiv ing  trea tm en t (4.5 M U  
in terferon  trea tm en t th rice w eekly  for 12 w eeks).
1 N on-responders. 2 Partial re s p o n d e rs .3 C om ple te  responders. 4 b ranched  D N A  
levels x 105 H C V  R N A  equivalen ts/m l.
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FIGURE 5.4
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HCV RNA + + + + + -
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co m p le te  response to IFN  had been attained  at w eek 12.
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(+) P C R  positive . ( - )  PC R  negative.
bD
NA
 
lev
els
 x 
10^
HC
V 
RN
A 
eq
/m
l
FIGURE 5.5
20 
15 
10 
5 
0
1 1 2 2 3 3
HCV Genotype
R ela tio n sh ip  betw een  geno type and the in itial v iral load  o f  six p a tien ts  receiv ing  
in terfe ron . G eno type in form ation  w as not ava ilab le  fo r 1 patien t w ho had an in itial 
v iral load  below  the b ranched  D N A  assay cu t-off. D ark  grey b lock  show s 
b ran ch ed  D N A  assay cu t-o ff at 3.5 x 105 H C V  R N A  equ ivalen ts/m l.
BbDNA levels at week12 CUbDNA levels at week 0
Chapter 6
Optimisation of Specimen Collection and 
Handling Methods for the Detection of 
Hepatitis C Virus in Saliva
INTRODUCTION
As explained in earlier chapters, saliva as a diagnostic fluid has many advantages 
over blood, especially when dealing with blood-borne pathogens. It is non-invasive for the 
patient eliminating the risk to healthcare workers of needlestick injuries and permits 
screening of large numbers of people for epidemiological surveys. However, a number of 
issues stand in the way of full acceptance of saliva testing. Low concentration of target 
(antigen or antibody), small sample volume and degradation of target by proteolytic activity 
are general problems associated with saliva testing.
With the emergence of AIDS, the search for a less hazardous specimen has 
focused on other body fluids such as urine and saliva. Although there have been many 
publications detailing the use of saliva to diagnose and monitor certain infections, the 
inconsistent specimens collection procedures that have been employed make comparisons 
difficult. As a result, the true benefits of saliva testing may have been under-estimated.
With regard to the use of saliva as a diagnostic fluid for HCV, critical analysis 
suggested that many discrepancies in our earlier attempts to detect HCV RNA in the saliva 
of HCV seropositive haemophiliacs (Roy et al.. in press) and blood donors (Roy et al..
1995) relate to sample handling techniques. This may also explain the discrepancies 
between papers in the literature. There is concern that specimen processing and storage 
conditions might influence the stability of the target, and hence the detectability of HCV 
RNA. Saliva is a complex fluid, with a variety of physiological and pharmacological 
factors that may influence target concentration or interfere with PCR. As a result, there is a 
need for careful evaluation of the methods for collecting, handling and storing saliva
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specimens prior to PCR analysis, thus maximizing the sensitivity and specificity of the 
technique.
To investigate these issues, we studied freshly collected saliva samples from 
patients who were previously shown to be HCV RNA seropositive. The samples were 
subjected to a number of handling and storage procedures that aimed to simulate conditions 
routinely encountered in a diagnostic laboratory. The samples were then examined for 
HCV RNA by PCR.
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METHODS AND MATERIALS
a) Study population
Fifty-five intravenous drug users (19 females, 36 males, mean age 31 years, range 
19-47 years) attending Ruchill Hospital, Glasgow, were studied. All patients were 
previously shown to be HCV antibody seropositive on the basis of screening by a second 
generation enzyme immunoassay (HCV EIAII System, Abbott Laboratories, Chicago), and 
by confirmation with a recombinant immunoblot system (RIBA 2/3, Ortho Diagnostic 
Systems, Raritan). Thirty one of these drug users were also HIV antibody positive.
A brief oral examination performed by an infectious diseases physician prior to 
sample collection indicated healthy oral mucosa in most of the study group, with the 
exception of 8 (14%) subjects who showed evidence of candidosis. Seven (87.5%) of these 
8 patients were also HIV antibody seropositive. With the exception of candidosis, HTV co- 
infection did not correlate with the oral findings in the drug users (P< 5%) (Table 6.1).
b) Sample collection
Peripheral blood (10ml) was collected by venepuncture in parallel with collection 
of saliva samples. Blood was transported to Ruchill Regional Virus Laboratory, where the 
serum was separated, and stored at -20°C until tested.
Whole saliva and oral fluid obtained from the Salivette™ were collected as 
described earlier (Chapter 2). A third device called the Omnisal™ (Saliva Diagnostic 
Systems, Inc., Oregon, USA), was also employed to collect oral fluid (Figure 6.1). Subjects 
were asked to allow saliva to collect in their mouths and the pad of the collector was placed
under their tongue. No chewing or sucking was necessary. Once adequate saliva had been 
collected, the indicator on the stem of the collector turned blue. At this point, the 
collection device was removed from the mouth and placed into the transport tube supplied, 
forcefully pushing the cap downwards until the cap ‘snapped’ level with the top of the tube. 
On arrival in the laboratory, the pad was separated from the stem with a series of ‘flicks’ of 
the wrist, flicking the tube against the palm of the operator’s hand. Once separated, the cap 
and stem were removed and discarded. The saliva sample could now be separated from the 
pad by inserting the separator into the tube and pressing down firmly. The eluate was 
aspirated directly from the separator for testing or storage (Figure 6.2).
c) Sample processing
On arrival in the laboratory, 200pl of each specimen underwent immediate RNA 
extraction followed by reverse transcription and nested ‘hot-start’ PCR. A second aliquot 
(200pl) went through the same procedure after storage overnight at room temperature. This 
manoeuvre was included to determine the effect of delayed processing on target stability. 
The residual saliva was further divided into two aliquots. The first was heat-treated (60°C; 
15 min) prior to storage at -20°C for one month. This aimed to denature salivary enzymes 
that may affect target stability or interfere with the PCR procedure. The second (unheated) 
aliquot was stored immediately at -20°C and subsequently examined for HCV RNA in 
parallel with the heated specimen after one month of storage. This procedure was to 
determine the effect of storage on target stability. HCV RNA positive specimens stored at 
-20°C were re-examined. This was to determine the effect of repeat freeze-thaw cycles on 
target stability.
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d) RNA extraction and reverse transcription
RNA was extracted using the QIAamp blood kit and reverse transcription was 
carried out as previously described (Chapters 2 and 3).
e) Polymerase chain reaction
For this study ‘hot-start’ nested PCR was employed to eliminate primer-dimers 
and non-specific products. This method was described in Chapter 3. Appropriate 
controls, as discussed in Chapter 2, were included in all runs. HCV negative saliva spiked 
with HCV RNA positive serum was employed as a positive control to determine any 
adverse effects of saliva on the PCR procedure.
f) DNA sequencing
DNA was sequenced by the dideoxychain termination method (Sanger et a l . 
1977), using the Sequenase PCR Product Sequencing Kit (Amersham Life Sciences). All 
reagents used in the protocol, with the exception of the label and primer, were supplied in 
the kit. As the expected sequence is G-C rich, 7-deaza-dGTP-containing reaction mixtures 
were employed to eliminate gel compressions which result when the DNA does not remain 
fully denatured during electrophoresis. PCR products were reamplified using the same 
protocol as described for second round PCR to attain sufficient quantities of DNA suitable 
for sequencing.
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i) Radioactive label
The radioactive label used for all the sequencing reactions was deoxyadenosine 5- 
[a -35 S] thiotriphosphate triethylammonium salt (dATP, Sp isomer) (Amersham Life 
Sciences). The specific activity of the [a -35 S] dATP label was >1200Ci/mmol and the 
concentration was lOmCi/ml.
ii) Enzymatic pretreatment
PCR products were enzymatically pretreated to remove residual single-stranded 
extraneous DNA and primers, and remaining dNTPs from the PCR mixture which would 
interfere with the labelling step of the sequencing process. To 0.2 - 0.5 pmol of PCR 
product, 10 units of Exonuclease I and 2 units of Shrimp Alkaline Phosphatase were added, 
and the reaction incubated for 15 min at 37°C. Both enzymes were inactivated by heating 
to 80°C for a further 15 min.
iii) Denaturing reaction
To 0.5 pmol of treated PCR product, 5-10 pmol of primer 211 was added and 
dlLO to a final volume of lOjil. Denaturation was carried out at 100°C for 2 -3 min. 
Samples were immediately placed on ice and allowed to cool for 5 mins. This ice-cold 
DNA template was used immediately in the annealing reaction.
iv) Annealing reaction
The annealing mixture comprised lOjxl DNA template, 2jil 5 x reaction buffer, 
lpl 0.1M dithiothreitol, 2|il labelling mix (7.5pM each of 7-deaza-GTP, dCTP and 
dTTP), 0 .5 j l l 1 (5pCi) [35S] dATP and 2j l l 1 of Sequenase DNA polymerase. The contents of
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the annealing reaction were mixed well and incubated at room temperature for 2  -3  min. 
3.5|il of the labeling reaction mixture were added to the side wall of each of four 1.5ml 
microcentrifuge tubes labelled A, C, G and T, which contained 2.5pi of each termination 
mix (A, C, G and T) respectively. The reactions were started by spinning briefly in a 
benchtop microcentrifuge and the samples were incubated at 37°C for 5 -10 min. Reactions 
were terminated by the addition of 4pl stop solution and samples were stored at -20°C 
until required. Samples were heated to 75°C for 2 min prior to the loading of 3|il of each 
sample onto the sequencing gel.
v) Polyacrylamide sequencing gel
The stock solutions and mixes used in the preparation of the gel are shown in Table 
6.2 . The concentration of acrylamide used was 6 %. The Macrophor gel sequencing system 
was used according to the manufacturers instructions (Pharmacia LKB). Wedge-shaped 
gels were used routinely. To allow for easier handling, gels were bound to the notched 
glass plate by treatment with Bind-Silane. Treatment of the thermostable plate with Repel- 
Silane prevented sticking of this plate to the notched glass plate containing the bound gel. 
After casting of the gels and insertion of the well-forming combs, they were allowed to 
polymerise for at least one hour at room temperature. Gels were pre-electrophoresed for 30 
min at 2000V and 60°C in lx glycerol tolerant buffer. Sample wells were flushed with 
running buffer prior to loading of samples, which were applied to the gels using duck­
billed tips. Gels were run at 2000V and 60°C until the bromophenol blue band had reached 
the bottom of the gels. Gels were soaked in gel fixing solution (10% acetic acid and 
methanol) for 30min prior to drying onto the notched glass plate with a hair drier and then 
subjected to autoradiography in a light proof box for 8 to 24 hours at room temperature.
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g) Analysis of DNA sequencing data
DNA sequence data were compiled using PELEUP from the University of 
Wisconsin Genetic Computer Group programmes. RFLP analyses were carried out using 
MAPSORT from this group of programmes. Cleavage of sequence data using Rsal/ HaelH 
and Hinfl/ Mval produces a number of cleavage patterns (Figure 6.3). When used 
together, they can successfully identify all six major genotypes of HCV (Figure 6.4). 
Further cleavage of genotype 1 with BstUl, or genotypes 2 and 3 with ScrFI can allow the 
identification of subtypes la,lb,2a,2b,3a and 3c (Figure 6.5).
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TABLE 6.1
H C V +, H IV ' H C V +, H1V+
(n  =  24) (n  =  31)
D enture w earer
Y es 6 14
N o 18 17
O ral H ygiene
G ood 5 10
M oderate 8 8
P oor 11 13
O ral m ucosa
H ealthy 23 24
C an d id o s is1 1 7
U lceration 0 0
L ichen  p lanus 0 0
X erostom ia
Yes 10 11
No 14 20
Sum m ary  o f  the oral health  o f the sub jects en ro lled  in the study  w ith  respect 
to their H IV  serostatus.
1 P< 5%  using  X 2
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TABLE 6.2 
Sequencing gel stock solutions and mixes
20 x Glycerol Tolerant Buffer 
Tris base 
Taurine 
EDTA 
dH20
Sterilise by autoclaving 
Stock acrvlamide 40% 
Acrylamide
Methylene-bisacrylamide
dH20
Urea mix
Stock acrylamide
1XGTB
Urea
dH2Q
10% Ammonium Persulphate (APS)
APS
dH20
Prepare fresh when required
216g
72g
4g
to 1 litre
38g
2 g
to 100ml
15ml 
5 ml 
42g 
to 100ml
0 .2 g 
2  ml
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Sequencing gel mix 
Urea mix 
10% APS 
TEMED
FIGURE 6.1
T h e O m n isa l™  co llec tion  dev ice consisting  o f  sterile  sa liva  co llec tio n  pad w ith  
sam ple  adequacy  ind icato r stem , and transport tube w ith  p reserv a tio n  bu ffer 
so lu tion  w ith  snap cap. B u ffe r con ta ins 0 .2%  so d ium  azide as a p reservative .
FIGURE 6.2
1 2 3
C o llec tio n  p ro toco l for the Om nisal™ . 1) O m nisal co llec to r, sep a ra to r and  tube 
co n ta in in g  adequate storage buffer. Subject p laces pad  o f  co llec tio n  d ev ice  under 
tongue tak ing  care not to suck or chew . 2) O nce an adequate  vo lum e o f  sa liva  is 
co llec ted , the pad is p laced  in the transport tube. 3) S a liv a  is ob ta in ed  by 
rem o v in g  the pad from  the stem  and inserting  the sep a ra to r p rov ided . S a liv a  can 
be asp ira ted  for testing or storage.
FIGURE 6.3
a 44 58 # 114/5 9 26
b 102 # 114/5 9 26
c 44 12 46 58 56 9 26
d 44 12 46 114 9 26
e 56 46 114 9 26
f 33 69 114 9 26
g 33 23 46 114 9 26
h 44 12 46 # 117 9 26
A 53 63 41 94
B 53 63 #44 94
C 53 56 # 142/3
D 53 198
Predicted cleavage patterns for digestion with Haelll / Rsal and Hinfl / Mva 1.
1) Cleavage with Haelll / Rsal. 2) Cleavage with Hinf 1 / Mva 1.
Used together with Figure 6.4 to identify HCV genotypes.
# represents the position of 1 or 2 bp insertions found in some 5’NCR sequences.
FIGURE 6.4
A B C D
a
b 1 4 5
c
d 2
e
f
g 3
h 6
Predicted combinations of RFLP patterns obtained from cleavage with Hae III/ 
Rsa 1 and Hinfl/ Mva 1, associated with sequences of HCV types 1 to 6 .
FIGURE 6.5
la 209 42
lb 179 30 42
2)
2 a 53 15 48 41 94
2 b
53 15 183
53 15 48 135
3)
3a 53 15 57 126
3b 53 15 48 9 32 94
Predicted cleavage patterns for cleavage with Bst U1 or Scr FI.
1) Cleavage with Bst U1 of genotype 1 to identify HCV subtype la  and lb.
2) Cleavage with Scr FI of genotype 2 to identify HCV subtypes 2a and 2b.
3) Cleavage with Scr FI of gentoype 3 to identify HCV subtypes 3a and 3b.
RESULTS
Fifty one complete sets of saliva were obtained from the 55 IVDU. HCV RNA 
vas detected in the saliva of 27 (52.9%). Table 6.3 gives the oral characteristics of the 51 
FD U  with respect to the presence of HCV RNA in their saliva. The two groups were 
smilar in relation to wearing dentures, oral hygiene, and the health of their oral mucosa. A 
complaint of oral dryness was, however, significantly more common in those with 
cfetectable HCV RNA in their saliva (P< 5%). HCV RNA was present in the saliva with a 
smilar frequency among patients negative (13 of 23) or positive (14 of 28) for HIV co­
nfection.
From the total number of positive saliva samples provided, HCV RNA was 
p esent in 16 (57%) of the whole saliva samples, 10 (35.7%) of the Omnisal™ specimens 
aid 10 (35.7%) of the Salivette™ specimens (Table 6.4). In only two patients was HCV 
FNA detected in all three specimen types, and for five patients, in two of three specimen 
types (Table 6.5). No collection method or device provided a sample that identified all 
pitients with HCV RNA in their saliva.
Of the 16 patients with detectable HCV RNA in their whole saliva specimens, 
seven (43.8%) were positive following immediate RNA extraction and PCR on the fresh 
simple within three hours of collection. Four (25%) were positive following overnight 
iicubation at room temperature, six (37.5%) were positive after incubation at 60°C for 15 
nin and storage at -20°C for 1 month and two (12.5%) were positive after storage at -20°C 
fcr 1 month (Table 6 .6 ).
From the 10 patients with detectable HCV RNA in their Omnisal™ specimens, 
FCV RNA was present in five (50%) of the fresh samples, 6  (60%) of the samples left
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overnight at room temperature, three (30%) of the samples heated and stored at -20°C and 
one (10%) of the samples frozen immediately (Table 6.7).
Of the 10 subjects with detectable HCV RNA in their Salivette™ specimens, five 
(50%) were positive following immediate RNA extraction, three (30%) were positive after 
incubation overnight at room temperature, and three (30%) were positive after freezing at 
-20°C alone (Table 6 .8 ).
Repeat freeze-thaw cycles were performed using the six samples that were HCV 
RNA positive following storage at -20°C. A second round of freezing and thawing resulted 
in a loss of detectable HCV RNA in all but one of the samples, which itself became 
negative following a third round of freezing and thawing (Table 6.9).
Serum from 49 of the 51 patients, collected at the same time as the saliva samples, 
was available for testing by PCR. Twenty eight patients were HCV RNA seropositive. Of 
the 23 patients who were HCV RNA seronegative, HCV RNA was detected in the saliva of 
10 (43.5%).(Figure 6 .6 ).
Of the 10 patients with HCV RNA positive saliva, but negative serum, 5 (50%) 
were co-infected with HIV. Oral hygiene was good in three of these subjects, moderate in 
two and poor in five. In general the oral mucosa was healthy in all but one of the ten 
subjects, who showed signs of oral candidosis. Six of these ten patients (60%) complained 
of xerostomia.
Of the 15 patients with HCV RNA positive saliva and serum, 9 (60%) were 
co-infected with HIV. Oral hygiene was good in three subjects, moderate in six and poor in 
six. The oral mucosa was healthy in all but two subjects who showed signs of oral 
candidosis (Table 6 .10).
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Eleven of the 28 (39.3%) IVDU with HCV RNA positive serum samples were 
infected with HCV genotype la, four (14.3%) were infected with genotype 2a, six (21.4%) 
were infected with genotype 3a and one (4%) with genotype 6 . Six of the 27 (22.2%) IVDU 
with HCV RNA positive saliva samples were infected with genotype la, 14 (51.8%) with 
genotype 2a, three (11.1%) with 3a and one (4%) with genotype 6  (Table 6.11). Genotypes 
are described using the proposed consensus nomenclature (Simmonds et a l .. 1994).
Comparison of genotypes isolated from the 15 IVDU with HCV RNA positive 
serum and saliva identified five patients with different genotypes in their serum and saliva: 
genotypes 3a and 2a in four cases and 2a and la in one. Two serum samples were 
untypable due to the small quantity of PCR product obtained even after further 
reamplification. Of the 10 IVDU with HCV RNA present in their saliva but not in the 
paired serum sample, serum collected prior to the study and which had been stored at 
Ruchill Hospital was available from seven for genotyping. Comparison of genotypes from 
these seven patients identified three with different genotypes in the paired serum and saliva 
samples: genotypes 3a and 2a in all three cases. Two serum samples were untypable.
The raw data for this study is shown in appendices 5 and 6 .
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TABLE 6.3
H C V  R N A  
P o sitiv e  S aliva  
(n =  27)
H C V  R N A  
N egative  S aliv a  
(n = 24)
H IV  Positive 14 14
N egative 13 10
D enture w earer
Y es 10 8
N o 17 16
O ral H ygiene
G ood 6 9
M oderate 8 7
Poor 13 8
O ral m ucosa
H ealthy 24 21
C andidosis 3 3
U lceration 0 0
L ichen P lanus 0 0
X erostom ia
Y es' 15 5
N o 12 19
O ral charac te ristics  o f  patien ts  w ith  respect to the p resence o f  H C V  R N A  in their 
saliva.
1 P < 5%  using C hi square.
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TABLE 6.4
W hole  sa liv a O m nisa l™ S aliv e tte™
H C V \  H IV ' 8 6 6
H C V +, H IV + 8 4 4
T otal 16 10 10
S um m ary  o f  total PC R  positive  sa liva  sam ples co llec ted  by the three d iffe ren t 
d ev ices from  the H C V  and H IV  co -in fec ted  in travenous drug  users.
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TABLE 6.5
P atien t W h o le  sa liva O m nisa l™ S aliv e tte™
5 + + -
6 + + -
7 1 + - -
9 1 + - -
131 - -
15 - -
181 + - -
191 + - -
20 - - +
211 + +
22 + + +
23 - - +
32 - + -
3 3 1 - - +
3 5 ' - + +
39 + - -
40 + + -
41 - - +
4 2 1 + - -
43 + - -
48 - - +
4 9 1 - + -
5 0 1 - +
5 1 1 - - +
52 4- + -
54 + - -
5 5 1 + - -
S um m ary  o f  PC R  on the positive  saliva sam ples co llec ted  from  H C V  
seropositive  in travenous drug user.
1 H IV  co -in fected  in travenous drug users.
(+) P ositive  PC R  result. (-) N egative  PC R  result.
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TABLE 6.6
P atien t T o O /N 60°C -2 0 °C
5 - + + -
6 - - + -
7 1 - - + +
9 1 + - - -
131 - - -
181 + - - -
191 4- - - -
211 - - + -
22 - - Hh -
39 + - + -
40 - + - -
4 2 1 + - - -
43 + - - -
52 + - - -
54 - + - -
5 5 1 - + - -
S um m ary  o f  PC R  on w hole  sa liva  sam ples.
1 H IV  co -in fec ted  in travenous drug user. (+) P ositive  PC R  result.
(-) N egative  P C R  resu lt. (To) S am ples p rocessed  im m ed ia te ly  upon arrival in 
laborato ry . (O /N ) S am ples p rocessed  fo llow ing  incubation  o v ern igh t at ro o m  
tem peratu re . (60°C ) S am ples p rocessed  fo llow ing  incubation  at 60°C  fo r 15 m in 
and  sto rage for 1 m onth  at -20°C . (-20°C ) S am ples frozen  im m ed ia te ly  upon  
arrival at labora to ry  and p rocessed  1 m onth  later.
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TABLE 6.7
P atien t T o O /N 60°C
• • . . . ' : . ■ 
-2 0 °C
5 - + — —
6 + + + —
15 + 4* — —
211 — — -f +
22 — — + —
32 — + — —
3 5 1 — —
40 + — — —
4 9 1 — 4* — —
52 + — — —
S um m ary  o f  PC R  on sam ples co llec ted  using the O m nisal™  device.
1 H IV  co -in fected  in travenous drug  user. (+) P ositive  P C R  result.
(-) N egative  P C R  resu lt. (To) Sam ples p rocessed  im m edia tely  upon arriv a l in 
labora to ry . (O /N ) S am ples p rocessed  fo llow ing  incubation  o vern igh t at room  
tem peratu re . (60°C ) S am ples p rocessed  fo llow ing  incubation  at 60°C  fo r 15 m in 
and sto rage for 1 m onth  at -20°C . (-20°C ) S am ples frozen  im m ed ia te ly  upon  
arrival at labora to ry  and  p rocessed  1 m onth  later.
141
TABLE 6.8
P atien t T o O /N 60°C -20°C
20 + - - -
211 - - - 4
22 - - - +
23 - - - +
3 3 1 + - - -
3 5 1 4 I - -
41 4 - - -
48 - + - -
5 0 1 + - - -
5 1 1 - Hh* - -
S um m ary  o f  PC R  on sam ples co llec ted  using the S alivette™  device.
1 H IV  co -in fec ted  in travenous drug  user. (+) P ositive  P C R  result.
(-) N egative  P C R  result. (To) S am ples p rocessed  im m ed ia te ly  upon arrival in 
labora to ry . (O /N ) S am ples p rocessed  fo llow ing  incubation  o v ern ig h t at room  
tem peratu re . (60°C ) S am ples p rocessed  fo llow ing  incubation  at 60°C  fo r 15 m in 
and sto rage for 1 m onth  at -20°C . (-20°C ) S am ples frozen  im m ed ia te ly  upon 
arrival at labo ra to ry  and p rocessed  1 m onth  later.
142
TABLE 6.9
P a tien t
, ^ CNvv if ^  > -V C-. V ;
F reeeze-thaw  C ycles
1 2 3
7 1 + - -
131 - -
212 + - -
213 + + -
223 + - -
2 3 3 + - -
E ffect o f  repeat freeze-thaw  cycles on the stab ility  o f  H C V  R N A .
1 W ho le  S aliva  spec im ens. 2 O m nisal ™  sam p le . 3 S a live tte™  sam ples. 
(+) P ositive PC R  resu lt. (-) N egative  PC R  result.
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TABLE 6.10
Serum  H C V  R N A  
P o sitiv e  
(n  »  15)
S eru m  H C V  R N A  
N eg ativ e  
(n »  10)
H IV  Positive 9 5
N egative 6 5
D enture w earer
Yes 6 4
N o 9 6
Oral H ygiene
G ood 3 3
M oderate 6 2
P oor 6 5
Oral m ucosa
H ealthy 13 9
C and idosis 2 1
U lceration 0 0
L ichen  p lanus 0 0
X erostom ia
Y es 7 6
N o 8 4
O ral charac te ris tic s  o f  patien ts w ith  detec tab le  H C V  R N A  in their 
saliva w ith respec t to H C V  serosta tus.
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TABLE 6,11
Genotype Serum
(n=28)
Saliva
(n=27)
Total
la 11 6 18
2a 4 14 17
3a 6 3 9
6 1 1 2
Untypable 8 3 11
V iral geno types o f  H C V  in the b lood  and saliva o f  IV D U . G en o ty p es d esc rib ed  
using the p roposed  co n sen su s n om encla tu re  (S im m onds e t a l ., 1994).
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DISCUSSION
Handling and storage conditions of blood and saliva could alter the stability of 
HCV RNA and hence the ability of PCR to detect it. Direct detection of HCV RNA 
confirms that in many a persistent, productive infection exists. Thus, it is important to 
establish standard conditions in the handling and storage of the samples to maximise 
sensitivity and specificity of PCR since it has now become a routine assay for HCV.
In general, expectorated whole saliva is most commonly used for diagnostic 
purposes, either unstimulated, collected by passive drooling, or stimulated using 
masticatory stimulation (eg rubber band) or gustatory stimulation (eg 2 % citric acid 
applied to the tongue). When volume measurement is not needed, a variety of collection 
devices such as the Salivette™ and Omnisal™ can be used. Indeed, when used correctly 
both claim to yield adequate volume. The question remains over which method of 
collection is appropriate for clinical investigation, though this is likely to depend on the 
aim of the investigation. With regard to HCV, we compared the collection of whole saliva 
with oral fluid obtained using two commercially available devices (Salivette™ and 
Omnisal™).
From the 55 drug users sampled, inadequate sample volume was a problem for 
only four individuals. Three subjects provided insufficient whole saliva, three insufficient 
Omnisal™ samples and three provided an inadequate volume from the Salivette™. Only 
one subject provided insufficient samples from all collection devices. This patient did, 
however, complain of xerostomia.
All three methods were easy to use, and acceptable to all subjects. However, some 
volunteers found the provision of a whole saliva sample somewhat distasteful. Both the
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Omnisal™ and the Salivette™ devices, when used correctly, provided sufficient sample 
volume. The incorporation of an indicator in the stem of the Omnisal™ gave visual proof 
of sufficient volume. The only disadvantage of using the Omnisal™ in this study relates to 
the preservation buffer, which while ensuring sample stability may also have served to 
dilute the sample and, as a consequence, the target. This would have to be taken into 
account if the Omnisal™ were to be used for quantitative studies.
It has been reported that specimens collected by swab or into a pot produce better 
results than other collection methods (Mortimer and Parry, 1988). Our results are in 
accordance with this finding. However, although the whole saliva samples provided more 
HCV RNA positive samples in total, the Omnisal™ and Salivette™ together identified an 
additional 11 HCV RNA positive specimens. In our earlier studies this pattern was less 
clear cut, yet there is agreement that whole saliva and oral fluid samples do not always 
identify the same subjects with HCV RNA positive saliva. There are several possible 
reasons. It is likely that whole saliva would contain more degradative factors, whereas oral 
fluid may be a ‘purer’ specimen. Alternatively, HCV may be associated with cell debris or 
even with the material of the collection device and as a result, would not be detected in 
the Omnisal™ and Salivette™ specimens or perhaps not released from the devices. Both 
these points will be expanded upon later.
Manipulation and storage conditions of clinical specimens are known to influence 
significantly the stability of viral nucleic acids and, consequently, their rate of detection 
(Busch et al.. 1992; Wang, et a l ., 1992b; Cuvpers et al.. 1992). Most previous studies have 
evaluated residual sera left over after routine serological testing has been completed. By 
this stage they have undergone varying periods of storage at room temperature and in a 
refrigerator as well as several freeze-thaw cycles. It is generally agreed that sera should be
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frozen as soon as possible after collection and that only short periods of room temperature 
storage and minimal freeze thaw cycles are allowable if the sample is to maintain stability. 
With regard to saliva the picture remains unclear, as appropriate handling conditions have 
yet to be ascertained. Our study, although confirming the effect of freeze thaw cycles on 
reducing target positivity, has not established a sample handling protocol that is completely 
satisfactory.
Of the 16 subjects with positive whole saliva samples, seven were identified 
following testing of their samples within three hours of collection (T0). A further four were 
positive following incubation of a second aliquot of sample overnight at room temperature, 
while seven subjects previously shown to have a positive sample at T0 , became negative 
after overnight storage. Heating a further aliquot of each sample, followed by a period of 
storage at -20°C, identified four more subjects with positive specimens but missed 10 of 
those previously identified. Only one subject with a positive aliquot at T0, and one with a 
positive aliquot after incubation overnight at room temperature remained positive after 
heating and storage at -20°C. Only one further subject, previously unidentified, and one 
identified using a different method of sample handling, were HCV RNA positive following 
freezing of an aliquot of the sample within three hours of collection, and without any 
further manipulations, for one month (Table 6.6)
For analysis of the specimens collected by the Omnisal™, leaving the samples 
overnight at room temperature identified more subjects with HCV RNA positive samples 
than testing at T0. However, once again, only three subjects were identified by both these 
methods of handling. A further two positive samples were identified using the aliquots that 
were heated and stored at -20°C. Simply freezing aliquots did not identify any new subjects
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with HCV RNA positive oral fluid. Only one sample was positive using this method of 
handling and this subject had been previously identified (Table 6.7).
From the 10 subjects with HCV RNA detected in their Salivette™ specimens, 
half were identified using the samples tested at T0. Only two more were picked up 
following testing of their samples that had been left overnight at room temperature. Unlike 
the whole saliva specimens, heating the sample prior to storage at -20°C did not maintain 
the target. Simply freezing the sample identified a further three subjects, unidentified by 
previous sample handling methods (Table 6 .8 ).
In conclusion, no single method of specimen collection and handling identified all 
subjects with HCV RNA positive saliva. Indeed, it seems that certain methods of handling 
are more suited to particular types of specimen. For example, a greater number of HCV 
RNA positive whole saliva specimens were identified by immediate testing within three 
hours of collection, while the Salivette™ samples left overnight at room temperature 
identified more HCV RNA positive saliva specimens. HCV stability was only maintained 
in the longterm in whole saliva samples following heating at 60°C. However, there was 
agreement for all specimens that simply storing the samples at -20°C was not suitable for 
maintaining detectable amounts of HCV RNA (Figure 6.7). This agrees with observations 
in our earlier study (Chapter 4), regarding the pellet and supemate samples collected from 
HCV-seropositive blood donors. It should be noted that while the Omnisal™ and 
Salivette™ specimens (both oral fluid) identified a similar total number of subjects with 
HCV RNA in their saliva, a concordant result was only shown with three subjects (Table 
6.5).
How can these discrepancies be explained?. Perhaps whole saliva, being a far 
cruder specimen, contains more degradative enzymes. With storage overnight at room
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temperature HCV is gradually broken down and thus fewer positive samples are detected. 
However, this would not explain why some samples shown to be negative at T0 became 
positive following incubation overnight. Perhaps whole saliva also contains factors capable 
of inhibiting PCR, but which break down overnight at room temperature, thus allowing 
identification of more positive samples, as a result of less interference. More likely there 
may be a combination of virus and inhibitor breakdown. Certainly heating is known to 
prevent salivary inhibition of PCR (Ochert et al.. 1994), and it is also capable of destroying 
degradatory enzymes. Heating the samples and then freezing them was possibly a mistake. 
Although heating may prevent degradation of HCV by enzymes and prevent PCR 
inhibition, it may not prevent spontaneous degradation of HCV which appears to occur 
with storage at -20°C. Oral fluid collected by the Omnisal™ and Salivette™ devices may 
contain less degradative enzymes and/or PCR inhibitory factors. Thus we may have 
expected to see a greater number of subjects identified as having HCV RNA positive saliva 
using oral fluid specimens. In the current study, HCV RNA negative saliva spiked with 
HCV RNA positive serum was employed as a positive control to determine if any 
inhibition of PCR by an unknown salivary component was occurring, but none was 
observed. It is unclear how and where HCV appears in the oral cavity, and oral fluid 
collected by the Omnisal™ and Salivette™ may not be appropriate for HCV diagnosis 
HCV sequences present in the saliva and serum collected were amplified with 
primers corresponding to sites in the 5’NCR that are well conserved between all known 
HCV variants. Sequencing of the PCR product allowed approximately 190bp in the centre 
of the region to be compared with equivalent published sequences. A number of sites are 
polymorphic within most genotypes while other substitutions are strongly associated with 
particular virus types (Smith et a l .. 1995) (Figure 6 .8  ). Comparisons of the sequenced
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PCR products indicated that PCR on saliva was specific. All saliva positive samples that 
could be sequenced contained isolates that were indeed HCV.
Genotyping was carried out by computerised RFLP analysis as opposed to ‘hands 
on’ RFLP analysis because of the low quantity of PCR product generated. 0.2-0.5pmol of 
PCR product is required for sequencing by this method. The manufacturers recommend 
reamplification to achieve sufficient template. However, reamplification often generates 
nonspecific bands capable of interfering with the seqencing protocol. Eleven samples could 
not be sequenced (eight serum and three saliva samples). With the exception of two serum 
samples, these were samples collected from those patients with either HCV RNA positive 
serum or saliva, but not both. This is suggestive of low level viraemia resulting in low 
quantities of PCR product. For these difficult samples, gel purification and concentration 
would be required.
In Scotland, 50% of anti-HCV positive blood donors are infected with HCV type 
1, most of which carry type la sequences. Forty per cent are infected with type 3, all of 
which correspond to type 3a. Only 10% are infected with type 2, in particular with 2b, 
although 2a and 2c can also be found. The results obtained with the serum samples in the 
present study were in agreement with this distribution, though all of the IVDU infected 
with type 2 carried 2a sequences. Genotyping the HCV RNA positive saliva samples 
provided an alternative picture. Genotype 2, and in particular type 2a, was four times more 
common in saliva compared to serum (P < 0.1%), while the relative frequencies of la  and 
3a were halved. The predominance of type 2 in saliva is of interest, because patients 
infected with type 2  show a lower level of liver function abnomalities which may indicate 
infection of non-hepatic areas such as salivary glands (P. Simmonds, personal 
communication). The predominance of type 2a sequences in particular is, however,
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unusual. Information to date regarding genotype distribution has been obtained from 
studies of blood donors, and the distribution may well differ within the drug-abusing 
community. The high prevalence of type 2a in these specimens requires confirmation by 
sequencing of another region, such as the core, that shows distinct sequences specific to 
viral type. Interestingly, type 6  was identified in both the serum and saliva samples from 
one IVDU. This genotype is particularly associated with Hong Kong and the Far East 
(Davidson et a l .. 1995).
The definitive method for deducing virus genotype is nucleotide sequence 
analysis. However, sequencing can only be employed if an individual is viraemic. 
Furthermore, sequencing cannot readily detect more than one virus type within an 
individual. The detection of type specific antibodies in a sample is possible using a 
commercially available enzyme immunoassay (Murex HCV Serotyping 1-6 Assay, Murex, 
UK). This assay uses synthetic peptides, representing the variable antigenic regions from 
the NS4 of HCV types 1-6 and is capable of identifying multiple infections. It is likely that 
those IVDU with different genotypes isolated from their serum and saliva specimens have a 
mixed infection, with a different predominant genotype in the different fluids. This can be 
confirmed by serotyping.
In those patients with the same genotype identified in both serum and saliva, 
comparisons of the nucleotide sequence were made to identify any distinct sequence 
variability associated with the isolates from these two body fluids. None was found. As 
anticipated, all patients were infected by genotypes showing 1 0 0% homology between 
serum and saliva isolates. However, if any difference in serum and saliva isolates exists, it 
is unlikely to occur in this region (5’NCR) currently used widely for genotyping and which 
was used in this study. The 5’ NCR appears to adopt a secondary structure suggestive of an
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internal ribosome entry site and overall, this untranslated region shows much less 
variability between HCV types than any of the coding regions (Simmonds, 1994).
Sequence changes associated with particular genotypes or the presence of other 
polymorphic sites appear not to disturb the secondary structure (Smith et a l .. 1995).
Several mechanisms may account for the ability of HCV to penetrate saliva. Virus 
could replicate in haematopoetic cells and/or epithelial cells frequently present in 
secretions. A number of studies have confirmed virus replication in peripheral blood 
mononuclear cells (PBMC) (Chen et al.. 1995; Muller et al.. 1993; Qian et al.. 1992; Wang 
et al.. 1992c; Young et al.. 1993). An obvious factor that could increase the serum PBMC 
content of saliva and hence its HCV concentration is inflammation or bleeding of the oral 
tissues. All of the subjects underwent a dental examination to exclude oral mucosal lesions 
as a source of contamination of the saliva. Most of the subjects had healthy oral mucosa 
with the exception of eight who showed signs of oral candidosis (Table 6.1). This did not, 
however, correlate with the presence of HCV RNA in saliva (Table 6.3). Finally, a gradient 
may exist between blood and secretions in which virus is passively transferred into 
secretions depending on the concentration of virus in the blood. More often than not, it has 
been agreed that transudation of fluid containing HCV from the general circulation into 
saliva occurs, rather than active replication at the site of secretion (Liou et al.. 1992; 
Loiseau et al.. 1994; Mariette et al.. 1995; Wang et al.. 1992a).
Our data are not in accordance with this theory, and provide evidence that HCV 
may reach saliva via routes other than the gingival crevicular fluid. First, serum transudate 
containing virus enters the mouth primarily by the gingival crevices and thus the 
concentration of HCV in saliva will be influenced by the degree of periodontal disease and 
the number of teeth present. Of the 27 subjects with HCV RNA positive saliva, 12 (43%)
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had less than half their adult teeth. Indeed four patients had no teeth at all (Table 6.12). 
Interestingly, these four patients had different genotypes isolated from their saliva and 
serum samples. Secondly, for a gradient to exist between blood and saliva, virus must be 
present in blood. Of the 25 subjects with HCV RNA positive saliva, whose blood was 
available for testing, 10 (40%) were HCV RNA seronegative (Figure 6 .6 ).
We have also shown previously among blood donors that the amount of virus in 
blood does not correlate with its presence or absence in saliva (Roy et al., 1995). The most 
obvious question regarding this group of 10 HCV seronegative patients is whether the 
positive saliva results are not merely false positives. In each assay, four controls (one 
positive and three negative) were introduced, all of which had to provide satisfactory 
results before the results obtained from the specimens were accepted. While HCV isolates 
have shown extensive sequence diversity, the 5’NCR of HCV has been shown to be highly 
conserved among different isolates. Therefore, in choosing primers based on the nucleotide 
sequence of the 5’ NCR we attempted to maximise and identify isolates that might have 
nucleotide sequence differences outside this region. However, as mentioned before, the 
presence of a DNA band whose length corresponds to the length of the expected PCR 
product does not provide a positive identification. Bearing this in mind, sequencing has 
been employed, not only to identify isolate genotype but also to confirm the amplified 
product as being a true HCV positive result and that the HCV RNA detected in saliva is not 
an artefact.
It is interesting to note that six (6 6 %) of the seronegative patients with HCV RNA 
positive saliva complained of xerostomia (Table 6.13). Xerostomia was the only significant 
(P<5%) oral characteristic that differentiated patients with or without HCV in their saliva,
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although, no particular HCV genotype was associated with xerostomia. Is this an indication 
of salivary gland dysfunction as a result of active HCV infection ?. Certainly, replication of 
HCV in salivary glands has been observed (Takamatsu et al.. 1992).However, this result 
should be interpreted with some caution. The normal unstimulated whole salivary flow rate 
is about 0.3ml/ min, but the range of normality is extremely large. Dry mouth can be 
experienced by patients not only with a salivary flow rate of zero, but also when flow rate 
is reduced to 40-50% of the normal for that patient. Thus, without baseline information on 
a patient’s salivary flow rate or unless the mouth is completely dry, it is almost impossible 
to be certain that the flow rate is less than normal (Dawes, 1993). Indeed, asking patients to 
qualify dry mouth would provide wide variations of what they consider ‘a dry mouth’.
The clinical value of PCR for the detection of HCV RNA does depend on the 
sensitivity and reproducibility of the applied procedure. It is possible that during the time 
between specimen collection, freezing, storage and subsequent RNA extraction, certain 
enzymes present in saliva (eg proteases and lipases) might disrupt the intact virus and 
allow ribonucleases to attack and degrade the genome, thereby destroying the template for 
PCR. This point cannot be stressed enough and has important consequences for the 
interpretation of previous studies in which investigators failed to indicate whether they 
processed and stored samples under uniform conditions. The observed variations in HCV 
RNA results may, therefore, have occurred in vitro rather than in vivo.
Unfortunately, this study has failed to identify an ideal collection and handling 
protocol appropriate to using saliva as a diagnostic fluid for HCV. Whole saliva processed 
within 3 hours of collection provided the best results but this is impractical in a routine 
clinical laboratory. We therefore conclude that collection of saliva for detection of HCV 
RNA is not yet a suitable alternative to blood as a diagnostic fluid for this infection
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TABLE 6.12
P atien t N o  o f  T ee th D entures O ra l M u co sa
5 0 Y es H ealthy
6 26 N o H ealthy
7 0 Y es C an d id o sis
9 20 N o C an d id o sis
13 23 N o H ealthy
15 24 Y es H ealthy
18 6 Y es H ealthy
19 17 N o H ealthy
20 24 N o H ealthy
21 14 Y es H ealthy
22 26 N o H ealthy
23 26 N o H ealthy
32 10 Y es H ealthy
33 25 N o H ealthy
35 0 Y es H ealthy
39 20 N o H ealthy
40 13 N o H ealthy
41 19 N o H ealthy
42 9 Y es H ealthy
43 18 Y es H ealthy
48 22 N o H ealthy
49 0 N o H ealthy
50 7 Y es C an d id o sis
51 6 N o H ealthy
52 11 N o H ealthy
54 22 N o H ealthy
55 25 N o H ealthy
O ral charac te ris tic s  o f the 27 in travenous d rug  users w ith  d e tec tab le  H C V  R N A  
in th e ir saliva.
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TABLE 6.13
Patient No of Teeth Oral Mucosa Xerostomia
5 0 H ealthy N o
20 24 H ealthy Yes
21 14 H ealthy N o
22 26 H ealthy Y es
33 25 H ealthy Y es
39 20 H ealthy Y es
42 9 H ealthy Y es
48 22 H ealthy N o
50 7 C and idosis Y es
51 6 H ealthy N o
O ral charac te ristic s  o f  the in travenous d rug  users w ith  H C V  R N A  p o sitiv e  sa liva  
bu t nega tive  serum
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Chapter 7 
General Discussion
Following HCV infection there is characteristically a prolonged period before 
seroconversion occurs. This limits the usefulness of currently available serological assays. 
Following determination of the HCV genomic sequence, RT-PCR has been used to detect 
viral RNA during the acute phase of illness, and in the absence of anti-HCV antibodies.
The presence of viral RNA also appears to be a more accurate predictor of infectivity.
A major part of the studies presented in this thesis sought to determine the 
appropriateness of PCR as a routine diagnostic tool for HCV infection, and in particular 
its suitability with regard to use of saliva as an alternative specimen to blood. PCR is a 
complex technique that entails numerous manipulations. Many attempts have been made 
to simplify the process and thereby facilitate the application of this method in a routine 
clinical laboratory . However, assay simplification alone would not be sufficient to allow 
PCR to become a routine diagnostic tool for any organism, because a more serious problem 
must be solved. Owing to the exquisite sensitivity of PCR, a single molecule of target 
DNA can be amplified to the point of detectability. Inadvertent transfer of minute amounts 
of previously amplified DNA corresponding to the region of interest results in the 
phenomenon of PCR end product contamination dubbed “carryover”. The avoidance of 
such contamination is critical to generating consistent, correct results. The low molecular 
weight amplified DNA is easily aerosolised by opening sealed test tubes or by pipetting and 
this can result in the contamination of all reagents, instruments and personnel. During the 
course of the study, the guidelines of Kwok and Higushi (1989) were adhered to strictly. 
Furthermore, all equipment was UV sterilised prior to each use. Every effort was made to 
prevent the physical transfer of DNA, but even when following these precautions, low level 
contamination may occasionally occur. Appropriate negative controls were included with
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every run to rule out reagent contamination, although it must be realised that these cannot 
control for random contamination of individual samples attributed to aerosolised DNA.
The only way to be certain that carry-over contamination will not be a problem is 
to chemically or enzymatically inactivate the amplified DNA. There is a commercially 
available kit for HCV diagnosis with serum samples, based on the principles of restriction 
modification and excision repair systems of cells (Amplicor PCR Diagnostic, Roche 
Diagnostic Systems). This method allows the selective destruction of previously amplified 
DNA, while DNA from clinical samples is unaffected. The protocol involves substitution 
of deoxynucleoside 5’ uridine triphosphate (dUTP) for deoxynucleoside 5’thymidine 
triphosphate (dTTP) in the master mix, thus ensuring that all new amplified DNA will 
contain uracil rather than thymidine. Any carry-over to the next reaction is destroyed by 
incorporation of the enzyme uracil-N-glycosylase (UNG) which catalyses the excision of 
uracil from single-stranded and double-stranded DNA thus destroying the contaminating 
templates. UNG is inactivated at most temperatures used in PCR cycling so newly 
synthesised amplicons will not be destroyed prior to detection. There are several further 
advantages to employing the Amplicor diagnostic kit, in particular the provision of all 
components for every aspect of the assay (sample processing, amplification, and detection) 
in a bid to ensure reproducibility, sensitivity, and specificity.
The issue of false negative results is an equally important problem as false 
positive results. Certain specimens, as well as specimen handling procedures and 
instruments, can contain or introduce inhibitory factors which reduce the efficiency of the 
PCR process (Busch et a l .. 1992: Cuypers et al.,1992). With regard to sera, it is now 
routine to collect blood samples in non-heparinized tubes, as heparin has been shown to 
inhibit PCR (Wang et al.. 1992b). The effect of storage or freezing and thawing is less
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clear, but researchers advise the aliquoting and freezing of samples as soon as possible 
after collection. Saliva has been shown previously to interfere PCR, but the unknown 
inhibitory factor appears to be removed by appropriate specimen preparation methods 
(Ochert et al.. 1994). This situation was controlled for in the current studies by mixing a 
known HCV-positive serum sample with a known negative saliva sample to produce a 
‘spiked’ specimen prior to cDNA synthesis. Identification of the correct product was 
illustrated by competent cDNA synthesis and PCR amplification. This in turn was 
indicative of the absence of inhibitors.
False negative results can also occur following the use of inappropriate primers. 
The selection of primers used in a particular system is based upon a number of criteria. The 
specificity includes both inclusivity and exclusivity. Thus, it is necessary to be able to 
amplify all isolates of the target of choice, while avoiding the amplification of closely 
related micro-organisms. The 5’NCR of the HCV is the most highly conserved region of 
the virus genome and as a result this region is often used as the target for detection of HCV 
RNA by RT-PCR. However, genotype-specific sequence polymorphisms exist throughout 
the 5’NCR. Consequently it is possible that a given primer pair will not support 
amplification due to minor differences within the primer binding site which prevent 
annealing or elongation by the polymerase.
Recently, Smith et al/1995) investigated the variation in the 5’NCR of HCV 
isolates by comparing 314 5’NCR sequences of viruses of genotypes 1 to 6. Through 
identifying the polymorphic sites within the 5’NCR, improved oligonucleotide primers 
were proposed that would be equally efficient in detecting RNA of different virus 
genotypes. The primers employed during the course of the present study were based on the 
HCV-1 sequence. This would of course result in different efficiencies of detection with
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genotypes other than type 1. As such, we cannot rule out the existence of false negative 
results through primer mismatches when interpreting the results of our studies. However, 
genotypes 1, 2, 3 and 6 were amplified and sequenced from our study population.
HCV RNA was found in the saliva of all three subject groups at varying rates 
(34-52.9%). However, the studies also confirmed that saliva does not provide a reliable, 
consistent and stable specimen for detection of HCV RNA. In Chapter Six it is shown 
clearly that specimen type and handling conditions can affect the success of detection of 
HCV RNA by PCR. As shown previously for serum, multiple freeze-thaw cycles and 
prolonged periods of storage of saliva specimens reduce the chances of amplifying HCV 
RNA. Both these points were alluded to in Chapter Four and confirmed in Chapter Six, 
when the sample handling protocols employed were studied in more detail.
This study also failed to identify a saliva collection and handling protocol that 
would optimise the detection of HCV RNA by PCR. Saliva is a complex biological fluid, 
and much remains to be learned about its normal constituents. Factors are likely to be 
found that inhibit PCR, although in the studies reported here this did not appear to be a 
major problem. It is more likely that the inconsistent nature of PCR for detecting HCV in 
saliva is related to the effect of saliva on the stability of HCV RNA. RNA is susceptible to 
in situ degeneration at ambient temperatures and this may well occur to a lesser extent at 
-20°C over a period of time.
The appropriateness of PCR as a diagnostic tool for HCV in a routine clinical 
laboratory remains ambiguous. There is no doubt that it is sensitive and specific in 
confirming infected blood and blood products for the purposes of the Blood Transfusion 
Service. However, in this situation only those donors providing a RIBA-3 or indeterminate 
result are screened further by PCR. With the commercial production of the UNG system by
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Roche (Amplicor PCR Diagnostics for HCV), the Regional Virus Laboratory, Ruchill 
Hospital, began to employ PCR as a diagnostic assay. However, the National Health 
Service only provides funds for anti-HCV antibody assays and as a result PCR is restricted 
to those patients being considered for IFN treatment, or patients suffering acute hepatitis 
who provide a RIBA-3 indeterminate specimen. The problems of false positive and 
negative results remain too great to allow HCV diagnosis by PCR alone in a low risk 
population using blood, let alone saliva. In its present configuration, PCR cannot replace 
serological assays where broad based screening is required.
Even when all of the aforementioned problems associated with PCR are taken into 
consideration, this study has shown that HCV RNA can be detected in the saliva of a 
substantial number of individuals. Indeed, consideration of the problems involved suggests 
that this work may even have underestimated the true prevalence of HCV RNA in saliva. 
This poses the question of which route HCV takes to enter the mouth. As mentioned 
earlier, HCV may penetrate saliva by several mechanisms including serum transudate and 
migration of infected PBMC.
A recent study by Chen et al.11995) failed to detect HCV RNA in saliva obtained 
from the submaxillary glands. These workers also failed to detect negative stranded HCV 
RNA, which represents replicative intermediates of HCV. They concluded that HCV 
seldom replicated in the cells originating from the oral cavity and that salivary HCV RNA 
was a result of migration of HCV-infected mononuclear cells. This was in accordance with 
the general assumption that HCV enters saliva by serum transudation through the gingival 
crevices.
During the course of the present study, evidence has accumulated which questions 
this theory. First, HCV RNA was detected in both the supernate and pellet of some of the
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samples collected from the haemophiliacs and blood donors. However, it is conceded that 
the protocol employed only determined the presence of positive stranded HCV RNA, and 
that this does not indicate HCV replication within the mouth. In addition, information was 
not obtained on the dental or periodontal status of each patient and thus an external source 
of HCV cannot be ruled out in these studies.
Secondly, for a gradient to exist between blood and saliva to allow passive 
transfer of virus, HCV must be present in a greater concentration in blood. The lack of such 
a gradient was shown clearly in the patients enrolled in the IFN drug trial (Chapter 5).
Thus, HCV RNA was detected in the saliva of some patients for whom serum HCV RNA 
was positive by PCR but whose HCV RNA level as measured by bDNA was below the 
assay cut-off, but was undetectable in others whose serum HCV RNA levels were ten fold 
greater than the assay cut-off. This challenges the assumption that salivary HCV RNA is 
always derived from serum. Likewise, the presence of HCV RNA in the saliva of 10 HCV 
RNA negative IVDU suggests that transudation from serum is not the only mechanism. 
These patients may have had serum HCV RNA levels below the limit of detection with our 
assay (100 genomes/ml)(Dow et al.. 1993). Unfortunately, no sera were obtained in 
parallel with the saliva samples taken from the haemophiliacs and blood donors in the 
initial prevalence study (Chapter 4), as the source of virus was not being considered at that 
stage. In the study monitoring interferon treatment by saliva testing (Chapter 5), HCV RNA 
seronegative samples were obtained only from the patients receiving therapy and therefore 
it was assumed that absence of virus from the mouth was a result of the treatment.
Thirdly, if serum transudate, containing virus, enters the mouth by the gingival 
crevices the concentration of HCV in saliva is likely to be influenced by the number of 
teeth and the degree of periodontal disease. Periodontal lesions are inflammatory,thus
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causing exudation of serum into saliva and increasing the shedding of potentially infected 
mononuclear cells into the salivary pool. This source of salivary contamination was taken 
into consideration in the final study. Severe periodontal disease is common in intravenous 
drug users, but in the present study showed no correlation with the presence of HCV RNA 
in saliva. Similarly, salivary HCV RNA was detected in almost 50% of the patients who 
had less than half their adult teeth, and in some who were edentulous.
It is possible that in addition to transudation of fluid containing virus from the 
general circulation, there is also active replication at the site of salivary secretion in some 
individuals. More research is needed to identify the cells (if any) that harbour the virus. 
Techniques such as in situ PCR are available which would enable the assessment of gland 
biopsies for the presence of replicative intermediates.
Xerostomia is a prominent clinical sign associated with Sjogren’s Syndrome (SS). 
This is an autoimmune disease which is characterised by lymphocytic infiltration and 
destruction of the major and minor salivary glands, leading to varying degrees of salivary 
hypofunction. The factors that trigger such a focal immune response remain unknown but 
viral infection has often been suggested (Fox> / 1 9 9 4 ) .  Recent evidence indicates that 
HCV should be considered as a candidate trigger in this disease.
HCV may be associated with a number of symptoms and signs involving salivary 
glands, including complaints of oral dryness. Reports of HCV associated with SS have 
been published in the recent literature (Aceti et al.. 1992; Almasio et al.. 1992; Haddad _et 
al., 1992; Mariette et al.. 1993). HCV infection appears to induce a complex immune 
response that may partly account for its propensity to cause persistent infections and 
autoimmune phenomena such as low titre autoantibodies. Such phenomena may explain 
salivary gland lymphocytic infiltration resulting in a form of sialadenitis distinct from SS.
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At present, no consensus criteria exist for the diagnosis of SS and this is causing general 
confusion in the identification of causative factors of the disease. Evidence does, however, 
suggest histologically different patterns of lymphocytic infiltration associated with HCV 
salivary gland dysfunction and different patterns of autoantibodies.
Dry mouth is a common symptom and has a variety of causes. Symptomatic 
complaints of xerostomia or quantification of salivary output alone are not sufficient to 
establish a diagnosis of salivary gland dysfunction. Salivary secretion may be decreased by 
a number of factors, the most common of which is medication. Sedatives, opiates, 
antipsychotics, antidepressants, antihistamines and diuretics are the classes of drugs most 
often associated with xerostomia. All of the IVDU enrolled in the present study had been 
prescribed, or were abusing, at least one drug capable of reducing salivary output.
When first identified, HCV was believed to be acquired almost exclusively 
through percutaneous exposure. This early view evolved from the fact that the virus was 
first recognised in the context of transfusion studies. Subsequent investigations focused on 
an analysis of risk factors for viral acquisition within the community. Risk factors 
associated with the illness included previous receipt of blood or blood products and 
parenteral drug use.
In approximately 40-50% of cases of HCV infection, a history of either 
transfusion or injecting drug use is inapparent and the precise route of infection cannot be 
defined. This raises the possibility of less obvious modes of transmission. Virological 
studies of body fluids other than blood is of importance when evaluating possible non- 
parenteral routes of transmission. It is possible that infection may occur through non- 
sexual household contact as a result of contamination of household items such as eating 
utensils or toothbrushes, or through the small spillages of blood and body fluids that may
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occur in the domestic situation. Transmission of HCV by body fluids is feasible and more 
likely to occur if exposure is repetitive and extends over a long period of time. It is also 
possible that transmission may only occur at times of peak viral replication and may also be 
dependent on viral genotype. Although such transmission may occur with low efficiency, 
the total proportion of new infections resulting may be significant.
Early epidemiological surveys appeared to support the concept of sexual 
transmission of HCV. In most cases the early studies were poorly designed with 
insufficient consideration being given to the exclusion of other risk factors or the general 
background rate of HCV infection in the study population. Furthermore, most studies were 
too small to give meaningful results. Infectivity is likely to be low and large numbers 
would be necessary to demonstrate significant results.
With the development of increasingly sensitive assays for HCV, it was anticipated 
that sexual transmission would be clearly established. The presence of HCV in saliva and 
semen has been reported (Chen et a l .. 1995; Couzigou et a l .. 1993; Liou et al.. 1992; 
Mariette et a l .. 1995; Numato et al.. 1993; Punchammer-Stockl et al.. 1994; Takamatsu et 
al_., 1991; Thieme et a l .. 1992; Wang et al.. 1991; 1992a; Young , et al.. 1993). 
However, it has been difficult to prove true sexual transmission and to identify the body 
fluid involved. Current evidence suggests that HCV can be transmitted sexually, although 
the importance of the route appears low.
The presence of HCV in saliva is of concern in dental practice, where the degree 
of exposure of dental staff to the saliva and blood of patients is high. However, studies to 
date indicate that the prevalence of HCV infection among health care workers is low. Only 
two studies have examined anti-HCV serology in groups of dental surgeons. An American 
study reported that dentists, especially oral surgeons, run an occupational risk of acquiring
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HCV infection (Klein et a l 1991). In contrast, a smaller study of 94 dentists in Wales 
showed no such risk (Herbert et al.. 1992). It is likely that the discrepancy in these studies 
results from differences in the patient populations treated by the two groups of dentists 
particularly with respect to intravenous drug users. It is argued that in general, the risk to 
dentists is dependent on the HCV prevalence in the patient population. However, this risk 
may increase substantially during oral surgery (Klein et a l .. 1991) and possibly even less 
severe trauma causing intraoral bleeding. It is difficult in such situations to distinguish 
transmission through saliva or blood. To argue that transmission of HCV through saliva is 
inefficient as a result of the low prevalence of detectable HCV in saliva may be inaccurate. 
Early reports of HCV detection in saliva may have underestimated the true levels. The 
work carried out in Chapter 6 shows clearly the difficulties of testing saliva for HCV RNA 
and we cannot ignore these when interpreting the earlier prevalence studies. It is likely that 
HCV is more widespread in saliva than acknowledged.
Although there have been no documented cases of HCV transmission through 
dental handpieces, the potential risk of HCV infection to patients receiving dental 
treatment must also be considered. Some types of reusable dental equipment might be 
responsible for cross-contamination if patient material were lodged in internal mechanisms 
that are difficult to disinfect. Air driven high speed handpieces and prophylaxis angles take 
up and expel patient material and could potentially provide a vehicle for cross-infection 
(Lewis et al.. 1992; Lewis and Arens, 1995). Depending on individual dental practice 
protocols, handpieces and attachments may only be externally disinfected between patients, 
rather than autoclaved. Infectious material present in the internal areas of the equipment 
may not be reached by such procedures. In addition, water jrepellent lubricants used inside
A
the equipment coating the internal mechanisms may prevent contact of steam or
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disinfectant solutions with infectious material. The probability of encountering this type of 
contamination will again depend on the HCV prevalence in the practice population and on 
the sterilisation and disinfection practices of the dentist. The British Dental Association 
(BDA) Advisory Committee recommends that all instruments and equipment must be 
cleaned and sterilised after use. Autoclaving at 134-138°C for 3 min is recommended for 
all instruments. Chemical disinfection must only be used for those items that cannot be 
sterilised by conventional methods.
A further source of infection to both the dentist and patient may be through direct 
contamination of surfaces in dental practices (Lewis et al.. 1992). Consistent environmental 
contamination through exhausts that leave the dental suction units has been shown in 
dental surgeries after treatment of anti-HCV and HCV RNA positive patients (Piazza et al.. 
1995). Environmental contamination through the dispersion of aerosols and/ or droplets of 
saliva and blood seems inevitable and unfortunately there are no definite data on HCV 
survival in the enviroment. The presence of HCV RNA on contaminated surfaces for at 
least 20 hours has been recorded (Piazza et al.. 1995). Impervious disposable coverings can 
be used to cover surfaces liable to contamination and can be changed between patients. The 
BDA Advisory Committee also recommends that between sessions all work surfaces 
should be thoroughly cleaned and decontaminated with detergent or a suitable virucidal 
disinfectant. The lack of data on the ability of many chemical agents to inactivate HIV, 
HBV and HCV makes recommendation of disinfectants difficult. A fresh solution of 
sodium hypochlorite is recommended for general surface disinfection and freshly activated 
2% alkaline glutaraldehyde for non-corrosive disinfection of metals.
The infectivity of saliva from HCV seropositive persons for sex partners, bite 
victims, and health care workers is a subject of continuing interest to epidemiologists,
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clinicians and virologists. The presence of HCV in saliva has been shown regularly but 
studies have failed to provide conclusive evidence that saliva may act as a vehicle for 
transmission. Comparisons can be made with HIV and the lack of transmission from 
sexual, occupational or casual contact with saliva and / or the oral cavity. Much research 
has been carried out to determine the infectivity of saliva from HIV-seropositive patients. 
However, epidemiological data and intensive family studies have failed to provide any 
conclusive data that saliva can act as a source of infection (Archibald and Cole, 1990, 
Qureshi et al.. 1995).
The virtual absence of oral transmission of HIV, together with reports of antiviral 
activity in the saliva of healthy and infected individuals suggests the presence of a factor in 
saliva that can inhibit transmission of the virus. It is believed that there are at least two 
mechanisms present in saliva that may provide antiviral activity in vivo. One of these is the 
physical entrapment of virus particles. Macromolecules such as mucin and other 
glycoproteins in saliva tend to form aggregates by binding to other salivary molecules 
including microbial and viral proteins. Therefore, virus can be trapped into these 
complexes and cleared from the mouth by swallowing or expectoration (Bergey et a l ..
1994; Yeh et al.. 1992). Specific and non-specific aggregation could also be a major host 
defence mechanism against HCV infection in the mouth. With regard to HIV, the other 
mechanism of salivary inhibition is a serine protease inhibitor known as secretory 
leukocyte protease inhibitor (SLPI). Evidence suggests that SLPI interacts with a host cell 
molecule(s) other than the HIV receptor, CD4 (McNeely et al.. 1995; Aldous, 1995). Saliva 
from which SLPI has been removed /  ^loses most of its ability to inhibit HIV. It is
possible that a similar mechanism could exist for HCV. Saliva is known to be one of the 
major host defence mechanisms yet our understanding of its antiviral actions is limited.
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There would appear to be several possible mechanism of antiviral activity but further 
studies are required to establish the role of saliva in preventing the transmission of HCV.
Given that the estimated general prevalence of HCV infection in the general 
population is between 0.4 and 2.2% and that there is currently neither an effective vaccine 
or treatment, it is clear that HCV represents a major clinical and public health problem 
(Viral Hepatitis Prevention Board, 1995). The control of HCV is a priority because of the 
frequency of occurrence of infection, its high chronicity rate, the common and serious 
nature of its sequelae and the high associated direct and indirect costs.
The prevalence of HCV infection in different groups of blood donors varies and 
because of the current policy of self-exclusion of at-risk donors, these rates cannot be 
considered to reflect the prevalence in the community, which is possibly several fold 
higher. The development of cheaper, simpler, but highly sensitive and specific tests would 
allow the collection of information on the distribution of HCV infection and spread 
through apparently non-parenteral routes. The use of saliva for broad-based community 
screening programmes would be advantageous. However, for the determination of HCV 
RNA, saliva is not appropriate. Future research should concentrate on detection of HCV 
salivary antibodies. The modification of commercially available HCV antibody testing kits 
has enabled successful detection of salivary antibodies (Piacentini et al.. 1993; Thieme _et 
al_., 1992). Confirmation of HCV infection by a saliva analysis would necessitate a testing 
algorithm similar to that with blood, namely initial detection with a screening ELISA, 
followed by an alternative ELISA and a supplemental assay. Such a procedure would 
require the availability of a range of screening and supplemental tests suitable for testing 
saliva.
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Research to determine the mechanisms and efficiency of transmission of infection 
through apparently non-parenteral routes is also needed. The presence of HCV in body 
fluids other than blood indicates their potential as an infectious fluid, yet little is known 
about the dynamics of such transmission. Research along these lines is necessary to support 
future development and refinement of strategies to control HCV infection and associated 
diseases.
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